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SUMMARY
(a) Clinical Aspects
The relationship between the molecular forms of oestrogen receptor 
(4S and 8S forms) in human breast cancer and subsequent response to hormone 
therapy is controversial. The data presented in this thesis show that 
several factors can effect the final sucrose density gradient profile of 
soluble oestrogen receptor under low salt conditions. These include incubation 
time with steroid, temperature, ionic strength, extent of aggregation and 
intratumoural variation. It is further shown that buffer made 50% in glycerol 
can be used to preserve the molecular form of oestrogen receptor in human 
breast tumour biopsies prior to and subsequent to transportation. Receptor 
8S form was preserved for up to 3 months under these conditions. Most 
tumour biopsies analyzed exhibited the presence of 8S form of the receptor 
either alone or in conjunction with the 4S form. Relatively few tumours 
exhibited predominantly the 4S form. Analysis of intratumoural sections 
revealed a loss of receptor concentration towards the centre of the tumour.
The molecular forms found across a tumour usually remained constant. However, 
when both 85 and 48 forms of receptor were detected, the relative concentra­
tion of each form changed across the tumour. These results indicate that 
strict criteria, with respect to analysis of molecular forms of oestrogen 
receptor, must be observed if these are to be related to potential response 
of individual patients to endocrine therapy.
(b) Receptor activation/transformation
The mechanism of receptor activation/transformation was studied 
in immature rat uterus, human breast carcinoma and endometrial tissue. 
DNA-cellulose binding was characterized as an vitro acceptor of activated 
receptor (SO^C, 30min). Up to 80% of the activated receptor from immature 
rat uterine tissue bound to DNA-cellulose in contrast to only a/ 20% from 
human breast carcinoma. In the presence of protease inhibitors, human
breast carcinoma ER still showed a lower level of DNA-cellulose binding
was significantly higher than control.
In the presence of sodium molybdate, an inhibitor of activation 
of immature rat uterine ER^,/v 20% of the receptor was found to be insensi­
tive to this inhibitory effect. A proportion of receptor may be permantly 
activated.
When SDGA was conducted in low salt buffers, DNA (calf thymus)
binding studies of ER^ indicated no requirement for heat activation. Both
immature rat uterine 8S ER and human breast tumour 8S ER behaved similarlyc c
and sedimented to the bottom of the tube in conjunction with the DNA. 
However, variation in the affinity of different molecular forms of ER^ 
from human breast carcinoma for the calf thymus DNA was observed. The 
4S form was found to bind with a lower efficiency than the 8S form (although 
in certain cases a large proportion of 4S form bound to DNA). In one case 
both 4S and 8S only partially bound to DNA. These results indicated that 
several factors, including proteolysis, dissociation of 88 complex, associa­
tion of 48 complex, and involvement of various inhibitors could regulate 
the extent of 48 and 88 binding to DNA. This therefore indicates a possible 
equilibrium between the 88 and 48 forms. A 48 proteolyzed form of receptor 
which is unable to bind to DNA is postulated.
Sucrose density gradient (8DG) profiles obtained after receptor 
activation (30^0 for 30min) showed the presence of only the 48 form in 
human breast carcinoma and endometrial cytosol when analyzed on high salt 
gradients at 4^0. In contrast, the immature rat uterine ER^ underwent a 
48 58 transformation in a time dependent manner, associated with the
acquisition of DNA binding potential.
In the presence of protease inhibitors the human receptor still 
sedimented at 48 when analyzed on high salt gradients at 4°C, after prior
X'f—
activation. Some tumour ER showed aggregation, resistant to 0.4M KCl 
conditions. Similar profiles were obtained in 0.15M KCl gradients. However, 
without previous warming and when extracted with buffers containing 0.15M 
KCl, the receptor sedimented at 6S at both 4°C and 2CP C centrifugation in
0.15M KCl gradients. At elevated centrifugation run temperatures the 
presence of protease inhibitors (DFP, Leupeptin) were found to be essential 
to observe the 6S form. The data suggests that the formation of 6S complex 
in isotonic conditions is dependent on the concentration of the 8S complex 
present in low salt. The 68 complex was found to be sensitive to>0.15M 
KCl and dissociated into the 48 form, even in the presence of DFP. It is 
therefore concluded that the possible reasons for low levels of DNA binding 
obtained with human tissue results from both proteolysis and aggregation 
of receptor on activation (30°, 30'). Proteolysis probably causes loss 
of the DNA binding site and aggregation masks this site. The 68 form 
observed with human receptor is similar in nature to the activated 58 form 
obtained from immature rat uterus. Thus, the 68 complex detected at 20°C, 
under defined conditions, may represent the activated form. It may be 
analogous to the progesterone receptor dimer.
Models are proposed for the interaction of the various sub-units
involved in function of ER in vivo.
c —  ----
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1. INTRODUCTION
1.1 PART A STEROID-RECEPTOR INTERACTION
1.1.1 Control and Regulation Mechanisms in Higher Organisms
The orderly development and co-ordinate functioning of higher 
organisms implies the existence of sophisticated control mechanisms.
In the human body, two control mechanisms (i) the central nervous 
system (CNS) and (ii) the endocrine system, meet this requirement.
The electrical signals from the CNS are the mediators of the voluntary 
and involuntary actions. The chemical signals (hormones) released 
from the endocrine glands are required for the co-ordination of meta­
bolism. Some interaction of the two control systems is now recognized.
The endocrine glands are ductless tissues which secrete the 
hormones directly into the blood stream. Whereas the response initiated 
by the CNS is usually instantaneous, responses initiated by hormones 
may be much slower, ranging from as little as a few seconds to as 
long as several days - the so-called short and long term responses.
The term 'hormone' is derived from a Greek word meaning 'I 
excite' or 'arouse', and was first used by Starling in 1905 (Starling, 
1905) in connection with secretin, a chemical which enhances the 
production of pancreatic juice. This led to the definition of a hormone 
as 'any substance normally produced in specific cells of some part 
of the body and carried by the blood stream to distant parts, which 
it affects for the good of the body as a whole'(quoted in Lee and 
Laycock, 1978). However, this is a very general statement (Robison 
et al., 1971) and several chemicals such as the neurosecretions and 
the prostaglandins, which mimic hormones, cannot be regarded in this 
category. The neurosecretions do not enter the general circulation 
and the prostaglandins are not necessarily synthesized by particular
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specialized glands and may, further, act directly on the tissues 
in which they are synthesized.
The endocrine glands, involved in the synthesis and release 
of hormones, are themselves under the influence of environmental 
fluctuations which may increase or decrease their activity. There 
is a close relationship between the neuronal and endocrine systems.
The complex control mechanism of the endocrine system may involve 
both a neural control loop and a feedback chemical control, via the 
blood supply.
Once in the blood stream the hormone will contact many tissues 
and organs. However, response is only initiated in specific organs - 
termed the target organs, and is reflected by appropriate metabolic 
changes. These may include changes in enzyme activity (e.g. by phos­
phorylation and/or dephosphorylation), transport activity and longer 
term responses leading to modulation of growth and cell division. 
Target organs may be sensitive to either one or a combination of 
hormones. Target organs are characterized by the possession of a 
specific receptor for the relevant hormone. The tertiary or quaternary 
structure of the chemical receptors in the target tissue allows only 
the biological hormone to be recognized. For the polypeptide hormones 
e.g. insulin, these receptors appear to be located in the plasma 
membrane. For the steroid hormones they are located in the soluble 
fraction of the homogenate and, therefore, may, in the intact cell, 
be soluble or loosely attached to membrane structures within the 
cytoplasm (Leake, 1976). They may even be present in the nucleus 
(Martin and Sheridan, 1982).
Polypeptide hormone action is still not fully understood. 
Insulin, for example, binds to cell surface receptors (Cuatrecasas,
- 3 -
1974) resulting in the activation of an intracellular messenger system. 
However, intracellular binding sites have been reported (Goldfine and 
Smith, 1976). Both receptor degradation and recycling of cell surface 
receptors may be the cause of detection of intracellular binding (Kahn 
et al., 1981; King and Cuatrecasas, 1981). Alternatively it has been 
suggested that cell surface receptors may be involved in the initial 
short term effects of polypeptide hormones, initiated through a second 
messenger, whilst the long term effects (if any) may occur after hormone 
entry into the cell (Kolata, 1978). This thesis is concerned with the 
molecular mechanisms of steroid hormone action and further analysis will 
be confined to steroid hormones.
1.1.2 General Occurrence of Steroid Hormones in Higher Organisms
There are six classes of steroid hormones represented by oestro- 
gens, progestins, androgens, glucocorticoids, mineralocorticoids and 
the recently included vitamin Dg (cholecalciferol) metabolites (Wecksler 
and Norman, 1980; Pike, 1982).
The sex steroids (oestrogens, progestins and androgens) act 
principally on the reproductive tissues. Reproduction, however, involves 
a complex inter-relationship between different target organs. It seems 
surprising, however, that such simple chemical compounds can produce 
such diverse effects on both metabolic and behavioural patterns.
1.1.3 Steroid Structure
Steroids are relatively small hydrophobic molecules derived 
chemically from the parent compound cholesterol. The strong hydrophobic 
and therefore lipophilic nature of steroids is thought to assist in the 
diffusion of steroids across the cell membrane (see Section 1.1.5.1.2).
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The two main organs synthesizing cholesterol are the liver and 
the intestine. The endocrine glands can, therefore, use plasma cholesterol 
for the synthesis of steroids. However, it has been shown that the adrenal 
cortex, ovaries, and other endocrine glands have the capacity to synthe­
size cholesterol from acetate. In the testis steroids are synthesized 
exclusively from acetate. In addition, Ramsey and Nicholas (1972) have 
shown that the brain also contributes to the body cholesterol pool but 
only to a very minor extent. The body cholesterol pool is therefore a 
balance of the extent of absorption from the diet plus the amount of 
de novo synthesis with excretion. Figure 1 shows the various dehydrogena­
tion reactions involved in the production of the final steroid structure. 
The 27 carbon cholesterol is converted to pregnenolone, a 21 carbon 
compound, by a series of biosynthetic steps common to all mammalian 
steroidal hormones (Baird, 1972). Pregnenolone can then be converted 
to (i) 21 carbon atom progestins, glucocorticoids and mineralocorticoids, 
(ii) 19 carbon atom androgens and (iii) 18 carbon atom oestrogens. Three, 
six membered rings and one five membered ring are common to all steroids 
(Figure 2). The steroid skeleton may be modified by various substitutions
21 22
2
3
Figure 2. Numbering and lettering of steroids
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such as double bonds, hydroxyl groups or ketone groups, either alone 
or in combination. The aldehyde group is less common and is only found 
in association with aldosterone. Biologically active steroids all possess 
an unsaturated A ring. Binding of the steroid to its specific receptor 
is determined by the spatial arrangement of the polar substituents. How­
ever, the nature of binding is largely non-polar due to the mainly non­
polar structure of the steroid (Liao et al., 1973). The structure and 
nomenclature of steroids is fully described by Gower (1979). Interestingly, 
Young et al. (1977) have described steroidal oestrogens in plants, the 
physiological significance of which is unknown.
1.1.4 Oestrogens
1.1.4.1 Synthesis
Oestrogens are involved primarily in the reproductive processes 
in females. Characteristically they have an A ring, bearing a phenolic 
group in position 3 of the steroid nucleus (Figure 3). Diethylstil- 
boestrol (DES), included in Figure 3, is a potent synthetic non-steroidal 
oestrogen which binds to the oestrogen receptor with a higher affinity 
than the natural ligand oestradiol-1^0 . The three-dimensional struct­
ural similarity between DES and oestradiol-1^8 , however, is recognised 
(Duax et al., 1980). Steroidal oestrogens are 18 carbon atom compounds 
with substitutions at various positions in the ring structure. In pre­
menopausal women the principal form is oestradiol-1 which is synthesized 
from cholesterol in the ovary as a result of stimulation by gonadotrophins 
from the anterior pituitary. A second, minor, source of oestradiol-1 
is the adrenal cortex. The ovaries of postmenopausal women synthesise 
little oestrogen. Oestrogen in postmenopausal women is synthesised 
mainly in the adrenal glands by the conversion of 4-androstene-3, 
17-dione to oestrone (England et al., 1974; Gower and
- 7 -
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Fotherby, 1975) and a similar conversion takes place in the peripheral 
tissues (Siiteri, 1978). During human pregnancy, the foetal-placental 
unit also produces substantial amounts of both oestradiol-1^8 and oestrone 
The predominant oestrogen, however, is oestriol, especially during the 
last trimester (De Hertogh and Thomas, 1975), The pathways involved in 
oestrogen synthesis are shown in Figure 4.
In males, oestradiol-1'^ is synthesized in the Leydig cells of 
testes and amounts to one-fifth of that produced in non-pregnant females 
(Longcope et al., 1972).
Once released into the circulation, the activity of the oestro­
gens has to be regulated. Consequently, oestradiol is metabolized to 
less active oestrone with which it forms an equilibrium. Oestrone can 
be further converted to oestriol. Other methods of inactivation include 
hydroxylation and méthylation at C-2, oxidation at C-6 and hydroxylation 
at 0-11. These conversions occur mainly in the liver, which is also 
responsible for the conjugation of oestrogens with glucoro.nic acid and 
sulphuric acid rendering the oestrogens more water soluble prior to 
excretion. The sulphate derivatives can be re-used after the removal 
of the sulphate group, as useful metabolic intermediates. For example 
dehydroepiandrosterone sulphate of foetal origin, is an important sub­
strate in placental steroid synthesis. Oestrogens excreted in the urine 
include oestriol, oestrone and oestradiol-l^S, as well as several 
unidentified oestrogens. Approximately 10% of total oestrogen excretion 
is by the faeces.
1.1.4.2 Physiological Actions
The principal actions of oestrogens include the following:-
(a) the development of female sex characteristics and female repro­
ductive organs such as uterus, vagina and mammary glands. During
Figure 4. Pathways involved in Oestradiol and Oestrone
Synthesis (adapted from Lee and Laycock, 1978),
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the proliferative phase of the menstrual cycle, oestrogens promote 
growth and development of the uterine endometrium. During preg­
nancy, both the glycogen and the actomyosin content of the 
myometrium are increased by oestrogens which also help in sensi­
tizing the myometrium to the stimulatory actions of oxytocin,
2+
perhaps by making available the free Ca ions (Lee and Laycock,
1978),
(b) the proliferation during pregnancy of the mammary ducts in pre­
paration for lactation,
(c) in combination with progesterone, oestrogens are involved in
the controlled development of the embryo,
(d) oestrogens regulate the hypothalamus and the anterior pituitary
glands through positive or negative feedback loops. Oestrogens 
also regulate the activity of cortisol and thyroxine by increasing 
the concentration of transcortin and thyroxine binding globulin
by regulating their synthesis in the liver, and
(e) some of the general metabolic effects of oestrogens include
mild retention of water and sodium, lowering of plasma cholesterol 
concentration, fat and bone metabolism and the stimulation of 
cervical mucosa, making the mucus thinner and more alkaline for 
the survival and capacitation of spermatozoa.
The elucidation of the mechanisms by which the above-mentioned 
processes are brought about was greatly assisted when it became possible 
to designate 'oestrogen target tissues', as those which contained specific 
oestrogen receptors. It should be noted that not all the oestrogenic 
responses, for example water retention, are necessarily mediated by 
receptor-genome interaction (Tchernitchin, 1979).
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1.1.4.3 Development of the Concept of Receptors
The physiological responses to oestrogens have been recognised 
for several years but the biochemical mechanisms by which these responses 
are mediated and regulated are far from understood,
A major advance was made with the assumption that receptors were 
involved in the action of hormones (Szego, 1957; Hechter and Halkerston, 
1964; Bush, 1964). It was assumed that the distribution of receptors 
determined tissue specificity and that the nature of the hormone-receptor 
complex controlled the tissue response. Jensen sind Jacobson (1962) demon­
strated that with tritium labelled oestradiol-1'^, rat uterus, and vagina 
selectively bound and retained the steroid, unlike the non-target tissues. 
It was also demonstrated that oestradiol was retained in the unmetabolized 
form. Thus, it was proposed that target cells contain specific receptors 
which combine with oestrogen to form a complex. The sequence of events 
which constitutes the uterine response to oestrogens was thought to be 
receptor mediated. These studies were extended by Noteboom and Gorski 
(1965) who reported that the oestrogen receptor is stereo-specific and 
probably a protein. After in vivo administration of oestradiol-1^8.
Toft and Gorski (1966) detected the specific binding to an intracellular 
protein in the soluble uterine extract. Toft et al. (1967) identified 
it by sucrose density gradient analysis (SDGA) in wholly in vitro experi­
ments. This also confirmed the earlier results of Talwar 
et al.(1964) who had shown separation of a protein bound fraction from 
free tritiated oestradiol using sephadex chromatography.
The proposal that uterotrophic action of oestradiol depends on 
its binding to specific receptors, was substantiated by experiments with 
specific binding inhibitors such as nafoxidine which was known to inhibit 
the characteristic uterotrophic response of oestrogens and was shown
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to compete for the receptor (Lerner et al.,1958; Jensen, 1962; Callantine 
et al., 1966). Actinomycin D and puromycin also blocked the uterotrophic 
action (Ui and Mueller, 1963) but these did not decrease the uptake and 
binding of hormone (Jensen, 1965) suggesting that these inhibitors act 
at later stages in a sequence of biochemical events in which the hormone 
receptor binding is an early step. The finding that in vivo binding can 
also be achieved in vitro (Terenius, 1966) permitted rapid analysis of 
receptor properties.
As detailed investigations were undertaken it was realised that 
the interaction of oestrogen with uterine cells is not a simple associa­
tion effect. Using autoradiographic and ultracentrifugation techniques 
radioactive hormone was found to be located in two separate regions 
(Leblond, 1951; Toft and Gorski, 1966; Toft et al., 1967). The data 
indicated that bound receptor was principally associated with the soluble 
and nuclear fractions. This led Jensen to propose a two step model for 
the interaction of oestrogen with the uterus (Jensen et al., 1967; see 
Section 1.1.5).
Other target organs identified through retention of labelled 
oestradiol-1^5 were the hypothalamus (Eisenfeld and Axelrod, 1966) and 
the mammary glands (Sander, 1968). Recently reports ^have been published 
which indicate that in addition to the abundance of oestrogen receptor 
in the target tissues, there are low concentrations of high affinity 
oestrogen receptor in what previously were considered as non-target 
tissues. These include the liver (Aten et al., 1978), kidney (Li et al..
1974), adrenal glands (Muller and Wotiz, 1978) and ovary (Richards et al.. 
1976). In the mammalian liver, for example, oestrogen enhances the pro­
duction of plasma renin substrate, some blood clotting factors and some 
other serum proteins. In the ovary, oestrogen receptor may be involved 
in modulating binding of follicle stimulating hormone and, therefore,
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corresponding follicular development (Gorski and Gannon, 1976).
1.1.4.4 General Properties of Oestrogen Receptor
The proteinaceous nature of oestrogen receptor was demonstrated 
by Toft and Gorski (1966). King (1968), using chromatographic purifica­
tion, confirmed this observation. Oestrogen receptor was found to be 
sensitive to pronase but not to nucleases (Toft et al., 1967; Korenman, 
1968). Mester et al. (1970) demonstrated the pH profile of oestrogen 
receptor and the optimum value was found to be pH 7. No binding was 
observed below pH 6 or above pH 9. Thus, ionic charges on the protein 
molecule influence receptor oestradiol interaction. The importance of 
sulphydryl groups for the binding of the oestrogen molecule has been 
demonstrated (Jensen et al., 1967; Terenius, 1967; Muldoon, 1971). The 
relevance of the sulphydryl group in oestrogen-receptor interaction in 
human breast cancer cytosol has been noted by McGuire and De La Garza 
(1973a)who further confirmed the heat lability of receptor. Receptor 
activation (Section 1.1.5.3) is also shown to depend on intact sulphydryl 
groups (Young et al., 1975; Nielsen and Notides, 1975; Kalimi and Love, 
1980; Kalimi and Banerjee, 1981). ^ eightley et al. (1978), conversely, 
did not find inclusion of thiol reagents beneficial for oestrogen- 
receptor interaction. It has been suggested that steroid receptors are 
metalloproteins (Shyamala, 1975) and that activation causes an allosteric 
change, involving the altered availability of metal ions (Schmidt ^  
al., 1981). The metal ion is thought to be located close to the DNA bind­
ing site. King et al. . (1978) demonstrated that protein conformation 
is an integral part of receptor for determining its association with 
oestrogen. Lyophilisation has been shown not to alter the protein con­
formation (Koenders et al., 1978, 1980).
The appearance of a peak concentration of oestrogen receptor
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during the rat oestrous cycle is controversial (Fehertv et al., 1970;
Lee and Jacobson, 1971; Kielhorn and Hughes, 1977; Fishman and Fishman,
1979). The picture has been further complicated by the report of White 
et al. (1978) who found no variation in the oestrogen receptor levels 
throughout the oestrous cycle. In the human endometrium, Soutter et al. 
(1979) have reported a peak value of nuclear oestrogen receptor at day 
9 of the menstrual cycle. Bayard et al. (1978) and Follow et al. (1981), 
have presented results similar to Soutter et al. (1979) and in addition 
have shown that cytoplasmic progesterone receptor concentration is high 
in the proliferative phase and declines in the early luteal phase. These 
studies have demonstrated that subcellular distributions of oestradiol- 
V7^ and progesterone receptor reflect the plasma concentration of the 
respective hormones. A change in the affinity of the receptor for oestra­
diol during the oestrous cycle has been reported, perhaps indicating 
some form of regulatory phenomena (Buchi and Keller, 1980).
1.1.5 Molecular Mechanisms of Steroid Hormone Action
Figure 5 illustrates the general concept involved in the mechanism 
of steroid hormone action. This general model was put forward in 1968 
by two independent groups (Gorski et al.,1968; Jensen et al.,1968). After 
several years of intensive investigation, the general principles still 
hold true. However, modifications in the overall scheme have been 
suggested (Linkie and Siiteri, 1978; Sheridan et al., 1979; Martin and 
Sheridan, 1982).
After its entry into a target cell, the steroid is bound by specific 
receptors. The possession of specific receptors defines a target tissue 
(Jensen and DeSombre, 1972; Leake, 1976). The steroid-receptor complex 
then undergoes some form of ill-understood transformation or activation
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process (see Section 1.1.5.3). The receptor then translocates to the 
nucleus, binds to the chromatin and results in the modulation of transcrip­
tion (Leake,1981a) of certain specific messenger ribonucleic acid (mRNA) 
molecules (Aziz et al.,1979). This leads to the synthesis of certain 
specific proteins. Much work has been done on the kinetics of regulation 
of ovalbumin and conalbumin mRNA synthesis by oestrogen and progesterone 
in the chick oviduct (Mulvihill and Palmiter, 1980).
1.1.5.1 Mechanism of Steroid Entry into the Cell
1.1.5.1.1 Steroid Hormone Binding Proteins
Hormones are released into the blood stream by the endocrine 
glands.The steroids are then transported in the blood stream by sex 
hormone binding globulin (SHBG) and albumin (Clark and Peck, 1979) and 
other plasma proteins. The blood proteins bind steroid with varying affin­
ity and the free hormone level determines the amount of steroid available 
to the tissue (Westphal, 1970). An additional function of these binding 
proteins seems to be the protection of the steroid from metabolism 
(Westphal, 1971, 1980).
1.1.5.1.2 Steroid Entry : Passive Diffusion or Facilitated Uptake?
■It is generally believed that steroids enter target cells by 
passive diffusion (Higgins and Gehring, 1978) which explains steroid 
entry into both target and non-target cells (Jensen and Jacobson, 1962). 
However, the facilitated transport mechanism proposed by Milgrom et al. 
(1973a) cannot be ruled out. These authors demonstrated that by using 
sulphydryl blocking reagents, oestrogen uptake by target cells was 
inhibited. However, Peck et al. (1973a),using different sulphydryl block­
ing reagents from Milgrom's group, could not repeat the results. In 
addition,studies have been reported indicating involvement of a rate
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limiting step in oestrogen uptake (Baulieu, 1973) but these have been 
contradicted by Williams and Gorski (1974) who provided evidence that 
rate limiting steps could result from artifacts.
Studies of Pietras and Szego (1977), using affinity chromato­
graphy, have demonstrated the existence of oestrogen binding sites on 
the surface of endometrial and liver cells . These sites were not found 
on non-target intestinal cells. Similar findings were reported by others 
(O'Malley and Means, 1974; Wittliff, 1975). Recently Pietras and Szego 
(1979) and Mueller et al. (1979) have demonstrated specific oestrogen 
binding sites associated with uterine plasma membranes. Enzyme digestion 
involved in the preparation of cells could result in an abnormal distribu­
tion of receptors or the binding sites could represent 
steroid metabolizing enzymes. Affinity of the binding was not always 
reported in these studies.
Interestingly, Terayama et al. (1976)have demonstrated that some 
plasma membrane steroid binding sites are lost during malignant trans­
formation of cells, perhaps reflecting the de-differentiation process. A 
similar loss of oestrogen binding sites from plasma membrane of neoplastic 
breast tissue, in contrast to non-neoplastic tissue, is reported by 
Zanker et al.(1981) who further suggested that, in normal cells, receptor 
at the plasma membrane may be serving as the modulator of intracellular 
hormone levels, protecting the cell from excess exposure to hormone.
The studies of Nenci et al. (1980a, 198 1), using fluorescent 
oestradiol-1'^, have indicated involvement of plasma membranes in the 
initial uptake of oestradiol. However, these studies should be inter­
preted with caution due to the very high concentration of fluorescent 
oestradiol used (Chamness et al. , 1980;Penney and Hawkins, 1982), and 
the low temperatures involved (4°C) which are known to alter the cell
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membrane.
It appears that the major difficulty in the interpretation of 
results on uptake is the failure to distinguish between binding of steroids 
to receptor and to other proteins. Based on various studies, Rao (1981) 
has suggested that perhaps both passive and facilitated processes may 
be involved in steroid uptake.
1.1.5.2 Cytoplasmic Binding of Steroid
After its entry into the cell the steroid must be retained over 
several hours for responses to be effected (Anderson et al.,1972). The 
receptors are characterized by their high affinity (dissociation constant 
value of 10 - 10 ^M) low capacity and high specificity (Shyamala and
Gorski, 1969; Giannopoulous and Gorski, 1971). Low affinity sites are 
also detected (dissociation constant 10 ^ - 10 ^M) and probably represent 
non-specific sites (McGuire and Julian, 1971). King (1975) has indicated 
that the high affinity sites are the physiologically important ones for 
response. The possession of these highly specific sites is a prerequisite 
in defining a target tissue (Folca et al.,1961; Higgins et al., 1973a).
It has been estimated that there are between 10,000 and 20,000 receptor 
molecules per cell in target tissues (a/10*"^ M). However only 2000 of 
these are required for response (King and Mainwaring, 1974; Leake, 1981a). 
The remaining receptor is thought to concentrate steroid from the blood 
(Clark and Peck, 1979).
In addition to the high affinity receptors, another form of 
specific cytoplasmic receptor has been reported with a dissociation 
constant value ofrvlO ^M (Clark et al., 1978; Eriksson et al., 1978; Smith 
et al.,1979; Clark and Markaverich, 1981). These latter sites are termed 
type II sites, in contrast to the classical type I sites. Type II sites 
do not translocate into the nucleus and are more abundant in the target
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cells than are the type I (high affinity) sites. The type II sites have 
recently been demonstrated in human breast cancer (Panko et al., 1981), 
and such sites may have a role in concentrating steroid (Gorski and Gannon, 
1976), or may represent a precursor or product of the type I site. Little 
et al. (1975) have reported an early 3.5S and a late 4.5S receptor entity 
isolated from microsomes. Maturation of receptor may be a prerequisite 
to its transformation and translocation. Such post-translational modifi­
cations are recognised (Blobel and Dobberstein, 1975). The nuclear type 
II sites detected by Eriksson et al. (1978), which are a distinct entity 
from cytoplasmic type II sites, may simply represent a processed form of 
nuclear type I receptors (Horwitz and McGuire, 1978a). Occupancy of the 
nuclear type I sites increases aldosterone-induced epithelial sodium 
transport but no further increase occurs when type II sites are occupied 
(Farman et al., 1978). This lends further support to the idea that 
type II sites are a non-functional form of the receptor.
Fishman and Fishman (1979) have reported yet another heterogeneous 
form of receptor binding site - one form which binds tamoxifen (an anti­
oestrogen) and another which does not. Guilino and Pasqualini (1982), 
using foetal organs of the guinea pig, showed that tamoxifen bound both 
the oestrogen receptor, and another, distinct site.
Lysozymes (Szego, 197%) and microsomes (Little et al., 1975;
Parikh, et al,, 1980) have also been demonstrated to possess the oestrogen
binding sites but the physiological significance of this is unknown.
1.1.5.2.1 Application of Sucrose Density Gradients in the Analysis of 
Cytoplasmic Oestrogen Receptor
A major advance in studying cytoplasmic proteins was made with 
the advent of the technique of sucrose density gradient. Initially, the
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designated value for the oestrogen receptor was 9.5S (S represents Svedberg 
units, representing sedimentation coefficient) in low salt media (Toft 
and Gorski, 1966, Jensen et al.,1968). Later, values of 98 were reported 
(Shyamala and Gorski, 1969; Steggles and King, 1969) and following further 
studies the value of 8-98 was agreed upon (McGuire and Julian 1971;
Shyamala and Nandi, 1972; Jensen et al.,1974). With the advent of radio­
labelled marker proteins it has become possible to be more precise. Some 
variation remains with the 88 entity reflecting perhaps the various 
degrees of aggregation of receptor with itself or non-specific protein 
(Mueller et al.,1972; Stancel et al.,1973a). In high salt gradients 
(0.4M KCl) the results are less variable. Under these conditions receptor 
disaggregates to the 48 form. The 48 form has been assigned a molecular 
weight of between 60,000 and 80,000 daltons (Notides and Nielsen, 1974; 
Yamamoto, 1974). Under isotonic conditions (0.15M KCl) Reti and Erdos
(1971) reported the detection of the 68 form of oestrogen receptor where­
as Yamamoto and Alberts (1974) and Notides and Nielsen (1974) both 
reported detecting only the 48 form.
Analysis of mature rat uterine cytosol in hypotonic conditions 
yields a second peak at approximately 48, in addition to the 88 form 
(King and Mainwaring, 1974). In the immature rat uterine cytosol this 
peak is not always present or is present at very low concentrations.
Uriel et al. (1976) postulated that the 48 peak obtained may be due to 
oC-fetoprotein contamination, which is known to exist in very young rats 
in high concentration and binds oestradiol-1^0 with high affinity. How­
ever, oc-fetoprotein is not present in adult rats, although Laberbara 
and Linkie (1978) could still detect it at 20 days post partum. Using 
diethylstilboestrol, which has a very low affinity for oc-fetoprotein, 
the 48 form can still be detected in adult rat uterus (8ection 3.1.5).
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Both 4S and 8S forms of receptor have also been described in the lacta- 
ting mammary gland (Muldoon, 1978) and human breast cancer (Wittliff 
and Savlov, 1978).
Interestingly, a calcium-derived 48 oestrogen receptor has been 
reported in low ionic strength in the cytosol fraction obtained from 
calf uterus ^ Molinari et al.,1977; Puca et al., 1977). Other reports 
have suggested that mild trypsinization of the 88 form of the oestrogen 
receptor can also result in its conversion into the 48 form which now 
fails to bind to chromatin or DNA (Andre and Rochefort, 1975). However, 
this 48 form still binds to crude uterine nuclei (Rochefort and Baulieu, 
1973). A protease mediated 88 —* 48 conversion has also been observed 
in human breast cancer cytosol (Schneider and Dao, 1977). Park and 
Wittliff (1980) have shown that the 48 receptor from human breast tumour 
cytosol also lacks DNA binding properties. The significance of the non­
aggregating type of 48 receptor is not known. Sica and Bresciani (1979) 
have isolated to apparent homogeneity, the calf uterine oestrogen cytosol 
receptor. A single band of molecular weight 70,000 was observed on poly­
acrylamide gels. However, this probably does not represent the native 
form but the proteolyzed 48 form (Murayama et al., 1980a).
In conclusion, 8DGA has led to the discovery of the presence of 
two or more different 48 populations of oestrogen receptor, (i) a fraction 
which on lowering ionic strength can aggregate with either other oestrogen 
receptors or with other proteins (Murayama et al.,1980b), and (ii) a 
fraction which has lost this aggregation property. It may be significant 
that it is only when the 88 form is present that transfer of oestrogen- 
receptor complex to the nucleus occurs (Lukola et al.,1980).
1.1.5.2.2 Specificity of Oestrogen Receptor
The oestrogen receptor is specific for biological oestrogens.
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It binds oestradiol-1'^ with very high affinity (Kd 10 ^^-10 ^M) but 
oestradiol-17o<. very weakly. It has a very high affinity for certain 
synthetic non-steroidal oestrogenic compounds such as diethylstilboestriol 
(DES) and selected triphenylethylenes (Duax et al., 1980). These non­
steroidal oestrogenic compounds compete effectively with oestradiol-1^# 
for the steroid binding site (Puca and Bresciani, 1968, 1969). Both 
oestriol and oestrone bind receptor but with a lower affinity than 
oestradiol-1'^. These studies have led to the elucidation of the type 
of configuration required by the receptor for specific binding. By using 
various competitive steroids, Hahnel and Twaddle (1974) suggested that 
steroids must have an aromatic A ring, ethanolic hydroxyl group at C-3 
and oxygen function in ring D (Figure 3). Powell-Jones et al.(1975) then 
studied the actual binding of oestradiol-1^3 to the receptor. They con­
cluded that two sites exist on the carbon skeleton : a highly specific 
one at the C-3 hydroxyl group which is involved in the initial attach­
ment, and a less specific site at the ^ -hydroxyl group of carbon-17.
These studies led to the synthesis of various antioestrogens such as 
tamoxifen, and nafoxidine.
1.1.5.3 Steroid Receptor Activation/Transformation
The two terms, activation and transformation of oestrogen receptor 
have been used interchangeably in the literature and this has led to 
much confusion. It would therefore be useful to clarify each one. All 
steroid receptors, including vitamin Dg (Brumbaugh and Haussier, 1974) 
show a temperature dependent activation step which gives the receptor 
an increased affinity for binding to DNA, chromatin and other polyanions 
(Section 1.1.5.5; see also Toft, 1972; Buller et al.,1975; Parchman and 
Litwack, 1977; Miller and Toft, 1978). The accompanied transformation
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process, however, seems to be unique to the oestrogen receptor and in­
volves a 4S to a 5S conversion (Notides and Nielsen, 1975). Other steroid 
receptors do not undergo this transition prior to binding to chromatin. 
Other physical changes in non-oestrogenic steroid receptors, such as 
the isoelectric point of the glucocorticoid receptors have been noted 
and are claimed to distinguish between the activated and non-activated 
receptor (Katzenellenbogen, 1980).
1.1.5.3.1 Activation/Transformation and the Two Step Model
A major advance in the study of steroid receptor interaction 
was made when a relationship between the cytosol and nuclear oestrogen 
receptor complex was detected. The first indication of this phenomenon 
came from the observations of differences between the two complexes on 
sucrose density gradients (Toft and Gorski, 1966). Jensen et al. (1969) 
incubated uterine nuclei with oestrogen in the presence of cytosol and 
found a 5S receptor complex which was indistiguishable from that found 
in the whole uteri. They concluded that the complex was made in the nucleus 
Subsequently it was discovered that the 5S hormone-receptor complex can 
also be obtained in the absence of nuclei (Gschwendt and Hamilton, 1972) 
by warming the cytosol in the presence of oestradiol-1^8. (Sato et al.
(1979) suggest that transformation can occur at low temperatures and 
that oestradiol is not an absolute requirement). It was also shown that 
the transformed receptor, a term used by Jensen et al.(1973),led to 
the stimulation of RNA polymerase in uterine tissue (Mohla et al.,1971; 
Jensen et al., 1972). The conclusion, therefore, was that the alteration 
in oestrogen receptor may be a prerequisite to translocation into the 
nucleus.
Gschwendt and Hamilton (1972) demonstrated that the transforma­
tion reaction was temperature dependent. The process was found to be
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pH and ionic strength dependent i.e. accelerated with increasing pH 
(6.5 — ^ 8.5), and increasing ionic strength (0 - 0.4M KCl). The transforma­
tion process was reduced by the presence of divalent ions and EDTA.
Oestrone was first found to be ineffective in inducing transformation 
(Jensen, etal., 1971a). However, it was later shown to be effective at higher 
concentrations (Rochefort etal., 1972). Oestrone, in a single dose, has sub­
sequently been found to initiate only the early genomic responses in 
immature rat uterus reflecting the shorter nuclear retention time of 
the oestrone-receptor complex (Clark and Peck, 1979). Thus these findings 
strengthened the two step model of Jensen et al. (1968) and Gorski et al.
(1968) indicating that the extranuclear 88 form undergoes temperature 
dependent transformation and is then translocated to produce the 58 
nuclear complex. Greene et al. (1977, 1980) have now shown the similarity 
between the nuclear and cytosolic receptor, using immunological methods.
8alt disaggregated receptor (88 receptor is converted to 48 in 0.4M KCl) 
can also be transformed to the 58 form and 8tancel et al. (1973a) have 
proposed the 48 form as the physiological form of receptor. Under low 
salt conditions it either self aggregates or aggregates with other 
specific or non-specific uterine proteins to form the 88 complex. Recently 
a 48 88 converting protein has been characterized and this protein
is thought to be three times as abundant as the native 48 receptor 
(Murayama et al.,1980b). This protein fails to act on proteolyzed 48 
oestrogen receptor.
Most experimental findings are consistent with the two step model, 
but do not prove it. Munck and Foley (1979), for example, have been able 
to detect non-activated receptor complexes in thymus cells at 37^C after 
very short intervals of exposure to hormone. The initial exclusive 
presence of such a form was rapidly succeeded by the appearance of the
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activated species. The studies of Weichman and Notides (1977, 1979) on 
receptor activation as a function of temperature, receptor concentration 
and ionic strength further lend support to the two step model. Gorski 
and Gannon (1976) have stressed, however, that subfractionation of cells 
may lead to artifactual redistribution of receptors. Nevertheless, 
autoradiographic analysis of receptor distribution in tissues prepared 
under conditions of minimal cellular damage, do demonstrate a temporal 
sequence of specific steroid binding which progresses from the cytoplasm 
into the nucleus (Stumpf and Sarr, 1977). In addition, using cell sus­
pensions, Pavlik et al. (1979) and Munck and Foley (1979) have shown that 
the rate of nuclear accumulation of oestrogen receptor complex is 
measurably slower than the rate of uptake into cells. The studies of 
Nenci (1981) using fluorescent oestradiol would also favour such a view.
1.1.5.3.2 Inhibition of Activation/Transformation
Some results are difficult to reconcile with the two step model. 
In contrast to the temperature dependent transformation in the uterine 
cytosol, which takes place only if the receptor is complexed with an 
oestrogen, the alteration (88— > 58) that accompanies 
ammonium sulphate precipitation proceeds rapidly in the cold and does 
not require oestrogen (Traish et al., 1979). These authors have shown 
that, in the intact uterine cells both at 0°C and 37^C, the activated 
58 complex can be formed in the absence of oestradiol. The rate of 
formation remains temperature dependent. When the uncomplexed receptor 
of calf uterine cytosol is precipitated with ammonium sulphate and radio­
active oestradiol-l^S then added to the redissolved precipitate, the 
58 complex is found ( DeSombre et al.,1972). Nielsen and Notides (1975) 
and 8ato et al. (1978a) were unable to obtain similar results. The latter 
report suggests that the dialysis procedure employed by De8ombre e t a l .
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(1972) to remove ammonium sulphate may have resulted in the transforma­
tion process, indicating involvement of a low molecular weight inhibitor(s) 
of the 5S formation.
Evidence for low molecular weight inhibitors of activation in 
rat uteri, and mouse Leydig cell tumours have been reported (Sato et al. , 
1978a, b* 1979). The rat liver glucocorticoid receptor complex has a 
similar inhibitor (Goidl et al.,1977). Dialysis was found to increase 
the nuclear binding of the oestrogen receptor (Sato et al., 1979) but 
the 5S complex was only observed if the oestradiol-1^0 was added prior 
to SDGA in high salt. Thus these authors have questioned the necessity
of 5S formation prior to nuclear binding. However it should be pointed
out that (i) these studies were conducted in low salt, perhaps resulting 
in spurious binding of receptors to nuclei (which is used as a measure
of activation), (ii) the SDGA in high salt in the absence of oestradiol-
Yljh may well have resulted in the dissociation of the 5S complex back 
into the 4S form and (iii) the extracted nuclear receptor sedimenting 
at 4S rather than 5S could have been a consequence of the very low con­
centration of receptor being loaded onto the gradient. Nevertheless, 
low molecular weight inhibitors do seem to be a common feature for steroid 
receptors (Bailly et al.,1977; Shyr and Liao, 1978; Sato et al.,1979). 
Fishman (1981) has presented an interesting report showing that electro­
lysis of the rat uterus resulted in a marked increase in nuclear binding 
of steroid receptor, a result attributed to removal of an inhibitor. 
Shyamala and Yar-Fen (1977) have also provided evidence for a dialyzable 
substance which inhibits activation in the rat mammary gland.
In contrast to the low molecular weight inhibitors of activation, 
low molecular weight inhibitors of DNA or chromatin binding are also 
described (Cake et al.,1978; Isohashi et al.,1980). Pyridoxal-5'-phosphate
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has been suggested as one such inhibitor (Nishigori and Toft, 1979;
Muldoon and Cildowski, 1980). These factors seem to modulate the binding 
of activated receptor to chromatin and have been shown to be physiologi­
cally important ( DiSorbo et al.,1980). Recently, pyridoxal-5'-phosphate 
has been shown to activate receptor but block subsequent DNA binding 
(Sekula et al.,1982). A class of macromolecular inhibitors may also 
regulate the binding of activated receptor to nuclei, DNA or chromatin 
(Milgrom and Atger, 1975; Liu and Webb, 1977; Simons, 1977; Atger and 
Milgrom, 1978).
Recently it has been reported that, in vitro, ATP can activate 
both the glucocorticoid (Moudgil. and John, 1980) and oestrogen receptor 
(Moudgil and Sssalau, 1980). Further, it has been suggested that inactiva­
tion of oestrogen receptor in the nucleus involves dephosphorylation. 
(Auricchio et al.,1982). This would imply that activated receptor is 
phosphorylated. However, experiments of Nishigori and Toft (.1980) and Sando 
et al. (1979a, b) suggest that activated receptor is dephosphorylated 
and, purified progesterone receptor subunits do not show any phosphory­
lated amino acids (Schrader et al.,1977; Coty et al., 1979). Although 
the nature of the activated receptor, with regard to phosphorylation 
is in doubt, the phosphorylation process is required for the actual 
steroid binding (Sando et al., 1979a, b; Auricchio et al.,1982). Sodium 
molybdate is thought to stabilize receptors (Anderson et al., 1980;
Noma et al.,1980; Krozowski and Murphy, 1981; Ratajazak et al., 1981) 
by inhibition of either phosphatase(s), a direct interaction with receptor 
phosphate groups or interaction with sulphydryl groups.
Sodium molybdate has been found to inhibit the process of activa­
tion and transformation (Leach et al.,1979; Nishigori and Toft, 1980; 
Shyamala and Leonard, 1980; Kalimi and Banerjee, 1981; Muller et al.,
1982; Notides et al.,1982). The inability of receptor to disaggregate
— 28 —
from the 88 form in the presence of sodium molybdate, is thought to be 
the reason for its failure to activate (Grody et al.,1980; Redeuilh 
et al. ,1981; Muller et al.,1982). On the other hand, molybdate could 
retard the dissociation of the inhibitory factors by binding directly 
to them. There is still controversy over whether the molybdate effect 
of preventing activation/transformation is reversible or not (Shyamala 
and Leonard, 1980; Muller et al.,1982; Notides et al.,1982). It is further 
reported that molybdate retards the 4S — => 5S transformation of the anti- 
oestrogen-receptor complex (Rochefort and Borgna, 1981). Other, less 
commonly used inhibitors of the activation/transformation process are 
discussed by Grody et al.(1982).
1.1.5.3.3 The Mechanism of Activation/Transformation of Oestrogen 
Receptor
Calcium activated proteolysis as a means of receptor activation 
(Puca et al.,1972) is now largely discounted because such proteolysis 
of receptor generally leads to the loss of DNA binding properties (Andre 
and Rochefort, 1973).
A second mechanism proposed, confines receptor activation to 
a simple conformational change within the native molecule, leading to 
the exposure of certain acidophilic groups (Bailly et al.,1980; Rochefort 
et al. ,1980). Using kinetic studies in low salt conditions, Bailly et al«
(1980) could only demonstrate a first order plot for receptor activation 
suggesting that other molecules are not involved in activation. These 
authors were using high salt gradients for the separation, of 4S and 
5S forms. This was followed by DNA binding studies to measure the extent 
of activation. Both the 4S and 5S forms bound equally well and hence 
this led to the proposal that activation and transformation are two
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independent events. However, in conducting the DNA binding studies, 
the high salt buffers, in which the 4S and 5S forms are present, have 
to be diluted to low salt. Such a dilution can lead to a rapid formation 
of the 5S form (Notides, 1978), most probably as a result of removal 
of inhibitors on the gradient. Bailly et al. (1980) claim that this 
was taken into consideration. The problem remains unresolved.
In keeping with the simple conformational change, Rochefort 
et al. (1980) found that both the native soluble receptor and the micro-
coccal nuclease extracted nuclear receptor showed similar properties 
in terms of their densities. It is not clear however, whether enzymatic 
treatment leads to some form of modification within the receptor 
structure.
The most popular model for receptor transformation (4S— > 5S) 
is that involving the addition of another subunit(s) to the native 
oestrogen receptor. This could result from either dimerization of the 
4S receptor (Nielsen and Notides, 1975; Notides and Nielsen, 1975) or 
the addition of other protein(s) (Yamamoto, 1974). The immature rat 
uterine oestrogen receptor has been the principal model of investiga­
tion. The transformation process has also been documented in various 
other tissues including the hypothalamus (Fox, 1977) and the pituitary 
(Linkie, 1977). However, this process may not occur in human breast 
tissue (Fazekas and MacFarlane, 1980).
Kinetic analysis of 4S (/v 80,000 daltons ) to 5S ( /\/ 130,000 
daltons) transformation (Notides and Nielsen, 1974; Notides et al.,1975) 
has shown the process to obey second order rate kinetics, independent 
of initial 4S concentration, in high salt buffers. This suggests a 
dimerization process with a similar or a dissimilar macromolecule present 
in approximately the same concentration as the 4S receptor. In low salt
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buffers, in contrast to the report of Bailly et al. (1980), a complex
second order reaction was observed, possibly suggesting the dissociation 
of an inhibitor(s) from the receptor molecule prior to the binding of 
the second subunit(s). The involvement of a second polypeptide(s) was 
also suggested by the studies of Yamamoto (Yamamoto, 1974; Yamamoto 
and Alberts, 1972, 1974). Although studying the same tissue as Notides 
and Nielsen (1974), Yamamoto reported a molecular weight change from 
60,000 daltons for the 4S molecule to 105,000 daltons for the activated 
58 form. Yamamoto has further designated the putative second subunit 
as subunit 'X' of approximately 50,000 daltons. Subunit 'X' was found 
in both 'target' and 'non-target' tissue suggesting that subunit 'X' 
could be a chromatin associated protein, present in the soluble fraction 
as a result of vigorous homogenization.
Notides et al. (1975) have shown that 48 — » 58 transition 
requires an activation energy of ^  21Kcal/mol and this has been sugges­
ted as the energy required to bring about the necessary conformational 
change in the oestrogen receptor providing the increased affinity for 
the second subunit(s). The receptor was shown to undergo drastic con­
formational changes in the presence of urea (Notides and Nielsen, 1974,
1975). The physiological significance of such changes is not known but 
the studies of Katzenellenbogen et al. (1975) and Peck et al. (1973b) 
suggested that the oestrogen-receptor complex is more stable than the 
empty receptor. Further studies have shown that activated receptor 
acquires an increased affinity for oestradiol-1^6, (Weichman and Notides, 
1977, 1979; DeBoer and Notides, 1981).
It is not clear whether the second subunit(s) involved in 
receptor transformation is similar or dissimilar to the native 48 mole­
cule. The data of Thampan and Clark (1981) would suggest that the
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'activation factor' is different to the native 4S receptor. Notides 
et al-(1981), however, have presented evidence of positive cooperativity 
of oestrogen receptor at equilibrium binding, suggesting that the acti­
vated oestrogen receptor is a homodimer. Receptor purification and 
associated studies must allow for dissimilar subunits. The lack of 
detection of such a transformation process for other non-oestrogenic 
steroid receptors may perhaps be due to present technical difficulties. 
Rapid analysis techniques using vertical tube rotors (Jordan and 
Prestwich, 1977) and high pressure liquid chromatography (Pavlik et al. 
1982), may serve to clarify the situation.
It is interesting to compare the transformation process with 
other activation systems. There are several enzymes which show ligand 
induced structural changes, accompanied by a rise in their activity 
(Dunne and Wood, 1975). cAMP, for example, binds to the regulatory sub­
unit of the protein which then leads to the release of the catalytic 
subunit and subsequent activity. It has been noted that cAMP has a very 
similar three dimensional structure to oestradiol-1^4 (Liao, 1975).
1.1.5.3.4 Cellular Site of Transformation
Linkie and Siiteri (1978), using cell free extracts, demon­
strated that 48—»5S transformation takes place in the nucleus in the 
precursor/product fashion. Sheridan et al.(1979) suggest that the unbound 
receptor is partitioned between the cytoplasm and the nucleus according 
to their respective free water content. This equilibrium hypothesis 
is based on the water exclusion theory of Horowitz and Moore(1974). 
Accordingly receptor transformation is not a prerequisite to its trans­
location as previously proposed (Jensen et al., 1968; Puca et al., 1972) 
and the whole process may take place in the nucleus. However, under
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conditions of minimal redistribution as a result of homogenization,
Pavlik et al, (1979) found translocation of oestrogen-receptor complex 
to occur at a slightly slower rate than the rate at which oestradiol-17/6 
was specifically bound to free cells or receptors. Further, Nenci et al, 
(1980b) using fluorescent oestradiol-l^# have demonstrated that in certain 
breast tumour biopsies, a heterogeneity in cell types with respect to 
receptor distribution can be obtained. Certain cells only show the cyto­
plasmic staining, suggesting a defect in translocation perhaps as a result 
of a defect in transformation, whereas the majority of cells show an 
intact translocation process. The cellular site of transformation there­
fore, remains undefined.
1.1.5.3.5 Differences between Activation/Transformation of Oestrogen 
and Progesterone Receptor
The progesterone receptor has been shown to be composed of 
two subunits A and B, both of molecular weight /v 100,000 (Schrader et al. 
1981). These subunits can be separated by ion-exchange chromatography 
(Schrader and O'Malley, 1972). The native receptor sediments as 6-8S and 
is composed of an equimolar amount of A and B subunits (Schrader et al., 
1975; Schrader et al., 1977). Processes which transform oestrogen receptor 
lead to the dissociation of the progesterone A-B dimer into individual 
subunits sedimenting at 48. Only subunit A shows an affinity for DNA 
(O'Malley and Schrader, 1972). Subunit B binds specifically to chromatin 
but only to the target tissue chromatin (Schrader and O'Malley, 1978; 
Schrader et al., 1981). Theory suggests that the A-B dimer binds to
specific acceptor sites after which subunit A dissociates and functions 
as a DNA unwinding protein. This then leads to increased transcription.
It is only the 68 complex which increases the in vitro transcription
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(Buller et al., 1976) and the nuclear uptake of 6S complex has been found 
to be temperature independent (Schrader et al., 1972). This suggests that 
the 6S complex is physiologically important and that either the active 
6S complex is extracted from cells or that the active 6S complex is gener­
ated in vitro.
Schrader and O'Malley (1978) have extended the progesterone 
model to other steroid receptors, a proposal which has lately come under 
criticism (Gschwendt, 1980). The latter report has shown that the two 
components of oestrogen receptor are not present in equimolar amounts, 
the non-DNA binding receptor can be transformed into a DNA binding form 
and that proteolysis of receptor leads to the appearance of a single peak 
on the gradients, unlike progesterone receptor where two peaks are observed 
(Schrader et al., 1981). Based on their studies with oestrogen receptor. 
Notides et al. (1981) have suggested that the A and B peaks identified
on DEAE-cellulose chromatography may represent the non-activated and the 
activated form of the progesterone receptor. Furthermore, more than 80% 
of the oestrogen receptor is capable of DNA binding in contrast to the 
predicted 50% if the situation was analogous to the progesterone receptor 
(Gschwendt, 1980). This however, does not rule out the possibility that 
a second non-oestrogen binding component is involved in receptor activation.
Spelsberg and Boyd-Leinen (1980) have shown that the two com­
ponents of the progesterone receptor undergo seasonal variation. However, 
the possibility that the two components of progesterone receptor arise 
as a result of a specific limited proteolytic cleavage of the parent molecule 
cannot be ruled out (Schrader, 1982).
1.1.5.3.6 Activation/Transformation in other Systems
It must be emphasised that the above studies of the mechanism 
of activation have been conducted with animal models. Species as well ^5
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organ differences may be obtained with respect to transformation 
Linkie, 1977). Park and Wittliff (1977) have reported that the oestrogen 
receptor from the lactating mammary gland of the rat exhibits temperature 
dependent activation but does not show 4S—»5S transition. They have ascribed 
such a difference to the different functions of the receptor in different 
organs. Mouse mammary gland however, has been reported to show a 4S —» 5S 
transition (Muldoon, 1978). The data from human tissue, with regard to 
receptor activation is very limited (Notides, 1978; Fazekas and MacFarlane, 
1980; Sato et al., 1981a).No 4 S — ^ 5S transformation could be shown for 
the soluble oestrogen receptor although the receptor showed temperature 
dependent activation. Thorsen and Stoa (1979) observed a 5S nuclear 
oestrogen receptor from human breast tumour preparations. However, reports 
of nuclear receptors from human endometrium or myometrium, isolated under 
similar conditions failed to show the 5S form of nuclear receptor (Fleming 
and Gurpide, 1980; Katzenellenbogen et al., 1980; Follow et al., 1981).
The detailed analysis by Notides et al. (1976) of human myométrial oestrogen 
receptor transformation established a difference in the mechanism of action 
of the rat and human receptor. They suggested that whereas the 48— > 58 
equilibrium for the immature rat uterine oestrogen receptor transforma­
tion is very much in favour of the 58 form, for the human receptor, it 
is in the opposite direction. The equilibrium in the latter case is very 
sensitive to temperature, ionic strength and receptor concentration.
In conclusion, receptor activation/transformation is not the 
simple process previously envisaged (Jensen et al., 1968). Whether such 
a process is physiologically important and whether second and subsequent 
subunits are involved, is unknown.
1.1.5.4 Receptor Translocation
If it is accepted that, in vivo, unfilled receptor is either
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in equilibrium throughout the soluble fraction of the cell or associated 
specifically with either the cytoplasm or a membrane component, then 
translocation of the filled hormone-receptor complex to the nucleus must 
occur. It is known that high molecular weight compounds tend to diffuse 
very slowly across the nuclear membrane (Paine and Feldher, 1972) whereas 
translocation occurs very rapidly (Sheridan et al., 1979). Gurdon (1970) 
has indicated that nuclear transfer of proteins takes place via nuclear 
pores. The data of Nenci et al. (1980c) would support this observation 
for steroid receptors. It is therefore quite possible that transformation 
of receptor may involve a change in the axial ratio as a requirement 
for passing through the nuclear membrane. It has been shown that the 
steroid remains bound to the same protein in the cytosol and nuclear 
compartments (Greene et al., 1977; Greene and Jensen, 1982). The process 
of translocation has been attributed solely to inherent properties of 
receptor subsequent to binding of steroid because (a) translocation does 
not function efficiently at low temperature (Jensen et al., 1968; Nenci,
198.1 ) and (b) it is reported not to be energy or protein synthesis
dependent (Shyamala and Gorski, 1969).
1.1.5.4.1 Physiological Significance of Receptor Trams formation - 
Translocation Process
The transformation process of oestrogen receptor, accompanied 
by association of other subunit(s) is thought to be required for directing 
rapid binding of the complex to the correct acceptor sites on the chromatin 
(Leake, 1976). Since the transformation process has not been detected 
for other receptors, this raises the question as to whether the second
subunit(s) is a nuclear protein, the acquisition of which leads to tighter
binding of the complex to chromatin.
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Both Thrower et al. (1976) and Thampan and Clark (1981) have 
provided evidence of an activation factor in the rat uterine cytosol.
This is thought to be directly involved in stimulating RNA polymerase. 
This suggestion is based on the evidence that low molecular weight pro­
teins from the cytosol can stimulate chromatin bound RNA polymerase 
(Jacob, 1973; Natori et al., 1973). Furthermore cytoplasmic control 
of gene expression and involvement of regulatory proteins in eukaryotic 
gene regulation is well known (Gurdon and Brown, 1965; Davidson and 
Britten, 1973). In addition, the development of certain tissues is 
associated with the appearance of cytoplasmic proteins in the embryonic 
phase, these are capable of regulating nuclear transcription and further 
development (Brothers, 1976). It is therefore possible that the trans­
formation or activation factor for oestrogen receptor may serve an 
analogous function (Haselbacher and Eisenfeld, 1976). It has been found, 
for example, that in the female rat hypothalamus (McEwen et al., 1974), 
adult concentrations of soluble oestrogen receptor occurs as early as 
day 20 but adult levels of nuclear receptor are only attained on day 
26, that is a 6 fold increase in nuclear binding without a comparable 
rise in cytoplasmic binding (Plapinger and McEwen, 1973). No change 
in plasma oestradiol-1^8 is observed at this time. The studies involving 
post-natal development of rat uterus, indicate that the full range of 
responses, associated with oestradiol-1'^, do not appear simultaneously 
reflecting either the presence of multiple species of receptor, activa­
tion factors or the sequential appearance of specific gene acceptor 
sites (O'Malley et al., 1972; Plapinger and McEwen, 1973; Somjen ^  al. , 
1973). Thus the physiological role of translocation in carrying gene 
recognition or activation factors into the nucleus is still in doubt. 
Powell-Jones et al. (1978) claim that 48—>58 transformation of oestrogen
receptor is not essential for binding to DNA, however whether such a
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4S form can stimulate RNA polymerase remains to be established.
According to the equilibrium hypothesis of Horowitz and Moore
(1974) and Sheridan et al., (1979), unbound receptors would be found princi­
pally in the nucleus of an intact cell. Indeed "empty” nuclear receptors 
have been reported in several systems (Jackson and Chalkley, 1974; Zava 
et al., 1976, Carlson and Gorski, 1977) including human breast tumours 
(Garola and McGuire, 1977; Kato et al., 1978; Panko and McLeod, 1978; 
Thorsen, 1979). These unbound receptors are thought to be inactive, although 
this cannot be stated with certainty. This poses the question as to whether 
it is the oestrogen which is required for the transport of the receptor 
into the nucleus or vice versa?
Studies by Szego (1974) have questioned the biological function 
of receptor. Szego's hypothesis is that the lysozomes carry the steroid 
into the nucleus and the steroid allows the lysozomes to carry certain 
proteins into the nucleus. This poses the question as to whether soluble 
receptor is necessary physiologically. The evidence for and against a 
physiological role of soluble receptor has been reviewed (Clark and Peck, 
1979; Leake, 198ia).
1.1.5.4.2 Defects Associated with the Receptor Activation/tranaformation 
and/or Translocation Mechanism
Impressive evidence that the steroid receptors are bifunctional 
or multifunctional has been obtained in the studies of genetic variants 
of mouse lymphoma cells in tissue culture (Sibley et al., 1974). Yamamoto 
et al. (1976) have studied the receptors of nt" mouse lymphoma cells
in detail. Whereas only 8-20% of nt“ receptor enters the nucleus no defect 
in the activation process is seen. However some differences from the wild 
type receptor are seen after SDGA. No detectable alteration in the prop­
erties of the nucleus was observed. Changes, therefore, in size or
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conformation of nt receptor must explain why they fail to translocate. 
Another type of defect has been detected in a receptor containing steroid 
resistant variant of human lymphoid cells (Schmidt et al., 1980). In this 
type of defect a stable form of activated complex cannot be formed.
In an oestradiol independent mouse mammary tumour, physiological 
concentrations of cytoplasmic receptor but no nuclear receptor could be 
detected (Shyamala, 1972). A defect in the cytoplasmic receptor was 
indicated. Some of the 'false positive' breast tumour biopsies from humans 
(Section 1.2.3.2), the so-called +/o type (Laing et al., 1977), could 
also be explained on a similar basis. Thorsen and Stoa (1979) further 
substantiated these observations of translocation resistant receptors 
in some breast tumour biopsies.
A 4S cytoplasmic receptor has been reported in some human breast 
tumours (Kute et al., 1978). This 4S receptor seems to be present in a 
form which cannot be activated (Wittliff et al., 1978) and does not bind 
to DNA (Park and Wittliff, 1980). On the basis of their clinical follow- 
up, Wittliff and Savlov (1975) have claimed that 4S receptor is found 
predominantly in the tumour cytosol from patients unresponsive to endo­
crine therapy. Conversely, the response rate is maximal if the 8S form 
of the receptor can be demonstrated (results from others have not substan­
tiated this claim - see section 1.2.4). Using dissociation kinetics 
Kaufman et al. (1982) have detected defective activation of androgen
receptor-complexes in androgen insensitive patients.
It is most likely that the unresponsiveness of receptor contain­
ing cells to hormones is due to a defect in the activation/transformation 
and/or the translocation process. However some unresponsiveness could 
be explained by considering post-chromatin binding defects (Brushovsky 
et al., 1975).
39 -
1.1.5.5. Nuclear Binding of the Steroid-Receptor Complex
1.1.5.5.1 The Acceptor Site Hypothesis
The term acceptor site has been used to designate the nuclear
sites that specifically bind the steroid-receptor complexes and result 
in a biological response (Leake, 1976). The concept was formulated when 
(a) it was observed that high salt concentration is required for extrac­
tion of steroid-receptor complexes from the chromatin, (b) in vitro satur­
able interaction between the nuclei and oestrogen-receptor complexes were 
demonstrated and, (c) in vitro interactions were observed in which RNA 
polymerase was shown to be stimulated by hormone-receptor complex in only 
certain target tissues (Spelsberg, 1976),
Milgrom et al.(1973b) suggested that the receptor may have a 
site for binding hormone and an independent site for interaction with 
chromatin. Recent evidence has substantiated such a view (Khan et al.,
1980; Myatt et al., 1982a, b).
Several components of the nucleus have at different times been
proposed as the acceptors for the steroid-receptor complexes (Gorski and
Gannon, 1976). However, the bulk of evidence is now in favour of the 
tightly bound non-histone proteins (Spelsberg et al., 1971; King and Gordon 
1972; Puca et al., 1974, 1975; Mainwaring et al.,1976) with a subsidiary 
role for DNA (Clemens and Kleinsmith, 1972; Higgins et al., 197 3a;
Musliner and Chader, 1972; Yamamoto and Alberts, 1975).
The chromosomal non-histone protein fraction AP^ (a group of 
acidic proteins) which binds progesterone receptor has received most atten­
tion (Spelsberg, e^aj. 1972; Spelsberg et al., 197^). The acceptor protein 
is found to be tightly bound to DNA, sensitive to protease but not to 
nuclease and is confined to and generally distributed within the chromatin.
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This acceptor is active in target tissue and masked in non-target tissues 
(O'Malley et al., 1972; Chytil, 1975; Pikler et al., 1976; Spelsberg 
and Toft, 1976). Non-histone protein acceptor activity has also been 
demonstrated in human mammary tissue (Charreau and Baldi, 1977). However, 
chromatin reconstitution, on which many of these studies are based, is 
a controversial technique which has been shown to give rise to a number 
of artifacts (Biessman et al., 1976; Fulmer and Fasman, 1979; Stein, 1979)
The direct involvement of DNA in the acceptor activity was con­
cluded from several studies. DNAase treatment abolished acceptor activity 
(Shyamala-Harris, 1971; King and Gordon, 1972) and Marver et al. (1972) 
demonstrated that preheating of nuclei or RNAase activity did not diminish 
acceptor activity. King and Gordon (1972), Spelsberg (1974) and Leake 
(1976) concluded that both DNA and chromatin were involved in the acceptor 
activity in an essential three dimensional conformation which may be 
altered as a result of cell disruption.
Recently, Thrall and Spelsberg (1980) have confirmed that non­
histone protein-DNA complexes show the characteristics of native acceptor 
sites. Studies to isolate the regulatory sequence of DNA are under way 
in several laboratories. Recombinant technology has led to the isolation 
and molecular cloning of certain steroid specific genes (Dugaiczyk et al., 
197g; Gannon et al., 1979; Payvar et al., 1981). Purified receptors com­
plexed to steroid stimulate the transcription of these genes. The egg 
white protein genes are perhaps the best characterized. Compton et al., 
(1982) have shown that the subunit A of the progesterone receptor binds 
selectively to the ovalbumin gene fragment. Mulvihill et al. (1982) have 
identified a consensus sequence for egg white protein which further lends 
support to the idea of specific DNA sequence involvement in the genomic 
binding of steroid receptors. It is of interest in this context that when
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cloned sequences of genes for glucocorticoid-induced proteins are intro­
duced into non-target cells, their transcription becomes hormone-inducible 
(Buetti and Diggelman, 1981; Hynes et al., 1981; Kurtz, 1981).
The concept of acceptor sites has been subjected to criticism. 
Acceptor site hypothesis predicts a saturable and a second order reaction. 
Chamness et al. (1974) found no evidence of saturation between the oestrogen 
receptor and nuclear sites. However, given controlled experimental condi­
tions, including the use of physiological ionic strength, saturation can 
be obtained (Buller at al., 1975; Spelsberg, 1976). The relevance of the 
saturation process was also questioned by Chamness et al. (1974) but 
recent evidence serves to indicate its importance (following section). Never­
theless , Higgins et al . ( 1973b ) demonstrated that the presence of steroid 
receptor in the nucleus, after in vivo receptor translocation had no 
influence on subsequent translocation in the cell free system.
These conflicting observations have been explained by Yamamoto 
and Alberts (1975) who found that oestrogen-receptor complexes bind to 
DNA with relatively low affinity. On the basis of their results Yamamoto 
and Alberts suggested that there exists a large number of low affinity 
binding sites and few genetically important sites of high affinity. They 
further suggested that the number of low affinity DNA binding sites avail­
able in the cell is vastly in excess of the number of oestrogen-receptor 
complexes and would mask the small number of high affinity sites. The 
loci of these low affinity binding sites is not target tissue specific 
(Yamamoto and Alberts, 1976). The kinetic studies of Williams and Gorski 
(1972) also suggested receptor binding to DNA was independent of high
affinity sites although, again, their study would not have detected a 
small number of high affinity sites.
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Two or three classes of steroid receptor acceptor sites having 
different affinities for steroid-receptor complexes are now proposed 
(DeBoer et al., 1977; Thrall et al., 1978). These sites are detected both 
in vivo and in vitro (Pikler et al., 1976; Spelsberg et al., 1976). 
Quantitative estimates have been based on the assumption that receptor 
binds to acceptor in a 1:1 ratio. The highest affinity sites (dissociation 
constant (Kd) of 10 ^^M) must be filled before any physiological response 
is observed. These approximate to about 100 sites/cell and are most 
probably fully saturated at plasma steroid concentrations. However, the 
number of sites to be occupied for a full physiological response has been 
estimated to be about 2,000 sites per cell (Clark and Peck, 1979). Occupa­
tion of the highest affinity sites has been shown to result in an increase 
of RNA polymerase II activity. Binding of the receptor complex to a second 
class of acceptor is required for RNA polymerase I activity (Spelsberg,
1976). The third class of chromatin binding sites, the lowest affinity 
sites, most probably comprises non-specific binding. Tsai et al. (1975), 
employing isolated chick oviduct chromatin and a rifampicin challenge 
assay, concluded that oestrogen treatment almost doubles the number of 
new initiation sites for RNA synthesis and, therefore, it seems that a 
large number of gene loci are involved with specific binding of the oestrogen 
receptor complexes to acceptor sites. However, the studies of Tsai et al. 
(1975) used Escherichia coli (E.coli) RNA polymerase and were subject 
to criticism. A repeat experiment using hen oviduct RNA polymerase gave 
similar results (Tsai et al., 1976) and showed that there was a preferen­
tial transcription of the ovalbumin gene. Progesterone treatment also 
showed a similar increase in initiation sites (O'Malley et al., 1976). 
However, the continual use of E.coli RNA polymerase (Schwartz et al.,
1977; Towle et al., 1977) has been severely criticised by Palmiter and 
Lee (1980) who concluded that E.coli RNA polymerase does not recognise
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steroid hormone induced changes in oviduct chromatin. Nevertheless, it 
is clear that hormonal treatment, both in vivo (Tsai et al., 1976) and 
in vitro (O'Malley et al., 1977) leads to changes in the chromatin struc­
ture as reflected in increased initiation sites. Similar results for 
initiation sites under androgenic control are reported by Davies et al. 
(1979). One major problem in these studies is that the initiation site 
numbers are always far in excess of both available RNA polymerase mole­
cules and the number of acceptor sites required for full physiological 
response (Clark and Peck, 1979). This suggests that even homologous RNA 
polymerase molecules may recognise spurious initiation sites or that the 
assumptions made in the analysis of data are false. Alternatively, these 
sites could arise during chromatin extraction procedures (Leake, 1976; 
1981a).
1.1.5.5.2 The Induction of Response
Although the exact relationship between acceptor sites and 
biological response remains unclear, a number of studies have correlated 
physiological response with the occupancy, quantity and retention of 
steroid-receptor complexes in the nucleus (Anderson et al., 1973; Spelsberg, 
1976; MeKnight and Palmiter, 1979; Mulvihill and Palmiter, 1977, 1980;
May and Knowland, 1981).
Historically, Billing et al. (1969) first demonstrated that 
increased RNA synthesis is an 'early uterine response' to oestrogen. This 
included the production of mRNA for a specific soluble protein (Baulieu 
et al., 1972). Further, it was shown that only the oestrogen complexed 
to receptor was able to stimulate RNA synthesis in a tissue specific manner 
(Noteboom and Gorski, 1963; Gorski, 1964; Raynaud-Jammet and Baulieau,
1969 ; Jensen et al., 1972).
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Classer et al. (1972) noted that the first indication of oestro­
gen stimulation in rat uterus was a rise in RNA polymerase II activity 
followed by a similar rise in RNA polymerase I activity. The rise in 
polymerase I was shown to be dependent on the rise in polymerase II and 
was cycloheximide sensitive (Borthwick and Smellie, 1975).
Modulation of RNA metabolism reflects most but not all bio­
logical actions of the steroid. Although post-transcriptional effects 
(modifications of heterogeneous RNA, processing or translation) may take 
place (Palmiter and Carey, 1974; Pennequin et al., 1978;), the bulk of 
the evidence is in favour of changes in the transcriptional activity 
(Aziz et al., 1979; Higgins et al., 1979; Leake, 1981a).The rate of trans­
cription of specific target cell genes has been shown to be enhanced by 
a variety of steroid hormones (Baker and Shapiro, 1977; Swaneck et al.,
1979 a,b; Taylor and Smith, 1979). In addition, tissue specific DNAase I 
sensitivity of vitellogenin genes has been shown to take place in Xenopus 
as a result of oestrogenic stimulation (Gerber-Huber et al., 1981) reflect­
ing changes in the structure of specific genes.
The data from Palmiter's group (Palmiter et al,, 1976;
Mulvihill and Palmiter, 1980) has shown that the kinetics of induction 
and appearance of mRNA for different proteins are different. This has 
led to the suggestion of sequential regulation of gene transcription and 
also involves co-operative interaction between steroid receptors at indi­
vidual initiation sites leading to both delayed appearance of certain 
species of mRNA and exponential dose response curves for some proteins 
(Thomas and Teller, 1981). The results of Palmiter et al. have recently 
been criticised by Swaneck et al. (1980), who suggest that, given certain 
experimental conditions, no lag in induction of ovalbumin mRNA occurs. 
Nevertheless, the concept of sequential gene induction is still accepted.
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'Late response' to oestrogen include sustained high activity 
of RNA polymerase I, a second peak in glucose metabolism, and a general 
rise in protein synthesis, DNA synthesis and cell division. Leake ^  al.
(1975) argue that some of the 'late effects' of oestrogen are neverthe­
less, primary responses, that is, dependent on the retention of the oestro­
gen- receptor complex by the relevant high affinity sites. This confirmed 
earlier data (Anderson et al., 1974; Clark and Peck, 1976) that the 
oestrogen-receptor complex must be retained by the nucleus for 6-18 hours 
in order to elicit late responses and subsequent uterine tissue growth.
1.1.5.6 Receptor Processing and Recycling
After the oestrogen-receptor complex has completed its func­
tion it is released from the chromatin (Clark and Peck, 1976). Oestradiol- 
is released from the cell unmetabolised (Puca and Bresciani, 1968) 
and passes back into the circulation. The fate of the receptor is less 
clear. Studies involving RNA and protein synthesis inhibitors have shown 
that, 24 hours after a single injection of oestradiol into immature rats, 
approximately 40% of the oestrogen receptor in the cytoplasm has been 
recycled, that is, the process was independent of mRNA or protein syn­
thesis (Clark and Peck, 1979). The remaining 60% was protein synthesis 
dependent. The cytoplasmic receptor population, therefore, appears to 
be composed of two populations, recycled and de novo synthesized receptor 
(Katzenellenbogen, 1980).
An interesting phenomenon described by Horwitz and McGuire 
(1978a) is receptor 'processing'. This was first described in the MCF-7 
human breast cancer cell line. Receptor processing involves an apparent 
loss of and subsequent release of nuclear receptors, following oestrogen 
interaction. This loss and release of receptor correlates with the
—  4G
appearance of oestrogenic responses such as the induction of progesterone 
receptor (Horwitz and McGuire, 1980). Processing does not seem to involve 
a proteolytic step and has been shown to be inhibited by those intercla- 
ting drugs, such as Actinomycin D, which bind to G-C base pairs, (Horwitz 
and McGuire 1978b, 1980). Actinomycin D does not prevent receptor trans­
location or chromatin binding nor does it bind to the receptor. It is 
suggested that Actinomycin D causes some form of conformational change 
in the DNA, which prevents processing (Horwitz and McGuire, 1980). Other 
inhibitors of RNA and DNA synthesis, including those which interclate 
in the A-T rich regions do not inhibit receptor processing.
Two different types of response are observed when the oestrogen 
receptor from MCF-7 cells is complexed with antioestrogens. The nafoxidine- 
receptor complex, although bound to chromatin. Is not processed 
and as a result, no progesterone receptor induction arises. However, sub­
sequent oestradiol-1'^ treatment results in a much greater progesterone 
receptor induction than that in controls not pre-treated with nafoxidine 
(Horwitz et al.. 1981). Using tamoxifen, an antioestrogen with oestrogenic 
properties in MCF-7 cells, the progesterone receptor was superinduced 
above the levels seen with oestradiol. Tamoxifen does this by markedly 
reducing the early lag phase for progesterone receptor induction. The 
mechanism by which this occurs is not known (Horwitz et al., 1978). For 
nafoxidine action, the two explanations put forward by Horwitz et al.
(1981) are 1) that the receptor remains at the nuclear acceptor sites 
to which it was brought by nafoxidine. When oestradiol replaces nafoxidine, 
a conformational change occurs in the receptor/acceptor complex which 
permits rapid processing; 2) when oestradiol displaces nafoxidine from 
the receptor, the protein moves along the chromatin to another site where 
it is processed. The exact nature of processing remains unclear. Hansen
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and Brooks (1982) have shown that receptor processing correlates with the 
the formation of oestrone receptor and this equals the loss of oestradiol- 
1"^ binding sites. The oestrone receptors so formed, are found in the 
cytosol and do not translocate, resembling the type II oestrogen binding 
sites seen in breast tissue (Watson et al., 1980). There are however, 
other properties which distinguish so formed oestrone receptor from type 
II sites. Firstly, the cytoplasmic type II oestrogen receptor concentration 
remains unchanged during oestradiol-1^# stimulation (Eriksson et al., 1978) 
whereas the oestrone receptor increases significantly following the exposure 
of MCF-7 cells to oestradiol-1^6 (Hansen and Brooks, 1982). Secondly, 
oestradiol-1^6 does not compete for the oestrone receptor in MCF-7 cells, 
whereas both oestrone and oestradiol-1^# are equally effective in the 
inhibition of tritiated oestradiol binding to type II sites (Clark et al., 
1978). Oestrone receptor, may therefore, arise, as a consequence of some 
form of alteration of oestradiol-1'^ type I receptors.
Schoenberg and Clark (1981) have found that the nuclear bound 
receptor resistant to exogenous DNAase treatment corresponds to those sites 
which are processed. This suggests that some of the nuclear receptors are 
involved in a function other than binding to chromatin sites and that only 
this subset of receptors are processed.
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1 . PART B
1.2. OESTROGEN RECEPTORS AND BREAST CANCER
1.2.1 The Mammary Gland
The mammary glands are specialized accessory glands of the skin 
that have evolved in mammals to provide for the nourishment of their off­
spring, which are born in a relatively immature and dependent state.
In their structure and mode of development, mammary glands resemble sweat 
glands. Their differentiation during embryonic life is similar in both 
sexes. In the male, however, little additional development occurs in post­
natal life, whereas in the female the glands undergo extensive structural 
changes correlated with age and the functional condition of the reproductive 
system. The female breast in fully developed by the twentieth year, with 
atrophic changes setting in by the age of 40 and becoming more marked after 
the menopause.
Figures 6A and 6B show the main anatomical parts of the human 
breast and the major sites which are affected by the different diseases 
of the breast. The resting mammary gland is a compound tubuloalveolar gland 
consisting of 15 to 25 irregular lobes radiating from the nipple. The lobes 
are separated by layers of dense connective tissue and surrounded by abun­
dant adipose tissue. Each lobe is provided with a lactiferous duct which 
is lined by stratified squamous epithelium. Beneath the areola each of 
the ducts has a local dilation, the sinus lactiferous. Each lobe is sub­
divided into lobules of various orders, of which the smallest consist of 
elongated tubules, the alveolar ducts, covered by small saccular évagina­
tions, the alveoli. The alveolar ducts open into the ductules. The secretory 
portions of the gland, the alveolar ducts and alveoli, consist of cuboidal 
or colomnar secretory cells resting on a basal lamina and a discontinuous 
layer of processes of myoepithelial cells.
Figure 6A. The nomenclature of the main anatomical sites 
of the breast
Figure 6B. Anatomical sites of the breast affected by 
different diseases
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Pregnancy and lactation bring about changes in the levels of
circulating hormones which result in profound changes in the mammary glands.
This is referred to as the active phase. During the first half of gestation,
there is a rapid growth and branching from the terminal portion of the 
duct system. The growth of the epithelial structure takes place at the 
expense of the interstitial adipose tissue which regresses concurrently 
with the growth of the glandular tissue. In the later months of pregnancy, 
the actual hyperplasia of the glandular tissue slows down. The subsequent 
enlargement of the breast is largely a consequence of enlargement of 
parenchymal cells and distention of alveoli through eosinophilic secretion 
rich in lactoproteins but relatively poor in lipid. This is colostrum, 
the first milk that has special laxative properties and contains antibodies 
which provide the newborn with passive immunity. During the first few days 
after delivery the degree of infiltration of the stroma of the gland by 
lymphoid elements becomes less intense, and the colostrum gives way to 
a copious secretion of milk, rich in lipid. Milk is produced in secretory 
cells lining the alveoli. This then drains into the duct system. Ducts 
in turn open onto the body surface via the teat or nipple.
1,2.2 Hormones, Receptors and Breast Cancer
1.2.2.1 Hormonal Involvement
The mammary gland exhibits absolute dependence on hormonal 
stimulation. The gland remains refractory prior to the onset of the cyclic 
secretion of ovarian hormones at puberty. The extent of development of 
the gland varies between individual species. In rats, for example, the 
growth is limited to extension and branching of the duct system. In the 
human female, however, ductal elongation and development of the alveolar 
system occurs.
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The precise function of the various hormones in promoting mamm­
ary gland development during pregnancy is not clear. It is known that these 
hormones show a very complex relationship, acting individually or syner- 
gistically in controlling breast cell functions. Figure 7 shows the 
relationship between various hormones and the development of the gland 
to the secretory stage.
Hormones, whether polypeptide or steroid, exert their effect 
via specific receptors, which are located in the soluble fraction of the 
cell for steroids and on plasma membrane for polypeptides (Leake, 1976; 
Kolata, 1978). Insulin function is not completely understood. However, 
it is known that the insulin-receptor complex is internalised (Kahn et al., 
1981). Insulin is thought to control the formation of milk secretory cells. 
Glucocorticoids have been assigned the function of controlling the secre­
tory proteins and prolactin is thought to initiate RNA synthesis in 
epithelial cells. Prolactin has been shown to induce oestrogen receptor 
synthesis and its requirement has been found to be essential for the growth 
of experimental mammary tumours (Leung and Sasaki, 1975), Lactogenesis 
is controlled by a combined effect of a number of different hormones 
(Denamaur, 1971). The precise role of individual hormones in lactogenesis 
is species specific (Nalbandov, 1976).
1.2.2.2 Oestrogen Receptor in the Mammary Gland
The normal mammary gland has been shown to contain oestrogen 
receptor, though at low levels (Sander, 1968; Block et al., 1975). Indeed 
selective retention of hexoestrdl in the breast was first observed in 1959 
(Glascock and Hoekstra,1959). It was demonstrated that in addition to 
ovarian and adrenal oestrogen, the mammary gland itself had the capacity 
to synthesize oestrogen (Adams and Li, 1975; Miller et al., 1982). Since
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normal human breast tissue is not readily available, the vast majority 
of studies have used animal mammary gland models to study the complexity 
of hormonal involvement with mammary tissue (Leung, 1978). It was found 
that the level of oestrogen receptor was very low in non-lactating glands 
and that this value increased considerably during pregnancy and lactation, 
although the quantitative levels during pregnancy and lactation are hard 
to establish (Leung et al., 1976; Bohnet et al., 1977; Forsyth and Hayden,
1977). Mammary epithelial and stromal cells both apparently have the capacity 
to synthesize oestrogen receptor.
1.2.2.2.1 Regulation and Molecular Form of Oestrogen Receptor in the
Mammary Gland
The oestrogen receptor has been detected in mouse and rat mammary 
glands (Shyamala and Nandi, 1972; Bohnet et al., 1977), and in human breast 
tumours (Jensen and DeSombre, 1972; Leake et al., 1981). The similarity 
between the rat and human mammary gland oestrogen receptor has been reported 
by McGuire and De La Garza (1973b).It has been assumed so far that oestrogen 
receptor action, at the molecular level, is the same in rat and mouse 
mammary gland, rat uterus and human mammary gland. However, temporal 
differences in oestrogen receptor action in different tissues of the same 
animal have been reported (Linkie, 1977). Again, differences, most
probably at the structural level, between rat and human oestrogen receptor 
are probable (Notides et al., 1976). Differences between rat uterine and 
mammary gland oestrogen receptor have also been documented, perhaps at 
the molecular level (Park and Wittliff, 1977).
On SDGA, in the absence of salt, oestrogen receptor from
immature rat uterus sediments solely at 8S, whereas the receptor ftom mature 
rat uterus can sediment in two peaks, one at 43 and the other at 83
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(Section 3.1.5). The molecular form of rat mammary gland oestrogen receptor 
shows a variation in sedimentation properties which may be related to plasma 
hormonal levels. For example, in early pregnancy only the 48 form is detec­
table while during lactation the 88 form can be demonstrated (Mohla
., 1981). A similar variation is observed in the mouse mammary gland 
and the 88 form was not a result of concentration dependent aggregation 
since dilution has no effect on the sedimentation profile (Muldoon, 1978). 
This latter report also provided evidence that the 88 form of receptor 
has a much longer half life than the 48 form.
The suggested function of the two types of receptor is that the
48 type is involved in mediating acute responses, since these appear to
be present at the time when blood oestrogen concentration is high, and
that the 88 type is involved in mediating long term or sustained response,
when the concentration of hormone may have dropped to low levels. Both
forms of receptor were shown to undergo 48— » 58 transition (Muldoon, 1978).
In contrast Park and Wittliff (1980) have reported that the low salt 48
form of oestrogen receptor from human breast tumours cannot undergo the
48— » 58 transition and bind to DNA and, therefore, perhaps represents a
non-functional form of receptor. It is possible that, whereas in human
tissue the 48 receptor represents proteolytic digest of 88 (Schneider and
Dao, 1977), in the mouse mammary tissue the 48 represents a dissociated
but functional form of the 88 complex, capable of aggregation to the 58
& Baulieu
form. Jensen et al. (1968) and Rochefort/(1971) have both observed that 
the aggregation (to 88) property of salt dissociated 88 complex is import­
ant to its ability to form 58. It is possible that a minor alteration of
the physical state of the receptor may cause dissociation of the 88 complex 
into the 48 form. A similar minor structural change is implied by the change 
in the dissociation constant associated with oestrous cycle (Buchi and 
Keller, 1980). Colvard and Wilson (1981) have assigned a cytosolic protein
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to the role of converting the 4S form of androgen receptor to the 8S form, 
implying that 4S androgen receptor similarly possesses this aggregation 
property.
The results of Gaubert et al. (1982) suggest that the 4S complex 
observed in mouse mammary gland is a proteolytic product of the 8-9S complex 
and represents a similar proteolytic species to that observed in human breast 
tumours (Sherman e^ a]^., 1980; Miller e^ a2., 1981). These results are in 
conflict with the idea proposed by Muldoon (1978) and difficult to reconcile 
with the observed 4S—»5S transition mentioned in Muldoon's study. Both 4S 
and 8S forms might bind to DNA but with different affinities. Although the 
4S— 5S change is not observed in human mammary gland extracts, temperature 
dependent activation of oestrogen receptor can be demonstrated (Park and 
Wittliff, 1977). The proportion of total receptor which can be made to bind 
to DNA is certainly lower than that in immature rat uterus. The small pro­
portion of receptor which can be activated in human breast tissue reflects 
the low level of activation found in rat mammary gland (Sato £t ^ .  , 1981a), 
The proteolytic activity which deprives the 4S receptor of its ability to 
bind DNA would, on this basis, be higher in mammary tissue than in uterus. 
Alternatively, a necessary activation factor(s) might be missing (Thrower 
et a^. , 1976). The heating process involved in the in vitro measurement of 
activation may also lead to aggregation, presumably occluding the DNA 
binding site.
In rat mammary tumours the concentration of both cytosol and 
nuclear oestrogen binding changes during the oestrous cycle (Shih and Lee, 
1978). Freedman and Hawkins (1980), studying the molecular form of oestrogen 
receptor during the oestrous cycle in DMBA induced mammary carcinoma of the 
rat, reported the presence of only the 48 form at pro-oestrous. The 88 form 
was present at all other stages of the oestrous cycle. Once again, plasma 
oestrogen levels are implicated in the regulation of the molecular form of
- 56 -
oestrogen receptor. It seems possible, therefore, that when the blood con­
centration of oestrogen is high, a proteolytic entity (Oestrogen induced?) 
is present (in the soluble extract) which is able to convert the 8S into the 
4S form in a specific manner. Whether such a conversion represent some form 
of ^  vivo regulation of the receptor (perhaps to a form which does not bind 
to nuclei) is unclear. It is possible that the conversion of the 8S form into 
the non-DNA binding 4S form protects the chromatin from excessive oestrogenic 
stimulation. Milgrom e^ (1972) have studied the molecular form of prog­
esterone receptor in the guines pig uterus at different stages of the oestrous 
cycle. The 48 is dominant at pro-oestrous and 8S at all other stages. Toft 
and O ’Malley (1972) also reported heterogeneity of progesterone receptor in 
the chick oviduct. No reports on the molecular form of rat uterine oestrogen 
receptor during the oestrous cycle are known.
Mammary gland oestrogen receptor is stable after ovariectomy (Hunt 
and Muldoon, 1977). Prolactin was found to have no effect on the oestrogen 
receptor from the lactating mammary gland (Bohnet et al., 1977). Prolactin, 
however, has been shown to increase oestrogen receptor concentration in both 
rat mammary gland and uterus and in mammary tumours of intact ovariectomized . 
and ovariectomized-hypophysectomized rats (Leung and Sasaki, 1973; Sasaki and 
Leung, 1974; Vignon and Rochefort 1976; Asselin e_t , 1977). It also pro­
motes the 48 to 8S conversion of oestrogen receptor in the mammary gland of 
the adult virgin mouse (Muldoon, 1978).
Finally, very little is documented about inhibition of oestrogen 
receptor synthesis. Progesterone (Bohnet al.. » 1977; McGuire, 1978; Clark 
and Peck, 1979) and prostaglandin(s) (Jacobson, 1974) are found to inhibit 
oestrogen receptor synthesis. There is evidence that progesterone inhibits 
oestrogen receptor in human endometrium at late follicular phase (Soutter 
et al., 1979).
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1.2.3 The Significance of Oestrogen Receptor in Mammary Carcinoma
When a mammary gland epithelial cell undergoes neoplastic trans­
formation, it could escape the normal influence of oestrogen, and either 
lose the capacity to synthesize oestrogen receptor or become extremely 
sensitive due to switching on and amplification of oestrogen receptor genes 
(Wittliff et al., 1972; Jensen, 1975). The increased sensitivity is not 
confined to female sex tissue and has also been observed in male tumours 
(prostatic and breast carcinoma)(Leclercq et al., 1975; Miller, 1978;
Grilli et al., 1980; Friedman et al., 1981).
Experimental systems which have proved very useful in studying 
control mechanisms in mammary tumours include (i) rodent mammary tumour 
(Topper, 1970), (ii) the DMBA induced, hormone dependent and independent 
rat mammary tumour (Geyer et al., 1953; Young et al., 1963; Hawkins et al.,
1978) and several other experimental mammary tumours (Wittliff, 1979), 
and (iii) the MCF-7 cell line which was originally derived from the pleural 
effusion of a patient with hormone dependent breast cancer (Soule et al., 
1973; Edwards et al., 1979).
There is extensive data that the growth promoting effects of 
oestrogens in mammary tumours (Wittliff, 1979) are receptor-mediated. The 
inherent assumption in all such studies is that the mechanism of steroid 
action is the same in normal tissue and in tumours. The oestrogen receptor 
itself appears to be similar in physical parameters in the rat and human 
mammary carcinoma (McGuire and De La Garza, 1973b).
The pituitary gland has been the centre of many studies since
it was observed that oestrogen alone cannot promote rat mammary tumour 
growth. The presence of prolactin is essential for the response to be 
mediated (Sinha et al., 1973). This finding supports an indirect role of
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prolactin in tumour growth. The involvement of prolactin in increasing the 
concentration of oestrogen receptor has already been presented for animal 
systems (Section 1.2.2.2.1), data for human tumours is very limited.
A relationship between tumour growth and menstrual cycle was 
known as far back as 1836 (Cooper, 1836). However, it was Beatson (1896) 
who first observed tumour regression following oophorectomy, in premeno­
pausal women with advanced breast cancer. Huggins and Bergenstal (1952) 
followed with a report of the efficacy of adrenalectomy in the treatment 
of post menopausal breast cancer patients. Reports by Luft et al. (1958) 
and Ray and Pearson (1958) showed benefits of hypophysectomy in similar 
patients. In all these studies it was obvious that not all patients res­
ponded to ablative endocrine therapy. A discriminant was therefore required 
to select patients who would benefit from surgical treatment, sparing 
those who would not (Baker et al., 1960).
With the development of steroid receptor theory, it was proposed 
that receptor measurements should be used to select the patients who are 
likely to respond to hormone therapy (Jensen et al., 1971b)* This idea was 
influenced by earlier findings that organs responsive to oestrogen had the 
capacity to retain tritiated hexoestrol when the compound was injected 
into rats (Glascock and Hoekstra, 1959; Jensen and Jacobson, 1960) and 
from the findings of Folca et al. (1961) that if the patients undergoing 
adrenalectomy were injected with tritiated hexoestrol prior to surgery, 
then those who responded had selectively retained a higher proportion of 
labelled hormone in the tumour than those who did not. The correlation 
obtained in the studies of Folca et al. (1961), however, was not strong 
enough to adopt the method for routine clinical analysis.
The potential of oestrogen receptor as an index of hormonal 
involvement in growth and development of the tumours was studied in
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various centres (Feherty et al., 1971; Maass et al., 1972; Englesman et al.,
1973). These early findings suggested a high response rate but they were
based on very few patients. The combined results of the Breast Cancer Task 
et al.,
Force (McGuire,/1975a)suggested that over 50% of patients who had cytosolic 
receptor in their tumour biopsies showed a response to endocrine therapy, 
whereas less than 10% of patients without oestrogen receptor, responded. 
Accumulated data suggests that 40-60% of patients with oestrogen receptor 
positive tumour biopsies show regression on hormone therapy (Byar et al., 
1979; Hawkins et al., 1980; Leake, 198lb).Using an extended technique of 
measuring both soluble and nuclear receptor the response rate is reported 
to be just over 70% (Barnes et al., 1979; Leake et al., 1981). It has been 
reported that the possibility of response is increased if receptor con­
centration is taken into account (Jensen, 1975;Leclercq and Heuson, 1977). 
This however, only appears to hold true for premenopausal patients (Hawkins 
et al., 1979) and may simply be an index of the proportion of tumour cells 
in the biopsy.
One important assumption in Jensen's proposal was that both 
local recurrencies and métastasés would show the same characteristics 
with respect to receptor status as the primary lesion. It is however, be­
coming clear that, whilst receptor negative status is generally maintained 
in advanced disease, receptor positive primaries do not always give rise 
to receptor positive secondaries (Leake et al., 1981). There is now much 
evidence that presence of oestrogen receptor in the tumour biopsy can serve 
as a prognostic index (Hawkins et al., 1980; Leake, 1981b).Some authors, 
however, failed to find such a relationship (Bloom and Degenshein, 1980; 
Hilf et al., 1980), while others note that the prognostic value of oestro­
gen receptor may be confined to patients with 1-4 axillary nodes involved 
(Howart & Barnes, 1981). Whether the difference in disease-free interval 
between receptor positive and receptor negative disease is sustained
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beyond 5 years from the primary remains to be seen.
Some receptor negative tumours are found to be fast growing 
(Meyer et al., 197,7) and aggressive in nature (Knight et al., 1977;
Maynard et al., 1978). Patients with receptor negative tumours show earlier 
recurrence rates and shorter survival times than patients with receptor 
positive tumours (Kiang et al., 1978; Bishop et al., 1979; Cooke et al., 
1979; Kinne et al., 1981). Westerberg et al. (1980) have reported a 
quantitative relationship between the receptor content of the primary 
tumour and disease-free interval. Certain pathological features of the 
tumour are also correlated with the hormone dependence or independence 
(Masters et al., 1979; Millis, 1980).
1.2.3.1 'False Negative’ Tumours
Some patients whose tumours contain no detectable oestrogen 
receptor respond, nevertheless, to hormonal manipulation. These patients 
are termed ’false negatives'.
The histochemical localization of oestrogen receptor has demon­
strated the coexistence of oestrogen receptor positive and negative cells 
within the same tumour (Nenci et al., 1976; Pertschuk et al., 1980). Some 
'false-negatives' could thus be explained on the basis of cellular hetero­
geneity in that the assay portion of tumour may have contained only receptor 
negative tumour cells. It is also, obviously, important to check that each 
biopsy assayed does contain sufficient tumour cells relative to fat and 
connective tissue.
One reason for 'false negatives' which cannot be ruled out is 
that some form of structural defect may render the functional receptor 
undetectable by conventional assay. The small group of tumours which con­
tain only nuclear receptor (Leake et al., 1981) could have explained some
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'false negatives' of this type but follow-up data suggests that these
{o/+ or ER /ER^) tumours are normally hormone independent. Histochemical 
c n
and immunochemical methods may be useful in the detection of 'non-oestrogen 
binding' functional receptor, in addition to truly functional receptor.
The validity of histochemical methods, however, has been questioned 
(Chamness et al., 1980; Penney and Hawkins, 1982),
Some of the 'false negatives' could arise as a result of the 
thermolabile nature of receptor. It is possible that receptor could get 
degraded from the time of excision to the time the tumour was assayed or 
stored. However, the two most likely explanations for false negatives are 
(1 ) a biopsy atypical of the tumour as a whole and (2 ) responses of 
tumours to antioestrogens by pathways that are not receptor mediated, such 
as the proposed inhibition of prostaglandin synthetase (Tisdale, 1977).
1.2.3.2 'False Positive' Tumours
'False positive' cases arise when the tumour biopsy shows the 
presence of oestrogen receptor, yet the patient fails to respond to subse­
quent hormonal therapies. This situation occurs more frequently than 'false 
negative' cases. Some of the more obvious reasons leading to such a situ­
ation include inadequate methodology (King, 1976) and imprecise clinical 
assessment (McGuire et al., 1975; Stoll, 1981). Other less obvious reasons 
perhaps contribute to a larger extent and are discussed below.
The cytoplasmic assay measures only the soluble receptor. A 
post-oestrogen binding defect in the sequence of events leading to hormone 
responsiveness, may occur. A defect in receptor structure and/or trans­
forming factor(s) may leave the receptor nonfunctional with respect to 
chromatin binding and growth (Maass, 1975). Evidence for such a defect is 
found in experimental systems including the oestrogen induced hamster
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kidney tumour (King et al., 1970) and the spontaneous GRA mouse mammary 
tumour (Shyamala, 1972). Similar defects occur in the unresponsive cells 
obtained from a glucocorticoid responsive lymphoid tumour (Yamamoto 
et al., 1974).
In some human breast tumours only the soluble receptor can 
be detected (Garola and McGuire, 1977; Singh et al., 1978; Thorsen and 
Stoa, 1979; MacFarlane et al., 1980; Leake et al., 1981). A similar situa­
tion has been observed with androgen receptors from human breast cancer 
(Singh et al., 1979). Tumours in such cases are generally hormone inde­
pendent but on the basis of only soluble receptor they would be classified
as hormone dependent. This class of tumours are referred to as +/o(ER^/ER~)
c n
Patients with such tumours have response rates of only 24% (Leake et al.,
1981) and this may go down even further with increase in the sample 
number.
Nenci et al. (1976) using their immunofluorescent technique, 
have reported independent evidence that such defective receptors can be 
present in breast tumours. They have further suggested that during early 
post-natal development, changes in the permeability of the nuclear mem­
brane to oestrogen receptor may occur to give protection to the tissue 
against circulating oestrogens (see also the possible role of 48 - 
Section 1.2.2.2.1). This suggestion was based on the fact that certain 
breast tumour cells displayed a perinuclear concentration of the fluor­
escent antibody, similar to a pattern observed in the uterus of very 
immature rats. Perhaps, therefore, similar changes may occur in malignant 
cells. However, since the fluorescent technique is probably imaging type II 
sites, this may be an overinterpretation of the data.
There is always the possibility that the receptor itself 
may be functional but the acceptor sites on the chromatin may be defective.
- 63 -
One report indicates such a finding (Charreau and Baldi, 1977). As with 
'false negatives' there are some tumours which show both nuclear and 
cytoplasmic oestrogen receptor but fail to respond to hormone therapy.
It is possible that in such tumours, the nuclear receptors are bound non- 
specifically or are bound to certain altered specific binding sites leading 
to tumour insensitivity. Examples of such malfunctions are found in gluco­
corticoid sensitive hepatoma cells (Thompson and Geleherter, 1971;
Croce et al., 1974), certain glucocorticoid sensitive leukaemias (Lippman 
et al., 1974) and the androgen responsive mouse mammary tumours (Bruchovsky 
et al., 1975)•
It has been demonstrated that target tissues possess the 
capacity to metabolize active oestrogens to less active compounds (Pack 
& Brooks, 1974). Thus, though the receptors may be present, these may 
not be engaged. On the other hand, reports of unfilled receptors (Horwitz 
and McGuire, 1978a) suggest that these may be able to promote oestrogenic 
responses independent of the steroid itself (Zava et al., 1976) and there­
fore ablative or additive hormone therapy may have no effect.
A major factor contributing towards 'false positives' would 
seem to be the heterogeneous nature of tumours with respect to cellularity 
and hence receptor concentration (Braunsberg, 1975; Hawkins et al., 1977). 
In certain cases of intratumoural studies this heterogeneity can actually 
alter the receptor status of the tumour, although such cases are rare 
(Leclercq et al., 1975; Tilley et al., 1978; Hawkins et al., 1979). It 
has also been documented that two tumours taken from the same breast show 
considerable variation (Braunsberg, 1975; Poulsen et al., 1981). Oestro­
gen receptor concentration may also vary from one tumour deposit to 
another (Liskowski and Rose, 1976; Hawkins et al., 1979), Tumours, other 
than breast tumours also show variation in cell types (Marx, 1982).
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Interestingly, some of the large endometrial carcinomas show an 'all or 
none' phenomena with respect to receptor concentration (Castagnetta etal., 
1983). Since breast tumours are composed of such mixed populations of 
cells, it is possible that the hormone independent cells (faster growing) 
may take over, converting the tumour to autonomy. In such cases an initial 
response may be followed by progression.
1.2.3.3 Tumour Markers of Hormone Dependence
Given that detection of both soluble and nuclear oestrogen 
receptor is not an absolute guarantee of physiologically functional 
receptor (Boylan and Wittliff, 1973, 1975; Jensen and DeSombre, 1977), 
other indexes are required which would indicate oestrogen induced responses. 
Several alternatives have been tested. These include caesin mRNA, but 
this was found only in 70% of hormone dependent mammary tumours (Rosen 
and Socher, 1977). Another protein tested has been o^-lactalbumin, one 
of the proteins required for lactose synthesis. However this also was 
not found in all hormone dependent rat mammary tumours, its absence most 
probably reflecting some damage, during malignant transformation, to the 
gene responsible for its synthesis (Ip and Dao, 1978; Hall et al., 1979; 
Woods et al., 1979). Peroxidase has been suggested as a marker for hor­
mone dependent tumours (DeSombre et al., 1975; Lyttle and DeSombre, 1977a). 
It has been shown to be produced by oestrogen action on the rat uterus 
(Lyttle and DeSombre, 1977b) where it may act to cross link uterine proteins 
(Keepings and Jelling, 1978). However the validity of peroxidase has been 
put into question with its detection in both benign and oestrogen receptor 
deficient tumours of mammary origin (Duffy and Duffy, 1977).
Recently, progesterone receptor has gained considerable support 
as a marker of oestrogen dependence. Oestradiol has been shown to stimulate
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the synthesis of this protein within the cell (Asselin et al., 1977). 
Inclusion of progesterone receptor as a marker for hormone responsiveness 
was based on the observation that some mammary tumours contain elevated 
levels of progesterone receptor (England et al., 1975; Horwitz et al.,
1975; McGuire et al., 1976). Martin et al. (1979) suggested that proges­
terone receptor may also serve as an index of hormone responsiveness in 
endometrial carcinoma. Horwitz et ah, (1975) suggested that patients whose 
tumours contain only oestrogen receptor should not be treated with endo­
crine therapy. McGuire's group (McGuire et al., 1977) reported that by 
considering both oestrogen and progesterone receptor, the response rate 
of patients can be elevated. However, both McGuire (1978) and Allegra 
et al. (1979) have found that some tumours containing oestrogen receptor 
but lacking progesterone receptor also responded to hormone therapy. 
Further, Ip et al. (1979) published a disturbing report concerning a hor­
mone independent tumour system, MTW9B, which contains both oestrogen and 
progesterone receptors. Similar hormone indepedence is shown by the mammary 
tumour cell line MXT3590 which nevertheless has detectable progesterone 
receptor synthesis, but does not undergo cell division in response to 
oestradiol. This suggests that there must be a step subsequent to proges­
terone receptor induction which is critical to growth and cell division.
As an alternative marker, Westley and Rochefort (1979) have reported 
three proteins which are a result of oestradiol stimulation and are 
inhibited by tamoxifen. Better still would be the demonstration of 
oestrogen-induced growth in organ or cell culture.
The idea of tumour markers for hormone responsiveness has been 
questioned by McGuire _al. (197 2) who found a mammary carcinoma, R3230 AC 
which is hormone independent with respect to its growth but hormone res­
ponsive relative to oestrogen-induced metabolic changes. However, it may 
be noted that this tumour contains very low levels of oestrogen receptor.
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1.2.4 The Clinical Significance of the Molecular Form of Oestrogen
Receptor in Human Breast Cancer
Some of the immediate aims of present research are to explain 
and, thereby, eliminate 'false positive' cases of hormone dependence. 
Although several markers have been suggested to assess the functionality 
of the oestrogen receptor (see previous section), these have not met with 
much success (Barnes et al., 1979; Thorsen and Stoa, 1979). In order to 
increase the clinical importance of oestrogen receptor in terms of indicat­
ing both potential hormonal response and prognosis, Wittliff and his 
colleagues have suggested that perhaps the molecular form of oestrogen 
receptor may provide a better index (Wittliff and Savlov, 1975; Wittliff 
et al., 1 9 7 6 ; Wittliff et al., 1977; Wittliff and Savlov, 1978). Based 
on the molecular form of oestrogen receptor five classifications of the 
tumours could be obtained. These are (a) no oestrogen receptor, (b) the 
8S form only, (c) the 8S and 4S forms together, (d) the 4S form only and 
(e) oestrogen binding moieties not coincident with either 8S or 4S form 
on SDGA.
In the study of Wittliff et al. (1977), no correlation could 
be obtained between the molecular form of oestrogen receptor and the histo­
logical grade of the tumour. However, there appeared to be a shift towards 
the 4S form from the primary to secondary or metastatic lesions. No signi­
ficant difference in receptor concentration was observed between the 
primary and secondary lesions (Wittliff et al., 1978). The initial clini­
cal correlation showed that none of the patients whose tumours showed 
only the 4S form of oestrogen receptor responded to hormonal therapy 
(Wittliff et al., 1977; Wittliff and Savlov, 1978), whereas 75% of the 
patients whose primaries showed either 8S or 8S and 4S forms of the 
receptor showed objective response to hormonal manipulation. In later
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reports, the response rate of patients with 8S or 88 and 48 containing 
primaries have been sustained but some of the 48 containing tumours have 
also been shown to respond, although with much lower frequency (responders 
33/44 in 88 and 88 + 48 class, responders 4/23 in 48 class; Kute et al., 
1978; Wittliff et al., 1978; Wittliff, 1980). This has led to the idea 
that the 88 form represents the functional form of oestrogen receptor.
It was further demonstrated that only the 88 form binds to DNA (Park and 
Wittliff, 1980).
When the experiments were conducted in buffers containing 0.15M 
KOI, the 88 form in low salt appeared as a 68 peak. No 68 peak in 0.15M 
KOI was seen in cytosols from tumours in which only the 48 form was found 
in low salt gradients. On the basis of such findings, Wittliff et al.
(1977) suggested that receptors in tumours containing the 88 form can 
undergo activation to the 68 form and become functional, whereas receptors 
in tumours containing only the 48 form fail to become functional due to 
the absence of a component(s) required for activation. Another explana­
tion, however, may be that the 48 receptor is defective in its attachment 
of the other subunit(s) and/or its conformational change required for 
activation. It is possible that the 48 receptor may be normal but the 
other subunit(s) may be missing or defective. It is interesting that the 
majority of tumours with high total receptor concentration were reported 
to show the presence of the 88 form, whereas lower receptor content often 
reflected only the 48 form. It should also be noted that whereas the 68 
form was detected in 0.15M KCl containing gradients, when the classical 
activation conditions were used (30°C, 30 min) only the 4.0-4.68 form 
appeared and not the 5.58 form (Wittliff et al., 1978).
Although Wittliff's idea is potentially useful, several investi­
gators have failed to confirm his observations, (Westerberg et al., 1978;
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Dao and Nemoto, 1980; Gapinski and Donegan, 1980). In addition, both 
steroid dependent and autonomous rat mammary tumours have an intact trans­
location mechanism (Hawkins et al., 1978) and show predominantly the 
presence of 8S receptor(Freedman and Hawkins, 1979, 1980). This questions 
the validity of the 8S form as an index of hormone responsiveness.
Based on studies to establish the stability of the 88 form, 
it was concluded that the 48 form of the receptor can arise from the 88 
form as a consequence of (1 ) storage, (2 ) the various experimental condi­
tions used and (3) in the case of DMBA induced mammary carcinoma, as a 
result of the hormonal milieu (Schneider and Dao, 1977; 8herman et al.,
1980; Freedman and Hawkins, 1980; Tilzer et al., 1981). All breast tumours 
are thought to possess the 88 receptor initially (Freedman and Hawkins, 
1980; Tilzer et al., 1981). In addition various protease inhibitors have 
been shown to protect the 88 form of oestrogen receptor from being 
degraded into the 48 form in human myometrium (Notides et al., 1976; 
Daxenbichler et al., 1980).
In conclusion, it seems strange that such differences in mol­
ecular form in relation to response can be obtained by different 
investigators supposedly analysing similar tissue. The implications are 
that not only is tissue heterogeneity a problem but so are the variations 
in procedures used in different laboratories. Several authors have called 
for a quality control scheme to reduce intra- and inter-laboratory varia­
tion (Wittliff, 1980k:Leake,1981b) and this should prove beneficial.
It is essential, nevertheless, to find out where in the process of analysis, 
the variations may have occurred. Some such results are reported in this 
thesis with respect to interconversion of the molecular forms of oestrogen 
receptor in human breast cancer.
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1.2.5 The Treatment of Breast Cancer
The treatment of human breast cancer falls into four broad 
areas. These are radiotherapy, hormone additive and ablative therapy, 
immunotherapy and chemotherapy (Gallagher et al., 1978; Stoll, 1981). 
These treatments are usually initiated after surgical treatment of the 
primary tumour. The precise selection of therapy for a particular patient 
is guided by both clinical and biochemical parameters (size of primary, 
extent of nodal involvement, age, receptor status etc.). A very general 
scheme based on receptor status is shown in Figure 8 .
1.2.5.1 The Mechanism of Action of Endocrine Therapy
Endocrine therapy, the treatment of choice for patients with 
hormone dependent disease, may be either ablative (removal of glands 
synthesizing the oestrogen nucleus) or additive (competitive blocking 
of oestrogen action).
1.2.5.1.1 Ablative Therapy
Removal of the ovaries is, of course, the first procedure in 
premenopausal women, whereas adrenalectomy and hypophysectomy are applic­
able to post-menopausal women. However, such surgery is traumatic for 
the patient. A synthetic compound, aminogluthetimide, is now available 
and causes chemical adrenalectomy by blocking synthesis of steroids at 
the conversion of cholesterol to pregnenolone, with an additional effect 
on aromatization (Santen et al., 1980). Such treatment has to be supple­
mented with glucocorticoids and inevitably leads to side effects (Siiteri,
1982).
Figure 8 . Possible schemes for the treatment of advanced 
breast cancer incorporating stratification 
according to oestrogen receptor status
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1.2.5.1.2 Additive Therapy
Additive therapy may act by (i) depleting cytoplasmic oestrogen
receptor, thus reducing the sensitivity of the tumours to endogenous
hormone, (ii) by blocking the steroid receptor acceptor sites, this 
perhaps happens when large doses of oestrogen or androgen are given and 
(iii) by an indirect pathway, such as depression of pituitary function 
or suppression of the immediate environmental factors which may be required 
for promotion of tumour growth. One such possibility is the depression 
of prolactin release (D jiane'^and Durrand, 1977).
In additive therapy, pharmacological levels of hormones may 
be administered. These include glucocorticoids, androgens, progestins 
and oestrogens. A recent addition, and now the most accepted among hormone 
therapies, is the administration of antioestrogens such as tamoxifen 
(Henningsen, 1980 a, b).
The mechanism of action of additive therapy is far from
understood. Glucocorticoids are thought to act both directly by inhibiting
mammary cell proliferation and indirectly by inhibiting the stimulatory 
effect of insulin (Osborne et al., 1979). Progesterone is known to be 
a regulator of oestrogen receptor synthesis (Hseuh et al., 1975). During 
the menstrual cycle, for example, the appearance of progesterone in the 
blood plasma is accompanied by inhibition of the synthesis of oestrogen 
receptor in late follicular phase (Soutter et al., 1979). This inhibition, 
at least in the rat, is a direct effect on the target tissue (Clark and 
Peck, 1979). However in some experimental model systems, progesterone 
may promote tumour growth. When given in conjunction with oestrogen, the 
progesterone-oestrogen combination seems to cause tumour regression 
(McCormie and Mason, 1973). One function of progesterone is to increase 
prolactin release and this may be the mechanism by which progesterone
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on its own can stimulate growth. Androgens, when administered in high 
doses, deplete the oestrogen receptor from the cytoplasm into the nucleus 
(Garcia and Rochefort, 1979). Lippman. and Huff (1976) however, by demon­
strating the pnes'enca of both androgen and oestrogen receptors in MCF-7 
cells, have confused the picture since it cannot be said which receptor 
may be involved in promoting regression.
1.2.5.1.2.1 Antioestrogens
Antioestrogens have been studied in considerable detail but 
their precise mode of action is not certain. It is known that they inter­
act with the oestrogen receptor in a manner analogous to oestrogens, 
promoting translocation and chromatin binding (Clark, et al. , 1973; Sutherland 
and Jordan, 1981). Antioestrogens, although having certain minimal side 
effects(Kiang and Kennedy, 1977), do not show the usual, initial upsurge 
of tumour growth associated with other additive therapies (Moseson, 
et al., 1 9 7 8).
Evidence that antioestrogenic effects are mediated after the 
oestrogen receptor translocation step comes from (a) suppression of 
oestrogen stimulated uterine growth (Clark et al., 1973; Ferguson and 
Katzenellenbogen, 1977), (b) inhibition of growth and development of 
oestrogen dependent mammary tumours in rats (Jordan, 1975; Tsai and 
Katzenellenbogen, 1977), (c) inhibition of growth of some oestrogen stimu­
lated human breast cancer cell lines (Lippman. and Bolan, 1975; Zava et al., 
1977), (d) stimulation of pituitary gonadotrophin output and subsequent 
ovulation in women by antagonism of oestrogen feedback at the level of 
hypothalamus and pituitary (Vaitukaitis et al.,1971) and (e) suppression of 
oestrogen receptor processing or recycling (Section 1.1.5.6). It should 
be noted that in some tissues such as the uterus, antioestrogens are not 
pure antagonists and possess some oestrogenicity themselves (Tarenius,
1971).
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The antioestrogenic property could be exerted at any point along 
the sequence of events which are proposed for steroid hormone action 
(Figure 5). The most likely sites of action involve the transformation 
step, DNA binding step, receptor replenishment and receptor processing 
(Katzenellenbogen e^al. 1981). Different antioestrogens have different 
modes of action in kinetic terms, although they all appear to act subse­
quent to the translocation step. Clark et al. (1973) observed that 
administration of antioestrogens to rats blocked the replenishment of 
the cytosolic oestrogen receptor. This observation, together with the 
apparent competition for the oestrogen receptor were thought to be the 
basic mechanisms involved in antioestrogenic action. Nicholson ejb (1976) 
and Koseki et (1977) on the other hand, found that in rat mammary tumours, 
tamoxifen, in amounts equivalent to those known to cause regression in human 
cancer, did not block this replenishment. More recent reports suggest that 
oestrogen receptor synthesis in human mammary tumours is, indeed, suppressed 
by tamoxifen (Sutherland and Jordan, 1981). The complexing of oestrogen 
receptor with an antioestrogen is also thought to interfere with 'pro­
cessing' (Mester et al., 1977).
Another mechanism of antioestrogenic effect, proposed by Jordan 
and Dowse (1976), is related to the hypothalamic oestrogen receptor. They 
suggest that antioestrogens mediate their effect by interfering with 
hypothalamic function, intefering with prolactin release and so rate of 
tumour progression (Leung and Sasaki, 1975). This hypothesis is opposed 
by the studies of Moseson £t ad. (1978) which showed that patients who 
had undergone previous hypophysectomy, did respond to tamoxifen.
Bouton and Raynaud (1978), have suggested that antioestrogen 
effects are due to their high dissociation kinetics which probably inhibit 
receptor from promoting its effect at the transcriptional level.
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Katzenellenbogen et al. (1981) have shown that compared to 60% binding 
of the oestrogen-receptor complex to DNA, only 25% of the antioestrogen- 
receptor complex binds to DNA, indicating a difference in the capacity 
of oestrogen and antioestrogen to activate the oestrogen receptor (DeBoer 
et al., 1981; Rochefort and Borgna, 1981). Additionally, differences in 
sedimentation behaviour of activated receptor, when complexed to oestrogen 
or antioestrogen, have been observed (Katzenellenbogen et al., 1981).
These studies together with those of Horwitz and McGuire (1978a) and 
Ruh and Baudendistal (1977) have suggested the effect of antioestrogen 
in antitumoural action is both on receptor replenishment and on receptor- 
chromatin interaction.
1.2.5.2 Chemotherapy of Humein Breast Cancer
Chemotherapy of human breast cancer is associated with consider­
able side effects. However, this form of treatment has to be used for 
patients whose tumours show oestrogen receptor negative status and/or 
are rapidly growing. Patients who develop secondaries in lung, liver or 
viscera are also selected for this form of therapy. The relationship between 
oestrogen receptor and response to chemotherapy is uncertain. Whereas some 
groups have found that oestrogen receptor negative tumours respond much 
better to chemotherapy (Lippman et al., 1978; Jonat et al., 1980) others 
claim that oestrogen receptor positive tumours are better responders 
(Kiang et al., 1978). Further studies indicate that oestrogen receptor 
status is not a determinant of response to chemotherapy (HiIf et al., 1980; 
Samal et al., 1980; Young et al., 1980).
It is now known that oestrogen receptor negative tumours show 
a high thymidine labelling index (Meyer et al., 1977), suggesting the 
presence of a higher proportion of dividing cells. It is now established
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that oestrogen receptor negative cells are often more aggressive (Byar 
et al., 1977). Normally premenopausal disease is especially aggressive
(Sonadonna et al., 1977; Knight et al., 1977).
The drugs used on aggressive disease include: 1) antimetabolites, such 
as methotrexate and 5-fluorouracil, which affect the synthesis of nucleic 
acids, 2 ) alkylating agents, such as cyclophosphamide, which cause cross 
linkage in the DNA molecule interfering with DNA replication, 3) antitumour 
antibiotics, such as adriamycin or bleomycin, which bind to DNA and cause 
breaks in the strands and interfere with the synthesis of RNA, 4) vinca 
alkaloids, such as vincristine or vinblastin, which are metaphase inhibi­
tors and interfere with the mitotic spindle. Usually a combination of
Ma*
drugs is used such as CMF, AV or FAC (see abbreviations section,^ iv) 
(Carbone et al. , 197?; Baum, 1981) since single agent chemotherapy
is not very effective (20-25% response rate). A major problem is drug 
resistance by cells. Therefore, some groups use alternating cycles of 
two combinations in an attempt to obtain maximal cell kill and delay drug 
resistance, while avoiding excessive damage to the marrow or bowel (Pannuti 
and Creaven, 1979).
There is evidence (Nenci et al., 1976) that some tumours are 
heterogeneous, that is contain both oestrogen receptor positive eind nega­
tive cells (Nenci, 1978, 1981). This may explain why complete remission 
is not obtained when either endocrine or chemotherapeutic treatment is 
used alone. Randomized trials, combining endocrine therapy and' chemo­
therapy have been reported. These studies have suggested an additive 
effect of this form of therapy. Higher regression rates, more prolonged 
remission and survival time are reported for premenopausal women where 
cytotoxic therapy is combined with oophorectomy (Ahmann et al., 1977).
In postmenopausal women, polychemotherapy in conjunction with tamoxifen
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administration is more effective than either modality alone (Heuson,
1976).
1.3 OBJECTIVES
Since Jensen first proposed that cytosolic oestrogen receptor 
could be the necessary clinical discriminant in human breast cancer in 
relation to hormone treatment (Jensen et al., 1971b),several groups have 
developed assays for measuring oestrogen receptors (McGuire et al., 1975; 
Laing et al., 1977). Various clinical correlations have been made with 
the intent of finding parameters which could be related to receptor status 
and possibly lead to enhanced understanding of the biology of the indivi­
dual tumour. However, only about 50% of patients whose primary tumour 
biopsies show the presence of soluble oestrogen receptor respond objectiv­
ely to hormone therapy (Hawkins et al., 1980). In addition, it is becoming 
increasingly clear that oestrogen receptors from human tissue may show 
characteristics different from those present in other animal systems 
(Notides et al., 1976; Fazekas and MacFarlane, 1980). The differences 
could arise at any of -the proposed steps in steroid hormone action 
(Figure 5).
Outstanding areas for the study of oestrogen receptor function 
in human breast cancer cells include,
1) Explanation and identification of 'false positive' cases, 
where the presence of soluble oestrogen receptor is detected yet the 
patient fails to respond to subsequent hormonal treatment. In this res­
pect, one of the molecular forms of oestrogen receptor in human breast 
cancer (the 88 form) has been proposed as an index of functional receptor 
(Wittliff and Savlov, 1975) and this has been put forward as an index 
of prognosis (Section 1.2,4). Other investigators have failed to define 
patients response on the basis of the molecular size of oestrogen receptor
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(Dao and Nemato, 1980). Therefore, further investigations in this area 
are required. Tumour sampling and subsequent handling may affect the 
molecular parameters. A satisfactory tumour storage system is also required 
which can be used as an alternative to the liquid nitrogen method.
2) The activation/transformation process of oestrogen receptor 
in rat or human tissue is far from being completely understood. There 
is conflicting data on the mechanism of this process (Notides, 1978; 
Rochefort et al., 1980). Other steroid receptors show the process of acti­
vation but this is not accompanied by the 4S— » 58 transformation observed 
(on 8DGA) in the oestrogen receptor system from immature rat uterus.
The process remains ill understood. Detection of 'false positive' 
patients could be due to detection of non-functional receptor either as 
a result of a structural defect in the receptor protein or absence of 
total compliments and/or defective compliments, required for activation 
(8pelsberg and Boyd-Leinen, 1980). Other reasons are plausible. Non­
functional receptors may be expressed in tumours. There is certainly pre­
liminary evidence for defective receptors in human breast cancers (Thorsen 
and 8toa, 1979; Leake et al., 1981) and in a mouse mammary tumour (Shyamala,- 
1972). It is therefore important to describe the components involved in 
receptor activation and to study their kinetic properties. The presence, 
detection and quantitation of such components are important for studying 
chromatin-receptor interaction. The activation/transformation process 
may also have other implications in drug-receptor interactions 
(Katzenellenbogen et al., 1981, Rochefort and Borgna, 1981). 8ome of the 
preliminary studies are therefore directed towards relating the activation/ 
transformation process of human breast tumour oestrogen receptor to the 
relatively better characterized immature rat uterine tissue oestrogen 
receptor.
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2. MATERIALS AND METHODS
2.1 MATERIALS
2.1.1 Fine chemicals were obtained as
Dithiothreitol (DTT)
Norit A activated charcoal 
(untreated powder)
Bovine Serum Albumin (BSA) 
(fraction V)
Human-%-Globulins 
(fraction II)
Ovalbumin
Deoxyribonucleic acid (DNA) 
(calf thymus type V sodium 
salt, highly polymerized). 
Deoxyribonucleic acid - 
cellulose (DNA-cellulose) 
Dextran T70 
Sucrose (AnalaR.)
Diisopropyl fluorophosphate 
(DFP)
Phenylmethylsulphonylfluoride
(PMSF)
Trasylol (Aprotinin in isotonic 
solution containing 0 .9% benzyl 
alcohol)
follows
The Boehringer Corporation 
(London) Ltd., and Koch-Light 
Laboratories, Colnbrook, 
England.
Sigma, London.
Sigma, London.
Sigma, London.
Sigma, London.
Sigma, London.
Sigma, London
Pharmacia, Sweden. 
Fisons, England. 
Sigma, London.
Sigma, London.
Bayer, Germany.
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Acetyl-L-leucyl-L-leucyl- Peptide Institute,
L-arginal (leupeptin) Japan and Sigma, London.
Sodium molybdate (AnalaR) BDH chemicals Ltd.,
England.
Unless otherwise stated, all other chemicals used were of 
AnalaR grade, supplied by BDH chemicals Ltd., England.
2.1.2 Buffers
N-2-Hydroxypiperazine-N'-2-ethane Sulphonic acid (Hepes) was obtained 
from The Boehringer Corporation (London) Ltd.,
N-Tris [hydroxymethyl] methyl-2-aminoethane Sulphonic acid (TES) was 
obtained from Sigma, London.
Tris (hydroxymethyl) aminoethane was obtained from Sigma, London.
2.1.3 Hormones
2.1.3.1 Radioactive Steroids
[2,4,6 ,7-^H]Oestradiol-17yô (^HE^), specific activity range 
91-112 Ci/mmol was obtained from the Radiochemical Centre, Amersham, 
now Amersham International. This was used in all sedimentation analysis 
studies (Section 2.2.2).
[6,7-^H]0estradiol-1^S (^HE^), specific activity 54 Ci/mmole, was also 
obtained from the Radiochemical Centre, Amersham. This was used for 
all Scatchard analysis studies (Section 2.2.2.3).
2.1.3 .2 Competitor for Receptor Analysis
Diethylstilboestrol (DES) was obtained from Sigma, London.
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2.1.4 Radioactive Sedimentation Markers
14
C-labelled BSA (4-.6S), molecular weight 69,000 and specific 
activity 58-60 uCi/mg was obtained from the Radiochemical Centre,
Amersham.
14C-labelled human-^^globulins (7.IS), molecular weight 150,000 
and specific activity 11.5-26.9uCi/mg was obtained from New England 
Nuclear, Southampton, U.K.
The sedimentation constants are taken from Fazekas and 
MacFarlane (1980) and S represents Svedberg Units (IS = 10 ^^  sec).
2.1.5 Scintillation Materials
The following materials were obtained from Koch-Light Laboratories 
Colnbrook, England.
Toluene ( AnalaR grade )
2,5-diphenyloxazole (PPG)
1,4-di-[2-(5-phenyloxazolyl)} -benzene (POPOP)
Triton X-100 was obtained from Rohm and Haas, Croydon, England.
2.1.6 Livestock
Mature (250-280g) and immature (16-21 days old) rats were 
female Albino Wistar rats (Glasgow University Colony).
2.1.7 Human Tissue
2.1.7.1 Human Breast Tumour Tissue
Human breast tumour tissue was kindly supplied by the following 
Health Board hospitals:-
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Victoria Infirmary, Glasgow 
Western Infirmary, Glasgow 
Gartnavel General Hospital, Glasgow 
Royal Infirmary, Glasgow 
Stobhill General Hospital, Glasgow 
Royal Beatson Memorial Hospital, Glasgow 
Southern General Hospital, Glasgow 
Hairmyres Hospital, East Kilbride.
Monklands General Hospital, Airdrie
Belvidere Hospital, Glasgow
Ballochmyle Hospital, Mauchline, Ayrshire.
2.1.7.2 Human Endometrial Tissue
Normal human endometrial tissue was obtained from the uteri 
of patients undergoing hysterectomy in the Gynaecology Department of 
the Western Infirmary, Glasgow.
2.1.8 Miscellaneous
Polystyrene tubes used in the receptor assay, and specimen 
jars used for human tissue collection were obtained from Sterilin Ltd., 
Teddington, England.
Cellulose nitrate tubes for sucrose density gradient analysis 
were supplied by Beckman, RIIC Ltd., High Wycombe.
Glass microfibre filter discs (GF/C 2.5cm diameter) were ob­
tained from Whatman Ltd., England.
Glass/glass tissue grinders were obtained from either Kontes, 
New Jersey, U.S.A. or Cowie Scientific, Middlesbrough, England.
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Glassware was washed and rinsed in glass distilled water, as the 
presence of divalent metal ions have been reported to affect the receptor 
measurements (Laing, 1980). All glassware which came into contact 
with human tissue was treated overnight with Kirbychlor, obtained 
from Kirby Pharmaceuticals, Suffolk, England.
All solutions were made in glass distilled water.
2.2 METHODS
2.2.1 Buffers and Solutions
2.2.1.1 Tissue Storage Medium
Human breast tumour tissue was collected fresh from the 
operating theatre. A parallel section was removed for pathological 
examination. The remaining tissue was put into an empty sterile con­
tainer which was then transported on ice to the laboratory for routine 
clinical analysis of steroid receptor content (Leake et al., 1981) 
by the method of Scatchard analysis (Scatchard, 1949). However, from 
the distant hospitals it was not always possible to dispatch and process 
the sample on the same day. In such cases tumour tissue was stored 
in a medium of 0.25M Sucrose, 1.5mM MgCl^, lOmM Hepes pH7.4/50% v/v 
glycerol (Sucrose/glycerol buffer) at -20*^ 0 until its arrival in the 
laboratory whereupon it was registered and stored at -20^0. The 
glycerol in the medium prevents the freezing of the tissue. Freezing 
and thawing of tissue is detrimental to receptor stability (King, 1979). 
This storage procedure preserves receptor for several weeks (Hyder 
and Leake, 1982; see also Section 3-1.1.7).
Fresh tissue was processed immediately if the biopsy was large
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enough for serial sections. Otherwise, sucrose density gradient analysis 
was performed after the receptor status had been determined by routine 
clinical analysis (Leake et al., 1981). Tissues stored in sucrose/ 
glycerol buffer for more than 60 days were discarded (except in the 
case of storage study - see Section 3-1-1.7). Before assay, stored 
tissue was rehydrated for 15 min. at 4°C in HED or HDK.^^ (see below 
for abbreviations), as appropriate.
2.2.1.2 Buffers Used in the Sedimentation Analysis of Oestrogen 
Receptor
2.2.1.2.1 Low Salt Buffers
To study the sedimentation profile of oestrogen receptor in 
low salt conditions, the following homogenization buffers were used :- 
lOmM Hepes, 1.5raM EDTA, 0.5mM DTT pH 7.4 (HED) 
lOmM Tris, 1.5mM EDTA, 0.5mM DTT pH 7.4 (TED)
2.2.1.2.2 Physiological Ionic Strength and High Salt Buffers
Physiological ionic strength (0.15M KCl) and high salt buffers, 
used mainly for activation/transformation studies, were as follows 
lOmM Hepes, 0.5mM DTT, 0.15M KCl pH 7.4 (HDK.^^) 
lOmM Hepes, 0.5mM DTT, 0.4M KCl pH 7.4 (HDK.^)
A few experiments were conducted in either lOmM or 40mM Tris 
(Notides, 1978) in place of Hepes - this buffer is referred to as TDK. 
EDTA was omitted from the activation/transformation buffers (because 
EDTA inhibits this process - see Sato et al., 1978a). High salt 
buffers were used in the gradients for the analysis of 4S— »5S transi­
tion, but not in the initial homogenization buffer (HDK.^^). The 4S— )5S
- 84 -
transition was also studied in gradients containing 0.15M KCl.
A few experiments involved the use of low salt buffers without 
EDTA (HD or TD) for the initial homogenization followed by activation 
and then centrifugation in high salt gradients. Buffers are indicated 
in the legends to the figures.
2 . 2 . 1 . 2 . 3  Dextran coated Charcoal Solution (DCC) f o r  the Separation 
of Unbound from Bound Steroid
0.5% w/v DCC solution was prepared by resuspending Norit A 
charcoal in HED containing 0.25M sucrose and 0.005% w/v dextran T-70.
When required, an aliquot was centrifuged at 2000 x g for 5 min. and 
the supernatant removed. The pelleted DCC was then resuspended to the 
desired final concentration in radiolabelled cytosol from various tissues
2.2.1.2.4 Preparation o f  [ ^ H ] 0 e s t r a d i o l - 1 7/3 (^HE^) S o l u t i o n s
o —7
Stock HE^ was prepared to a final concentration of 10~ M 
in absolute alcohol and stored at -20°C. Appropriate amounts of this 
were aliquoted to give the desired final concentration when resuspended 
in the cytosol preparation (see below). Another aliquot was added 
to an equal volume of DES (10"^M stock solution) in absolute alcohol.
The alcohol was evaporated in a stream of compressed air or nitrogen 
and the HE^ + DES redissolved in the cytosol. Tests to ensure full 
solution showed that never more than 2% of radioactivity remained 
attached to the walls of the tubes. The DES tube thus contained an 
1000-fold excess of synthetic oestrogen for the determination of non­
specific binding.
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2.2.2 Analysis of the Sedimentation Pattern in Low Salt Buffers
2.2.2.1 The Human Breast Tumour Cytosol Oestrogen Receptor
Sucrose density gradient analysis (SDGA) was originally 
described by Martin and Ames (1961) as a method for determining the 
molecular nature of proteins. It was first applied to the analysis 
of the oestrogen receptor by Toft and Gorski (1966). Lately, clinical 
implications of the molecular forms of the receptor have been proposed 
(Wittliff and Savlov, 1975; Kute et al., 1978). The results in this 
field are conflicting and the method described below was developed 
with the intention of studying some possible reasons for the contradictory 
results.
Either fresh or sucrose/glycerol buffer stored tumour tissue
(rehydrated in HED, 15 rain, at 4°C) was dissected free of fat and
visible necrotic tissue. It was then homogenized at 200-500 mg/ml in
HED using 2 x 10 sec. bursts from an Ultra-turrax (TP 18/2) at a setting
of 150, with intermittent cooling periods. This yielded the rough
horaogenate which was then further refined using a glass/glass homogenizer
(Leake et al., 1981). Great care was taken to maintain the cytosol
below 8°C at all times, as warming of the horaogenate causes receptor
loss (King, 1979). The horaogenate was then centrifuged at 50,000 rev/
min (226,395 x g^^^) in a Beckman 50 Ti rotor for 30 min at 4°C. The
clear supernatant was then carefully removed avoiding the thin layer
of fat which was usually present. This yielded a cytosol with a final
protein concentration in the range 3-10mg/ml. Within this protein
concentration range, no significant alteration of sedimentation profile
was observed, see Figure 25. Aliquots of the cytosol were incubated
with 5 X lO^M ^HE_ + 5 x 10"^M DES for 1h at 4°C. These were then 
2 —
transferred onto a pellet of dextran coated charcoal (DCC) and the
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DCC resuspended to a final concentration of 0.5% w/v. Incubation was 
continued for a further 15 rain, at 4^C, with mixing every 5 min. Tubes 
were then centrifuged at 2000 x g at 4°C for 5 rain, to pellet the DCC, 
and aliquots of cytosol taken for the determination of specific binding. 
Further 200ul aliquots were loaded onto 5ml linear 5-20% (w/w) sucrose 
density gradients prepared in HED buffer. Sucrose density gradients 
were made in cellulose nitrate tubes, using a simple gradient forming 
device (made in the Department workshop by Mr. N. Harvey) and chilled 
at 4^C for at least two hours prior to use. Specific binding was deter­
mined prior to loading the cytosol onto the gradients to monitor percen­
tage specific counts recovered. After layering the cytosol on top 
of the gradient the tubes were centrifuged at 45,000-50,000 rev/min.
(243,000 X g - 300,000 x g ) for 13-16 h. in a Beckman SW 50.1 max max
rotor at 4^C in a Beckman L2-65B ultracentrifuge. Each sample contained
14 14 ,C-labelled BSA and/or C-labelled human-% -globulins as internal
markers. Sedimentation values were determined according to Martin
and Ames (1961), and, in addition, the internal markers indicated the
quality of each gradient.
After centrifugation the bottom of the tube was punctured 
with an 18 gauge syringe needle and two drop fractions were collected 
directly into scintillation vials (37 vials per gradient), with a con­
trolled air flow from the top (1 ml/min). This was obtained by using 
the Gilford gradient scanner unit (accesssory unit of the Gilford 240 
spectrophotometer) linked to an air tight centrifuge tube holder. This 
method provided excellent resolution (see Figure 10) when compared 
to the Gilford gradient scanner attached to a flow cell which pumps 
dense sucrose from the tube bottom with collection from the top. The 
technical problems associated with using the Gilford flow cell system
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and the mixing of the sample in the outlet tube were found to reduce 
the sensitivity. However, using this system the protein profiles 
could be obtained by ultra-violet light absorption analysis prior to 
the sample entering the outlet tube, confirming the validity of the 
gradients obtained by the two drop procedure (data not shown). Resolu­
tion becomes increasingly important in the transformation studies 
(Section 3 .2).
The graphs are plotted showing the total and nonspecific or the 
specific counts ( HE^-DES counts, for every fraction) as a function of the
fraction number and the arrows on the graph indicate the position of
the sedimentation markers. To avoid confusion, the minor differences 
obtained in the sedimentation values of receptor from individual tumours 
have, in general, been ignored. Values are generally quoted as either 
4S (3.58 - 4.8S) or 8S (7.2S - 8.OS), in accordance with results pre­
sented in the literature.
The recovery of specific counts was in the range 70-114%.
The relative area under the sedimentation peaks was determined. Tumours 
were classified as of predominant 4S type, only if >70% of total counts 
in the sedimentation profile was found in this area and predominantly 
8S if >70% of total counts were under the 8S peak.
2.2.2.1.1 Development Leading to the Final Procedure of SDGA
Some developments carried out to reach the final procedure 
described above (Section 2.2.2.1) include -
(i) a reduction in time of incubation of the cytosol with 
^HEg + DES from 3h to 1h at 4°C. Although a 1-3h incubation may not 
result in any modification of the receptor, long term incubations
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certainly have an adverse effect on tumour receptor sedimentation 
profile (Section 3-1-1-2).
(ii) an increase in the final concentration of DCC from 0.25%
3
to 0-5% (w/v) to strip unbound steroid- Although most unbound H-steroid 
(>98%) was removed by 0.25% DCC (data not shown) some tumours contained 
non-specific components which masked the 4S area. The higher DCC con­
tent removed these and did not affect receptor concentration (Figure 16).
(iii) although total recovery of specific counts under the 
sedimentation peak was usually in the range 70-114%, for some tumours 
as little as 50% of the specific counts applied were recovered under 
the peaks. This prompted an investigation of the tube bottom to deter­
mine if any heavy aggregates had been precipitated. The tube bottom 
was cut and placed in 4ml absolute alcohol at 37^C for 1h in a tightly 
capped scintillation vial, after which 1ml aliquots were counted for 
radioactivity. Using this procedure recovery of specific counts was 
^90% (Table 1). The presence of heavy aggregates could, therefore, 
result in a false estimation of the 48 : 88 ratio if only one of 
these forms were able to aggregate.
2.2.2.2 Intratumoural Variation of Oestrogen Receptor Concentration
and Molecular Form in Human Breast Cancer
To study intratumoural variation of the oestrogen receptor 
two procedures were followed. Where possible, the peripheral section 
and adjacent sections moving towards the central area of the tumour 
were analyzed (selected sectioning approach) (Figure 98). A second 
approach was to randomize the sections prior to analysis (random 
sectioning approach) (Figure 9R). The homogenization procedure, cytosol 
preparation and sedimentation analysis were as described in Section
2 .2 .2 .1.
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Figure 9 : Sectioning procedure for analysis of tumour intersite variation,
In the"selected sectioning procedure" (S), section position was known 
with respect to the peripheral section. In the "random sectioning 
procedure" (R), position within the tumour was unknown.
2.2.2.3 Scatchard Analysis
Routine scatchard analysis to determine receptor status of 
the tumour prior to SDGA was described by Leake et al. (1981). This 
was carried out by Marion McMenamin, to whom I am most grateful.
Briefly, a 7 point competition assay over the range 10""^ M^ to 10”^M 
HEg using a 100 fold excess DES as competitor, was conducted. Incuba­
tion of steroid with tumour cytosol or nuclear fraction was for 18h 
at 4°C. For receptor positivity at least 5 of the 7 points were used 
in the construction of the Scatchard plot and the Kd (dissociation 
constant) was in the range 5 x 10  ^ - 7 x io ^
2.2.2.4 Sedimentation Pattern of the Rat Uterine Cytosol Oestrogen 
Receptor
2.2.2.4.1 Preparation of Immature Rat Uterine Cytosol
16-21 day old rats were anaesthetized with chloroform and 
killed by cervical dislocation. Uteri were dissected free of adhering
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fat and mesentry, quickly excised and placed in HED buffer on ice. Four 
or five uteri/ml were homogenized using a glass/glass homogenizer.
The centrifugation procedure for cytosol preparation and subsequent 
sedimentation analysis were as described in Section 2.2.2.1. The 
protein concentration obtained was 2-4mg/ml.
2 . 2.2.4.2 Preparation of Mature Rat Uterine Cytosol
Prior to killing, the oestrous cycle stage of the rats was 
determined by a microscopical examination of a vaginal smear. The 
uteri were excised and placed on ice. These were then finely chopped 
and homogenized in 2ml HED buffer/uterus. The centrifugation of the 
horaogenate and sedimentation analysis was as described in Section 
2.2.2.1. The protein concentration obtained was 4-6rag/ml.
2.2.2.5 Preparation of Human Endometrial Cytosol Fraction
Human endometrial tissue was homogenized in HED buffer at 
200-400mg/ml in a glass/glass homogenizer. This was followed by the 
high speed spin (226,395 x g^^^) cytosol preparation and sedimentation 
analysis as described in Section 2.2.2.1. Protein concentration was 
3-6 mg/ml.
2.2.3 Transformation Studies on Sucrose Density Gradients
2.2.3.1 Immature Rat Uterus
The method used was basically derived from the studies of 
Notides and Nielsen (1974).
Immature rat uteri were homogenized in HD or HDK.^^ buffer 
at 4 or 5 uteri/ml and cytosol prepared as described in Section 2.2.2.1
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EDTA was omitted from buffers for reasons previously mentioned (Section
2-2.1.2.2). After labelling the cytosol for 1h at 4°C with 5 x 10”^M 
3 -6HE. + 5 X 10 M DES and DCC-stripping free steroid, one set of aliquots 
2 —
was kept at 4°C and a second aliquot warmed to 30 *^ for 30' (unless
otherwise stated) to permit activation. After warming, the cytosol
was recooled to 4^C for 5 min. An aliquot was taken for determination
of specific radioactivity and a further aliquot loaded onto 5-20% w/w
(unless otherwise stated) linear sucrose density gradients (each of
14
5ral) prepared in buffers containing either 0.15M or 0.4M KCl. C-labelled 
markers were added. The salt concentration did not affect the precision 
of the sedimentation markers in their sedimentation properties (Figure 10). 
The centrifugation was at 4^C for times and speeds indicated in the 
Figure legends. In some instances the centrifugation temperature was 
20°C, without previous warming of cytosol. These will be indicated.
The sample recovery procedure was as described in Section 2.2.2.1.
2.2.3-2 Human Breast and Endometrial Tissue
Human breast tumour cytosol and human endometrial cytosol 
(Section 2.2.2.5) were prepared as described in Section 2.2.2.1. The 
buffers used for homogenization were HDK.^^ or HD. Inclusion of the 
protease inhibitor Leupeptin during the homogenization procedure resulted 
in the formation of froth (also observed by Sherman et al., 1980) possibly 
leading to a loss of receptor activity. For this reason, the protease 
inhibitors Leupeptin and/or DFP were added immediately following homo­
genization. PMSF and Trasylol, used in the studies reported in Section
3.1 were present during the homogenization procedure. However, as 
already noted (Lukola and Punnonen, 1982), the latter do not seem to 
be very effective inhibitors of the particular protease(s) activity
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encountered here.
The tumours used were generally those for which a high con­
centration of receptor activity had been detected using Scatchard 
analysis (Section 2.2.2.3). No difference was observed in specific 
counts obtained after 30 or 60 min. incubation with radioactive steroid 
at 4°C. This probably indicates that all the unoccupied sites are
rapidly filled (in some experiments involving the effect of DCC, the
-9 3concentration of radioactive steroid was reduced to 2 x 10 M HE^
+ 2 X 10”^M DES to prevent the excess smear of counts at the top of 
the gradient). Cytosol was then DCC-stripped (0.25% w/v final con­
centration) and aliquoted onto 5-20% (w/w) gradients. A few experiments 
involved initial heating of cytosol (30*^ C, 30 min) prior to centrifugation 
for activation purposes. The gradients were centrifuged at 42,000-
50,000 rev/min (211,000 x g - 300,000 x g ) for 7-11h at 20°C' ®max ' max
or 11-16h at 4°C in a Beckman SW 50.1 rotor. The procedure of collec­
tion and scintillation counting was the same as described in Section
2 .2 .2 .1.
2.2.4 The Assessment of Activation of Soluble Oestrogen Receptor 
from Immature Rat Uteri and Human Breast Carcinoma using 
DNA-Cellulose Binding
A modified method from Park and Wittliff, ( 1977) and Sato et al., 
(1981a) was developed and is described below.
2.2.4.1 DNA-Cellulose Binding of Rat Uterine ER^
Immature rat uterine cytosol was prepared in HDK.  ^^  buffer
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as described in Section 2.2.3.1. Labelling of the cytosol receptor
was carried out at 4^C for 60 min. with 5 x 10 + 5 x 10 DES.d. —
Labelled cytosol was then warmed at 30°C for 30 min. to activate the 
receptor. A second aliquot was kept at as a control. After warming, 
the cytosol was cooled at 4°C for 5 rain. Then 200ul aliquots were mixed 
with pelleted DNA-cellulose containing /^lOOug DNA (see 2.2.4.1.1). 
Pretreatment of immature rat uterine cytosol with DCC (0.25% w/v final 
concentration), either before or after activation, did not result in 
a significant increase of the final specific counts obtained and, there­
fore, stripping of unbound counts, prior to mixing of the cytosol with 
DNA-cellulose was not normally carried out. Specific counts in the 
cytosol prior to DNA-cellulose binding, however, were determined for 
every sample preparation from a DCC-stripped aliquot. Initial experiments 
confirmed that no significant retention of non-specific binding to the 
DNA-cellulose slurry occurred.
2.2.4.1.1 Preparation of DNA-Celluloae and the Binding Agsay
The DNA-cellulose powder, 4,1rag DNA/gm DNA-cellulose was sus­
pended in HDK.^^ and the slurry centrifuged at 2000 x g for 5 min. The 
supernatant was removed and 200ul aliquots of the labelled cytosol, 
either activated (30°, 30') or non-activated (4°, 30'), were added. 
DNA-cellulose, now containing /vIOOug DNA, was resuspended in the 
cytosol and incubated for 60 min. at 4°C with vortexing every 15 min.
At the end of the incubation, 0.8ml HDK.^^ was added, the tubes vortexed 
and centrifuged at 2000 x g for 5 min. at 4°C. The supernatant was 
removed (wash 1) and the DNA-cellulose was washed a further four times 
(washes 2-5) each with 1ml HDK.^^. At the end of wash 5, 1ml of HDK.^ 
was added (Park and Wittliff, 1977) to salt extract the DNA bound 
receptor. This incubation was carried out for 60 min. at 4°C
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(Sato et al., 1981a) with mixing every 15 min. When characterization 
of the DNA-bound receptor by SDGA was required, the volume of HDK.^ 
extraction buffer was reduced to 0.5ml in order to concentrate receptor 
for analysis. In addition, it was essential to introduce a carrier 
protein, described by Yamamoto and Alberts (1974)in both the HDK.^ 
extraction buffer and in the SDGA buffer. For SDGA, therefore, salt 
extraction buffer contained protein at 4mg/ml. After the salt extraction, 
tubes containing DNA-cellulose were again centrifuged and aliquots from 
the supernatant removed for scintillation counting or SDGA, The remain­
ing supernatant was discarded and the DNA-cellulose resuspended in 1m1 
absolute alcohol and left overnight at room temperature ( /»l4h). Next 
morning, an aliquot was removed for scintillation counting after 
pelleting of DNA-cellulose at 2000 x g for 5 rain.
The results are expressed as percentage (%) of total specific 
receptor binding, that is
amount of ER bound to 
c
DNA-cellulose
DNA bound receptor = amount of ER incubated
c
with DNA-cellulose 
The amount of receptor bound to DNA-cellulose was taken as the sum of 
salt extracted + alcohol extracted specific counts.
From the total DNA-cellulose bound receptor, % salt extractable 
and hence % alcohol extractable counts were determined.
2.2.4.2 DNA-cellulose Binding of Human Breast Carcinoma ER^
The cytosol preparation is described in Section 2.2.3*2. The 
DNA-cellulose binding procedure, as described for immature rat uterine 
ER^, was conducted with two modifications. After labelling the cytosol
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for 60 min with + DES, stripping of free ^HE^ with 0.25% DCC
(final concentration w/v) was included so that the exchange of endo­
genously bound steroid is minimized during the elevated temperature 
used for receptor activation. It is not clear whether Sato et al.
(1981a) took such a precaution. An error can be introduced into the 
results if specific receptor concentration is determined at 4°C prior 
to activation and % DNA bound is expressed relative to this value. The 
concentration of DCC in the experiments reported in this thesis in connec­
tion with activation studies was kept at 0.25% (w/v) since it is known 
that, at elevated ionic strength, DCC tends to both adsorb receptor 
itself and increase the stripping of bound HE^ (Peck and Clark, 1977).
2.2.5 DNA - Oestrogen Receptor Interaction Analysis on Sucrose 
Density Gradients (Low Salt Conditions)
A similar approach to that proposed by Park and Wittliff (1980) 
was employed, with a few modifications. Tumour tissue was homogenized 
and the cytosol prepared as described in Section 2.2.2.1. Cytosol was 
then incubated with 5 x 10 ^HE_ + 5 x 10”^M DES. After a 1h incuba-
c. -
tion at 4°C, calf thymus DNA in HED buffer was added to one set of
cytosols, to a final concentration of Img/ml, while keeping the other
set DNA free. The cytosol was further incubated at 4°C for 20 min.
after which the unbound counts were stripped with 0.5% DCC w/v (final
concentration) as described in Section 2.2.1.2.3. Aliquots (200ul)
were loaded onto 5-20% linear sucrose density gradients prepared in 
14HED. C-labelled marker proteins were used as internal standards and 
the samples centrifuged at the speed and time indicated in the legends, 
in a Beckman SW 50.1 rotor at 4°C.
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2.2.6 Expression of Results
2.2.6.1 Radioactive Counting
All vials from cytosol assays were counted in a Searle Mk.II 
liquid scintillation analyzer. Dual labelling was employed in sucrose 
density gradients and consequently the samples were counted in a dual 
label programme. The counting efficiency of /v26% for H was 
determined by 'spiking' with tritiated toluene. The quenching values
were monitored from the external standard pulse and there was no signi-
14 3ficant variation. The spill over from C channel into H channel was
estimated to be 20% and this value was therefore subtracted from the 
q
H channel values to give the corrected values which was then plotted 
as a function of fraction number.
2.2.6.1.1 Calculation of Receptor Concentration
After the determination of specific counts from the DCC aliquots 
prior to SDGA, the following relationship was used to convert the c.p.m. 
value into specific receptor concentration in fmoles/ml.
Specific c.p.m. _  counter efficiency = Specific d.p.m.
ml ml
then, Specific d.p.m. ^ speZÎFl"\otlvlty x 2.2 x 10^  . Specific nmoles
ml of ml
and Specific nmoles x 10^  - Specific fmoles
ml ml
The value thus obtained was used to monitor the percentage recovery 
on SDGA. The 4S and 8S profiles were quantitated by estimating 
the area under their respective peaks. In some cases the per­
centage recovery on SDGA was corrected by considering the specific 
counts at the bottom of the tube. Thus when the 48 + 88 profile was 
used to compute the 4S -to 8S ratio, the total percentage recovery
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of specific counts may exceed that under the 4S + 8S profile.
2.2.7 Protein Determination
The protein content of each cytosol was determined by the 
method of Lowry et al. (1951) using BSA as the standard.
2.2.8 DNA Determination
The DNA determination was made by the modification of the method 
of Burton (1956) described by Katzenellenbogen and Leake (1974).
2.2.9 Final Form of Results
Cytosol receptor concentration were determined in fmoles/ml 
(Section 2.2.6.1.1). These values were then divided by the cytosol 
protein concentration to yield the value in fmoles/mg protein or divided 
by the value of DNA to yield receptor concentration in fmoles/rag DNA.
2.2.10 Statistical Parameters
Statistical parameters of mean (x) and standard deviation (S.D.) 
were computed using a CASIO fx-19 scientific calculator. Where dupli­
cate or triplicate samples were used, the specific receptor concen­
tration is derived from subtraction of the mean of non-specific counts 
from the mean of total bound counts. Where the mean and standard 
deviations were calculated from separate experiments, the range is 
included.
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3. RESULTS
3.1 SUCROSE DENSITY GRADIENT ANALYSIS OF HUMAN BREAST TUMOUR
OESTROGEN RECEPTOR
3.1.1 Conditions for Sucrose Density Gradient Analysis (SDGA)
14
3.1.1.1 Separation of C—labelled Marker Proteins
Prior to the use of the sucrose density gradients, it was essential
to establish the quality of both the gradients and the separation of pro-
14teins. Markers used for this purpose were C-labelled such that they 
could subsequently be used as internal markers. Figure 10 shows that 
there is a very clear separation of 4.6S and 7.IS markers and these 
sediment in approximately a linear fashion. The top of the gradient may 
experience some disturbance during sample loading and this explains why 
perhaps the line joining the sedimentation points occasionally does not 
pass through the origin. The relationship of marker proteins, shown in 
Figure 10, is obtained in both Hepes and Tris buffer and linearity of the
markers is not affected by the presence of salt.
o
3.1.1.2 Effect of Time of Incubation with H-oestradiol on Sedimentation 
Profile
Two different types of effects of pre-incubation on oestrogen 
receptor profile, as a function of time are reported in the literature. 
Erdos (1968) and Stancel et al. (1973a) reported a time dependent aggre­
gation of receptor while Freedman and Hawkins (1980) have reported a time 
dependent interconversion of 88 into 48 species. Two different sources
of cytosol preparation were involved in the above studies.
The effect of time on the stability of soluble oestrogen receptor 
was studied with human breast tumour cytosol both in the presence and
14Figure 10. Separation of C-labelled marker proteins on sucrose 
density gradient
^^C-labelled BSA (4.68) and human-1$-globulin (7.18) 
(8ection 2.1.4) were mixed with 200ul aliquot of cytosol 
prepared from human breast tumour (patient 8N, protein 
concentration 9.8mg/ml). Cytosol was then layered on to 
of a 5-20% (w/w) sucrose density gradient prepared in HE: 
and centrifuged at 45,000 rev/min for I4h at 4°C. The 
rest of the procedure is described in 8ection 2.2.2.1.
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absence of oestradiol. Figure 11 demonstrates a predominant 8S profile 
from a tumour cytosol. Incubation for between 45-150 min. in the presence 
or absence of steroid resulted in no change in the profile. There was a 
slight but not significant increase in the receptor binding capacity after 
150 min. (412 fmoles/mg protein) compared to the 45 min. incubation (373 
fmoles/mg protein) in the presence of steroid. Pre-incubation of re­
ceptor in the absence of steroid for 105 rain, followed by labelling with 
H-oestradiol for 45 min. resulted in a comparable receptor content 
(388 fmoles/mg protein). It may however be quite fortuitous that the 
receptor profile did not change since tumour protease content is very 
variable and this tumour may represent the type in which such a protease(s] 
is at minimal level.
The receptor status of the tumour shown in Figure 12.1 was 4S + 88
3
type when tumour cytosol was incubated with H-oestradiol for 1h (A).
3
Incubation of the same cytosol with H-oestradiol for 24h resulted in a 
loss of the 88 component with a concomitant increase in the 48 area (B).
The redeptor concentration in both.these cases was comparable being 70 
and 68 fmoles/rag protein respectively, as determined with a DCC one point 
assay (8ection 2.2.2.1). However, when incubation of the same cytosol 
was carried out for 23h in the absence of steroid followed by incubation
3
with H-steroid for 1h, very little receptor activity was detectable 
(12 fmoles/mg protein). This confirms the view that receptor is less 
stable in the absence of added steroid.
Cytosol from a more receptor rich tumour than that shown in 
Figure 12.1 was taken through the same procedure of 1h or 24h incubation
3
with H-steroid, or 23h incubation in the absence of steroid followed
3
by 1h incubation with H-steroid, prior to stripping with DCC and analysis
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on sucrose density gradient. A similar 4S + 8S profile is again seen 
(Figure 12.2A) after a 1h incubation (receptor concentration, 1l6 fmoles/mg 
protein). Again a 24h incubation resulted in a decrease in the 8S peak 
with a concomitant increase in the 4S peak area (Figure 12.2B). There 
was also an increase in the receptor concentration to 134 fmoles/mg 
protein, this most probably represents exchange of endogenously occupied 
receptor and may or may not represent the reported increase in binding 
which can occur after mild trypsinization (Petterson et al., 1982).
The 23h incubation without steroid followed by labelling for 1h (Figure 
12.2C) resulted in a similar relative increase in the 4S area but the 
peak height and receptor concentration was now low (89 fmoles/mg protein). 
The two peaks observed in the 48 region in Figure 12.2A are also present 
in Figure 12.2C with now a higher proportion of the smaller peak (a/3-68). 
This splitting of the 48 peak is probably masked in Figure 12.2B due to 
the larger concentration of total receptor present. 8uch a splitting 
has been previously observed (Kute et al., 1978). It is probably not 
a simple aggregation effect since receptor sedimenting in the 48 area 
(in low salt, as opposed to salt disaggregated 48) is also inefficient 
in binding to DNA (see 8ection 3.2.2), an indication of lack of 
aggregation potential.
In Figure 12.2C, as compared to Figure 12.1C, the receptor is 
not totally absent and this most probably represents a lower proteolytic 
activity in the tumour cytosol reported in Figure 12.2. Unfilled 
receptor is, thus, thought to be more labile than filled receptor.
The results shown in Figure 13 support the view that 8S— »4S 
conversion is a proteolytic step, since such a conversion can be acceler­
ated by adding calcium ions (Figure 13B compared to Figure 13A control). 
This confirms the studies of Schneider and Dao (1977). The tumour cytosol
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represented in Figure 13 showed a high amount of heavy aggregates 
sedimenting to the bottom of the tube, a situation also observed by 
Kon et al. (1980). When DFP was added, prior to the addition of
calcium ions, the 8S peak was stabilized (Figure 13C) and the split 
present in the 4S area in Figure 13A was also absent. The total receptor 
concentration in the presence of DFP was actually lower than in its 
absence, an effect well recognized with the inclusion of this protease in­
hibitor (Lukola et al., 1980). This most probably is due to the iso­
propanol present in the DFP solution. However, a direct effect of DFP 
on receptor steroid binding site cannot be ignored (Lukola and Punnonen, 
1982). The same experiment, when repeated with immature rat uterine 
soluble oestrogen receptor (ER^), resulted in the slow cleavage of 
88— » 48 which could not be inhibited with DFP (data not shown).
Rochefort and Baulieu (1971) have reported observing the same effect 
and species dependent sensitivity of the protease is implied.
3 .1.1 . 3  Effect of Hormone Concentration
The tumour cytosol study generally involved an incubation time of
1h at 4°C with 5 x 10~^M + 5 x 10”^M DE8. It was therefore important
to establish that most unoccupied sites were labelled. 8uch conditions
are found by several authors to be satisfactory (Freedman and Hawkins,
1 9 8 0) since only a maximum of 30% of the soluble oestrogen receptor
sites may be occupied with endogenous oestradiol in breast tumour cytosols
(8akai and 8aez, 1976). However with respect to the present studies it
becomes important to establish if the different molecular forms had
different affinities for the radioactive steroids. Figure 14 represents
the effect of incubating the tumour cytosol at three concentrations of
-8
steroid in the range 10 - 10 M. The receptor concentrations measured
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by the single saturation dose analysis (counts prior to loading cytosol
for SDGA) were 44, 86 and 94 fmoles/mg protein at the concentration
1O"^ M, 5 X 10”^M and 10"^M ^HE2 respectively. This indicates that almost
-9 1twice the number of sites are detected with 5 x 10 M HE^ when compared
_ Cj 3
to 10"’ M HEg. The rise in receptor concentration when incubated with 
—8 S10” M HEg was only /v 10% higher when compared to the value obtained 
with 5 X 10”^M ^HE^ (Figure 14B). This may indicate the presence of 
some additional unoccupied sites or the exchange of endogenously bound 
steroid.
The tumour cytosol profile shown in Figure 14 was of the pre­
dominant 48 type (>70% specific counts in 4S area). The presence of
—8a large excess of steroid (10” M) did not result in any binding in the
_c\ o
88 area when compared to the 10 M HE^ incubation. It should be 
pointed out that in all cases of tumour cytosol containing the 48 receptor 
form, there was always an indication of an 88 shoulder. Wittliff et ai . 
(1976), have reported that no difference in the binding affinity of 48 
and 88 receptor forms can be demonstrated. Muldoon (1978), studying the 
receptor forms in the mouse mammary gland has indicated a difference in 
terms of the actual stability of the 88 and 48 forms, 88 being the more 
stable form. Some recent reports however, have indicated that the 
in vitro 88 form seems to be degraded to the 48 form which demonstrates 
greater stability to storage conditions (Namkung et al., 1979). In vitro 
artifacts could play a major role in the latter observation.
In addition to the above, the result presented in Figure 14 
shows the reproducibility obtained with the same homogenate with respect 
to the receptor molecular form.
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3.1.1.4 Effect of Temperature
A rise in temperature promotes receptor aggregation in the 
immature rat uterine cytosol (data not shown). Aggregation has been 
correlated with loss of receptor function in aged animals (Nishizawa 
et al., 1981). However, it should be noted that at least limited 
aggregation may be physiologically important as suggested from the 
fluorescence studies of Nenci et al. (1980c).
In human breast tumour cytosol, two different types of effects
were observed on warming the cytosol to 20°C in the presence of steroid:
(1) aggregation of the 8S form and (2) interconversion of the 8S into 
the 4S form. Both effects are seen in Figure 15. The receptor concen­
tration increased from 90 to 134 fmoles/mg protein on heating the cytosol, 
as determined by the DCC analysis prior to SDGA, but after the heating 
process only 61% of total specific counts were recovered in the gradient. 
The 4°C incubation showed a 95% recovery on the gradient signifying 
aggregation in the heated cytosol. Heating the tumour cytosol to 20°C 
also resulted in a diffuse 8S area and an increase in the 4S peak height,
when compared to the 4°C control, once again the 48 peak remained sharp.
The possibility exists that the 48 receptor detected after the heating 
process resulted from endogenous exchange during the warming of the 
cytosol. Further tumour cytosols were therefore analyzed and it was 
found that even with very low changes in receptor concentration after 
warming and equal recovery of counts on the gradients, the 88 profile 
is again lost, with a rise in the 48 peak (data not shown). 8harpness 
in the 48 peak was obtained once again confirming the view that 48 
receptor does not randomly aggregate (see also Section 3.2.3,2.6).
Figure 15. Effect of temperature on sedimentation profile of oestrogen 
receptor from human breast cancer
Human breast tumour cytosol was prepared as described in
Section 2.2.2.1 (patient CB; protein concentration 5.6mg/ml).
-9 3Cytosol was labelled for Ih with 5 x 10 M HE^ in the absence
or presence of 5 x 10 DES either at 4^0 (___) or at 20°C
(,...). Unbound steroid was stripped with DCC prior to SDGA. 
Specific binding (fmoles/mg protein) was 90 in 4^0 control 
with 75% recovery on gradient and 134 at 20°C incubation with 
61% recovery in gradient. In addition, specific counts deter­
mined at the bottom of the tube accounted for a further 10% 
receptor in 4^0 control and 20% for 20^0 incubation run. 
Centrifugation was at 45,000 rev/min for 16h at 4°C in
Beckman SW 50.1 rotor. Arrows indicate the position of 
14C-labelled marker proteins.
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3.1.1.5 Effect of Dextran Coated Charcoal (DCC) in Separating Unbound
from Bound H-oestradlol—1
Since the initial use of DCC by Korenman and Dukes (1970), it 
has become the most popular method for the separation of unbound from 
bound radioactive steroids. However certain limitations of the process 
are noted (Peck and Clark, 1977) and sensitivity to both ionic strength 
and the protein concentration are recognized. In the present study 0.5% 
w/v (final concentration) of DCC was used and it is demonstrated in Figure 16 
that such DCC concentration does not lead to an underestimation of receptor 
concentration. In some initial experiments 0.25% w/v DCC (final concen­
tration) was used but 0.5% w/v DCC was found to reduce the non-specific 
counts to a minimum. However, even when using 0.5% DCC, a variable 
non-specific proportion was observed (Figure 17A) in 10 
receptor positive tumour cytosols. The variability of non-specific counts 
perhaps indicates that different quantities of serum components are 
present in different tumour cytosols. With immature rat uterine cytosol 
comparatively lower values of non-specific counts were seen. Human 
tumours always contain substantial amounts of plasma contamination 
(Maass et al., 1975). The components contributing towards the non­
specific counts include albumin, -acidic glycoprotein, corticosteroid 
binding globulin (CBG) and sex hormone binding globulin (SHBG) (King 
and Mainwaring, 1974). It is further shown in Figure 17B that such 
non-specific binding appears independent of protein concentration.
3.1.1.6 Inclusion of Centrifuge Tube Bottom Alcohol Extraotable Counts
in the Analysis of the Final Percentage Recovery
The results obtained from sections taken from 13 tumours, showing 
both 4S + 83 and 83 forms of soluble oestrogen receptor (ER^), indicate
Figure 16. Effect of Increasing DCC Concentration on the Removal of 
Unbound Radioactive Steroid from Tumour Cytosol
Human breast tumour cytosol was prepared as described in
Section 2.2.2.1 (patient MW; protein concentration 3.9mg/ml).
-9 3
Cytosol was labelled with 5 x 10 M HE^ in the absence (----- )
or presence of 5 x 10."^M DES (....) for 1h at 4°C. The 
incubated cytosol was then transferred onto pelleted charcoal 
which was resuspended to yield a final concentration (w/v) 
of 0.125% in A, 0.25% in B and 0.5% in C. The suspension 
was incubated for 15 min. at 4°C with mixing every 5 min.
After the incubation,the DCC was pelleted at 2000 xg for 5 
rain, at 4^C. 200ul aliquots were then loaded onto 5-20%
gradients which were centrifuged for l4h at 45,000 rev/min 
in a SW 50.1 rotor at 4°C. Aliquots were also taken for 
determining specific receptor concentrations in fmoles/mg 
protein and there were 168 in A; 166 in B and 172 in C. 
Percentage recovery in gradients was near 70% in all cases.
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that there is a good correlation between counts loaded onto the gradient 
and counts recovered after the centrifugation, (mean + S.D = 82 + 11 - 
Table 1A). However some other tumour cytosols showed very low receptor 
recovery on the gradient (Table IB). This prompted the investigation of 
analysis of the bottom of the tube for the presence of heavy aggregates. 
This led to a better yield as shown in Table 1A and IB. Some tumour 
cytosols showed greater than 100% recovery of counts, presumably resulting 
from the combination of errors introduced in taking aliquots for DCC 
analysis, prior to SDGA, and taking a second aliquot for loading onto 
the gradients. Occasionally some H-steroid dissociated towards the 
top of the gradient during centrifugation due perhaps to proteolysis of 
receptor and/or altered affinity of the receptor for H-steroid.
Since no loss of total receptor is observed in calcium promoted 
proteolysis (Figure 13) and the process results in a very sharp 4S peak, 
limited proteolysis may release the receptor from the heavy aggregates 
and increase percentage recovery on the gradient (data not shown). This, 
however, results in the loss of the 8S form also. The idea of limited 
tryptic digestion has also led to increased resolution of the receptor 
on isoelectric focussing gels (Wrange et al., 1978).
3.1.1.7 Storage Studies in Sucrose/Glycerol Buffer
In contrast to the usually accepted tumour storage procedure 
which involves freezing in liquid nitrogen, followed by tumour pulveri­
zation (Brown et al., 1977) a different storage procedure was used during 
the course of the reported studies. Leake et al. (1979) reported that 
sucrose/glycerol medium (Materials and Methods, Section 2.2.1.1) is 
suitable for preserving the oestrogen receptor activity for at least 
1 week and possibly longer, as measured by Scatchard analysis. However
Table 1. Recovery of Aggregated Receptor in Relation to Total 
Percental Recovery of Specifically Bound Oestradiol
Details of breast tumour analysis and extraction of 
counts sedimenting to the bottom of tube are given in 
Section 2.2.2.1 and 2.2.2.1.1.
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Patient SDG Value 
fm oles/m g Protein 
(% of DCC value)
Value corrected 
after tube 
Bottom Analysis
Protein 
Concentration 
m g/m l
A.
1. FR 84 88 6.2
2. CMH 79 95 6.2
3. JW 91 94 3.6
4. FM 81 92 6.4
FM 81 89 5.4
FM 95 109 4.2
5. MM 80 102 4.2
6. CB 70 77 5.0
CB 75 85 5.6
7. SCR 86 91 2.8
8. MA 78 90 7.2
9. IH 80 95 8.0
10. GS 91 95 8.0
11. HB 99 104 10.4
HB 87 95 9.2
12. JA 82 103 6.0
13. SR 86 97 9.2
Mean ± S.D. 82 ± 11 94 ± 7 6.3 ± 2 .1
B. 14. SCH 48 89 4.9
SCH 68 84 5.4
SCH 75 95 6.2
SCH 56 71 4.2
SCH 56 85 3.0
Mean + S.D. 61 ± 10 85 ± 10 4.7 ±1 . 1
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it was essential to establish whether the molecular form of oestrogen 
receptor was also preserved.
At the time the reported studies were commenced, there was already 
evidence in the literature that storage can have a profound effect on 
tumour receptor activity (Wittliff and Savlov, 1975), and recent work 
has further shown that the 8S form of receptor is more prone than 4S 
to such degradation during 3 weeks of storage in liquid nitrogen (Namkung 
et al., 1979). Based on such results the conclusion was drawn that the 
time period in storage can affect receptor molecular form (Freedman and 
Hawkins, 1980). It therefore became essential to investigate the 
sucrose/glycerol medium for storage effects on receptor molecular 
form and concentration as a function of time.
A large left axillary node from a breast cancer patient was 
divided into several pieces and stored at -20°C in sucrose/glycerol 
medium. Sections were removed at intervals, rehydrated at 4°C in the 
homogenization buffer and analysed by SDGA. Up to 96 days the receptor 
molecular form and concentration is preserved (Figure 18). After 96 
days, although the binding capacity could be detected by the initial DCC 
assay, no molecular form was detected on the gradient (e.g. Day 264 
in Figure 18). Total recovery from the later gradients was below 100% 
suggesting that either the receptor has lost its high affinity binding 
property and steroid was therefore dissociating during the centrifugation 
run or that the receptor is present in the aggregated form after long 
periods of storage. To test the extent of aggregation the remaining 
sample was analyzed on the 517th day of storage in both low salt and 
high salt gradients. Figure 19 shows that in contrast to the low salt 
gradient, the 0.4M KCl containing gradient showed a 4S binding peak.
Thus age-related aggregation was a contributory factor. There was.
Figure 1 8. Effect of Storage in Sucrose/Glycerol Buffer at -20°C 
on the Molecular Form of Oestrogen Receptor from Human 
Breast Cancer
On arrival in the laboratory the axillary tumour mass 
(patient BM) was sectioned and placed in sucrose/ 
glycerol buffer at -20°C. Individual sections were 
then analyzed on the indicated day of storage.
Preparation and SDGA of tumour cytosol was as described 
in Section 2.2.2,1. Receptor concentrations as deter­
mined by DCC prior to SDGA are also included. Recovery 
of specific counts was near 100% up to 96 days and 90% 
for days 212 and 264. Receptor concentration in fmoles/mg 
protein for the analysis of 212th day could not be deter­
mined due to loss of cytosol.
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The 88 form is preserved for 96 days
Figure 19» Analyaia of Cytosol Oestrogen Receptor from Human Breast 
Tumour Tissue after long-term Storage in Sucrose/glycerol 
Buffer at -20°C
The same tumour shown in Figure 18 was used in this analysis. 
After 517 days of storage, cytosol was prepared as des­
cribed in Section 2.2.2,1 (protein concentration 8.6mg/ml). 
Cytosol was labelled with 5 x 10 in the absence
(-----) or presence (....) of 5 x lO'^M DES for 1h at
4°C. Free steroid was removed with DCC and 200ul aliquots 
loaded onto either a low salt gradient (A) or a high salt 
gradient (B). The total specific count recovery (no peak 
was seen) in low salt gradient was 73%, whereas the recovery 
of specific counts under the sedimentation peak in the high 
salt gradient was 91%. The receptor concentration as deter­
mined by DCC analysis prior to SDGA was 82fmoles/mg protein. 
Centrifugation was for l4h at 45,000rev/min at 4°C in 
Beckman SW 50.1 rotor.
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however, considerable loss of ^H-oestr;zradiol-17^ during centrifugation 
suggesting that alteration in receptor structure has indeed also taken 
place. The total receptor concentration was approximately the same on 
517th day as on 264th day but lower than in earlier samples. Although 
tumour heterogenity cannot be ignored it is suggested that receptor 
degradation must have taken place during storage for very long periods. 
Experiments reported in this thesis, outwith this storage study, were 
conducted with tumours which were either fresh or stored for less than 
60 days in sucrose/glycerol buffer.
In the initial large tumour used for the storage study inter­
conversion between the molecular forms was minimal. However, a second 
analysis conducted on a different tumour (Figure 20) gave an indication 
that such an effect could occur in this storage system, and presumably 
also in other storage systems. Figure 20 clearly demonstrates the 
8s— *»’4s conversion during 30 days storage. Receptor binding capacity 
did not seem to be destroyed during storage, in contrast to the reported 
results after storage in liquid nitrogen (Namkung et al., 1979). The 
possibility of tissue heterogeneity with respect to the molecular forms 
cannot be excluded but this generally does not seem to be the case in 
other tumours studied (Section 3.1.3.2). However, if analyzed fresh 
this tumour would have been classified into the 8S predominant type, 
and on day 30 of storage, into the 48 + 8S group. Due to sample limitation 
it was not possible to study if a total conversion of 8S into 4S would 
have occurred on longer storage but long term in vitro incubation of 
tumour cytosol demonstrates (Figure 12.1 and 12.2) that this may be 
possible. There were other tumours which preserved the 88 form for 
considerable periods (see below). This change from 8S— »4S, therefore, 
seems to depend on intrinsic protease activity of individual tumours.
rt
I
o CQ Cm4.» 03 O 43
3 03T3 O
C SU cn CO0) 3bO O >> m0) S OS1—1 3 T343 o<D S3£ c O >,<D 03x: T) QC 3 03•H N 43
•5^ >> OlXJ O iHH) o OSS3 CM•H OS5L, ShÜ OS CCQ <13 03<D c £ 03TJ 3 (d03 303 03 3%«3 3 CMGO rHT3 CQ stu 43 03CQ s: 03 bO03 3^ 30) oÜ Ü >>O Sh T3U Ü 03 03O. •H > S3tw O •H03 •H Ü 03ttJ Ü 03 S>
3 03 cn Sia o03
z: S3 OCO Cm lO O onO •H4J XJ Pc S3 OS 030) u 03 Sh Q'H 03 P+3 > S3 P03 O 03 03A Ü 03 Ü03 >, S3 CO
Sh cd O
£h X3 Ü G\<13 03C3 bO S3 C •oC 03 O •H S303 43 03 03Ü G T3 P03 S3 O LO•P a 03 SU03 Sm a. >,03 03 Si 03<D CL, 03 03 Q
U 03 U3XI Sh E-4 PCm cd
>> GOL T3 CO03 03 03
S 03 N bO*H SU 03SU 3 rH Shcx bO 03 o >,•H S3 p 03«1 {it OS 03 Q
<ü
a
- 120 -
S
0
1I0s
4
| k
0 1  
œ §■
M  Q  
^  0)
II
C 4-4
.«-4 Q
I
U
üa
M
en
I
u
ÇQ y
O
CC
O
i
o
3o
Eh
g&
1
G
O
S
co
&
a
Q
(U
s%
w2
O
O
coCQ
Ocq
CQco
o
oo ooo§ olO oo om
t H
CQ
CO
o
S
OCQ
r .  O
CQ
1—1
CQ
CO
O
o
co
CQ CO
O
B m •+-* oo
co
I
O o § oo
co
o
CM
U(DA
S
%
I"W
N
G
CQ
U0
1
I
(Dü
I
CQ
IU
S
CQ
CO
d
0 3
CQ
I
I
0 3k
JS
H
^3Hg mda
- 121 -
The observed 4S : 8S ratio changes indicates that such a ratio should 
only be related to patient prognosis in relation to the length of storage, 
However, the level of protease activity in itself may represent an index 
of some form (e.g. of invasion potential), and merits further study.
Table 2 represents data from 23 primary breast tumours (27 sections) 
which were stored in sucrose/glycerol for the number of days indicated. 
Table 2 includes analysis of two additional axillary nodes (numbers 24 
and 25). Some points to note include
a) Tumour number 3 shows no change in receptor profile (8S) when 
analyzed on days 6 and 55 after storage. Similarly, tumour number 14 
analyzed after 37 and 51 days shows no change in the predominant 8S 
profile (cf Figure 20 where the change could be observed by 30 days 
storage).
b) Tumour number 13 shows a predominant 4S profile after 33 days 
of storage. The initial status with respect to sedimentation profile 
was not known. Tumour number 25 (axilla) shows a much higher proportion 
of BS after 66 days of storage compared to tumour number 24 (also an 
axilla) which had been analyzed after 48 days.
c) Some tumour cytosol analyzed showed the presence of heavy 
aggregates, e.g. tumour number tf, and if only the 8S form is capable 
of aggregation then this would lead to an error in the 4S : 8S ratio. 
Alternatively these heavy aggregates may represent either receptor 
precursor or aged receptor perhaps bound to membrane fractions or 
other heavy structures which fail to sediment during the high speed 
centrifugation step in the cytosol preparation. Similar aggregates have 
been found by others (Sakai and Saez, 1976; Kon et al., 1980).
This storage system was also found suitable for the retention
Table 2. Effect of storage in Sucrose/Glycerol Buffer at -20°C 
on the Molecular Form of Oestrogen Receptor
Fresh tumour biopsies were sectioned and stored at -20^C 
in sucrose/glycerol buffer. One section was then used 
for routine determination of receptor content by Scatchard 
analysis (Section 2.2.2.3). The other section(s) were 
stored at -20^C in sucrose/glycerol for the time noted.
It was then rehydrated at 4^C and the assay carried out 
as described in Section 2.2.2.1. The time period indica­
ted does not apply to Scatchard analysis which were always 
performed prior to tissue being used for storage data.
* performed on a different Section 2.2.2.3-
** performed as described in Section 2.2.2.1.
*** represents the aggregated receptor at the bottom of 
centrifuge tube.
**** receptor could not be demonstrated on SDG.
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Effect of Storage in S u cro se /G ly ce ro l Buffer at -20 C on the M olecular Form  
of O estrogen R eceptor
P atien t T issu e
P eriod  of Storage 
in
Sue ro  s e/G lye e ro l 
(Days)
Soluble
*
Scatchard 
E R q/E R  n
Oestrogen Receï 
**
DCC one point 
A ssay
)tor fmoles
Sucrose
D ensity
G radient
/m g  P 
Molec 
4S
rotein 
:u lar I 
8S
’orm
***
Agg.
1 B reas t 1 246/1147 189 170 13 157 ND
2 B reas t 6 213/3500 112 99 36 58 5
3.1
3.2
B reast
B reast
6
55
293/8743 388
337
334
305
0
0
334
290
ND
15
4.1
4 .2
B reas t
B reas t
7
25
120/4615 90
625
80
538
19
248
24
101
37
188
5 B reas t 20 236/7318 409 389 0 389 ND
6.1
6 .2
B reas t
B reas t
20
57
8/2400 90 
. 38
87
27
28
20
50
7
9
ND
7 B reast 21 82/975 42 47 23 13 11
8 B reast 24 58/1334 65 74 36 7 21
9 B reas t 28 125/1096 52 59 18 30 11
10 B reast 30 23/876 - - - - -
11 B reast 30 358/11873 330 261 133 128 ND
12 B reast 32 64/3037 83 75 32 43 ND
13 B reas t 33 131/5345 164 148 104 44 ND
14.1
14.2
B reast
B reas t
37
51
186/10878 275
250
231
230
0
0
231
230
ND
ND
15 B reast 44 150/3077 155 151 66 65 10
16 B reast 45 194/3808 153 144 59 85 ND
17 B reast 45 118/987 70 66 29 26 11
18 B reast 47 97/4286 41**** - - - -
19 B reast 48 121/1648 93 94 40 40 14
20 B reast 51 112/3820 176 158 58 58 42
21 B reast 54 44/ND 53**** - - - -
22 B reast 67 161/4884 44 42 17 23 2
23 B reas t 71 120/2886 156 134 79 39 16
24 A xilla 48 100/1691 330 261 133 128 ND
25 A xilla 66 51/3168 201 189 74 115 ND
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of 8S form from human endometrial tissue for at least 30 days (data not 
shown).
An interesting contrast was noted between human breast tumours 
and immature rat uterine tissue with respect to storage in sucrose/ 
glycerol buffer. Rat uterine oestrogen receptor was found to be unstable 
in sucrose/glycerol and there was a considerable loss of both receptor 
activity and quality after only 1 week storage (Figure 21). The receptor 
does not leach into the storage medium, as judged by Scatchard analysis 
of the medium. It is shown in Figure 21 that the 8S receptor decayed 
and proteolytic fragments could be observed. The formation of the 4S 
form could be seen after day 1 in storage. It is further shown in 
Figure 57 (Section 3*2.3.3*1) that one day storage of rat tissue renders 
/^50% of the receptor non-transformable when compared to fresh tissue 
(Figure and Section ).
3.1.1.8 Effect of Ionic Strength, Sodium Molybdate and Protease Inhibitor
3.1.1.8.1 Ionic Strength
When breast tumour ER^ was analyzed in low salt gradients, 
following homogenization in low salt buffers, a 4S + 8S or 8S alone 
profile was generally observed (Section 3.1.2). However if the salt 
concentration of the centrifugation buffer was changed to either 0.15M 
or 0.4m KCl ( H E D K . o r  HEDK,^), there was a quantitative change from 
8S— >4S and a single sharp peak was observed (Figure 22 A and B - obtained 
from same cytosol). The same effect is observed with immature rat uterine 
ER^ (data not shown) in agreement with the observations of Yamamoto 
(1974)..
It is claimed by Wittliff et al. (1976) that when the human
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breast tumour ER^ is homogenized in TEDK.^ ^ and centrifugation performed 
in the same buffer, a 6S form is obtained. They suggested that this 
represented the active form of receptor. Although homogenization in 
0.15M KCl - containing buffer and centrifugation in the same buffer 
results in a 6S peak, centrifugation in 0.4M KCl-containing gradients 
yields a single 4S peak. Thus, the ionic strength of both the homo­
genization and the centrifugation buffers is critical to the molecular 
form of the receptor.
3.1.1.8.2 Sodium Molybdate
The result presented in Figure 22C (obtained from the same 
tumour as used for Figure 22A and B) further shows that if the 
homogenization is performed in the presence of sodium molybdate, the 
8S profile persists. There is no change in the sedimentation profile 
on inclusion of sodium molybdate in the homogenization buffer, as also 
noted by Mauck et al. (1982). The result is however, in disagreement 
with Nishigori and Toft (1980) who were able to find that sodium molybdate 
promoted increased sedimentation values.
It has been observed by Nishigori and Toft (1980) and Anderson 
et al. (1980) that sodium molybdate increases the amount of progesterone 
receptor detected in avian oviduct and human breast tumour cytosol, 
respectively. The latter report also indicates that sodium molybdate 
increases apparent ER^ concentration only in certain breast tumours.
In Figure 22C, the increased receptor value on inclusion of sodium 
molybdate may be attributed to a combination of molybdate and/or 
intra-tumour variation (Section 3.1.3.3). The routine use of sodium 
molybdate to stabilize the 88 form was avoided since, if the 48 and 
88 complex have any clinical significance, then they should be studied
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without masking the effect. In vivo conversion to 4S may explain why 
4S containing tumours do not respond to hormone therapy.
A further point of interest is that Figure 22 represents a 
tumour receptor profile from a male patient with breast carcinoma.
Very few studies have demonstrated the molecular forms of receptor 
in male breast carcinoma, Wittliff (1974) was the first to demonstrate 
that male breast tumours possess receptor similar to that of female 
tumours and he suggested that further consideration should be given to 
endocrine therapy for male breast cancer.
3.1.1.8.3 Protease Inhibitors
The effect of two protease inhibitors, PMSF and Trasylol are 
shown in Figure 23.1 and 23.2. In the presence or absence of PMSF 
during homogenization, no significant difference could be observed in the 
sedimentation profile (Figure 23.1). The tumour ER^ was of the pre­
dominant 88 type with a small 48 sedimentation peak unaffected by the 
presence of PM8F. The absence of an effect may be fortuitous due to 
a low content of protease activity in this tumour. Indeed this same 
tumour was studied for storage purposes and showed no significant inter­
conversion to 48 (Figure 18). Using a different tumour, Trasylol 
(Figure 23.2) failed to inhibit the appearance of 48 and, in addition, 
disturbed the 88 profile. The latter probably results from the medium 
in which Trasylol is supplied (see Materials and Methods, 8ection 2.1.1). 
The salt constituent of the Trasylol medium may result in some 8S 48 
conversion.
Thus proteases sensitive to PM8F and Trasylol were not apparent 
in these human breast tumours. However the protease inhibitors, Leupeptin
Figure 23.1 Influence of a Protease Inhibitor, PMSF, on Sedimentation 
Profile of Oestrogen Receptor from Human Breast Tumour 
Cytosol
Human breast tumour cytosol was prepared from two 
different sections of the same tumour (patient BM) as 
described in Section 2.2.2.1. PMSF (IraM final concentra­
tion) was Introduced into one set prior to homogenization. 
Labelling of cytosol, removal of free steroid and SDGA 
was as described in Section 2.2.2.1. Protein concentra­
tion was 7.0mg/ml for PMSF-free cytosol and ll.Omg/ml for 
PMSF-containing sample. Receptor concentration was 
324fmoles/mg protein in PMSF free and 304 fmoles/mg 
protein in PMSF containing cytosol. Percentage recovery 
was 90% in both samples. Centrifugation was for l4h at
50,000rev/min in Beckman SW 50.1 rotor at 4°C. Arrow
14indicates the position of C-labelled marker protein.
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Figure 23.2. Effect of an Alternative Protease Inhibitor, Trasylol, 
on the Sedimentation Profile of Oestrogen Receptor 
from Human Breast Cancer Cytosol
Human breast tumour cytosol was prepared from two
different sections of the same tumour (patient AK)
as described in Section 2.2,2,1. Trasylol (2000 units)
was introduced into one set prior to homogenization.
Labelling of cytosol, removal of unbound steroid and
SDGA was as described in Section 2.2,2.1. Protein
concentration was 6,0mg/ml for Trasylol-free cytosol
and 4,6mg/ml for Trasylol-containing cytosol. Receptor
concentration was 155fmoles/mg protein in Trasylol-free
cytosol and 176fmoles/rag protein in Trasylol-containing
cytosol- Percentage recovery of total specific counts
in gradient was 91%. Centrifugation was for I4h at 50,000
rev/min in Beckman SW 50.1 rotor at 4^C, Arrows indicate 
14the position of C-labelled marker proteins.
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and DFP, mainly used in the latter part of the study (Section 3.2), are 
effective against the formation of the non-aggregatable type of 4S 
receptor and so imply the presence of a relatively specific protease(s).
3.1.1.9 Effect of Buffers on Sedimentation Analysis
Tissue was normally stored in medium containing Hepes buffer.
Since some experiments were subsequently conducted in Tris buffer it 
was necessary to determine the effects of both buffers on the sedimentation 
profile. Figure 24 (A and C) shows that tumours stored in sucrose/ 
glycerol buffer (Hepes) then both rehydrated in and, subsequently, 
analyzed on gradients containing Tris or Hepes alone, resulted in a 
clear 8S peak. Figure 24 (B and D) further shows the effect of homo­
genization in one buffer and sedimentation in the other. This procedure 
showed loss of 8S when the homogenization buffer was Tris and centrifugation 
buffer Hepes. The loss of 8S, presumably due to dissociation of the 8S 
into the 4S form, may be due to a local effect at the point of contact 
between Tris and Hepes. The experiment was only performed once since 
such a use of different homogenization and centrifugation buffers is, 
hopefully, uncommon.
3.1.1.9.1 Quality Control of Every Batch of Buffer
In the initial phase of these studies a different source of Hepes 
(Ubichem Ltd), rather than that obtained routinely from the Boehringer 
Corporation,- was found to inhibit the formation of the 8S complex. 
Twenty-one tumours were studied and formation of 8S complex was never 
observed. Some of the components of the Ubichem buffer were thought to 
influence the final molecular form. Both immature rat uterine and human 
endometrial cytosol ER^ were tested and both showed loss of 88 (data
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not shown). Several alternative explanations were considered before 
the source of Hepes was once again changed to Boehringer. The receptor 
was then shown, once again, to sediment at 8S. This finding led to the 
quality control of every batch of buffer using immature rat uterine ER^.
3.1.1.10 Effect of Protein Concentration
Stancel et al. (1973a) have shown that protein concentration
of the soluble fractions can affect the final sedimentation patterns.
In the present study, low salt conditions similar to those of Stancel
et al. (1973a) were used. The protein concentration ranged generally
from 3-10mg/ml. Figure 25 shows that in this protein concentration range
(and lower) no marked change in sedimentation properties occurred. Slight
14
shifts in the position of the 8S peak can be seen but the C-labelled 
marker confirms that the sedimentation value is always greater than 7.IS. 
Similarly, 4S receptor ran below the 4.6S marker at all protein concentra­
tions tested (data not shown). The receptor, in salt containing gradients, 
sedimented in a very sharp 4S peak. However the actual peak value varied 
slightly with protein concentration, possibly as a result of non-specific 
components.
A  p l o t  o f  p r o t e i n  c o n c e n t r a t i o n  v e r s e s  t h e  'S' v a l u e  f o r  t h e  4 9  s e c t i o n s  
e x h i b i t i n g  b o t h  t h e  4 S  a n d  t h e  8 S  f o r m s  o f  r e c e p t o r  ( T a b l e  3 . 1 )  s h o w e d  t h a t  
t h e r e  w a s  n o  s i g n i f i c a n t  r e l a t i o n s h i p  b e t w e e n  t h e  8 S  f o r m  a n d  p r o t e i n  c o n c e n t r a ­
t i o n  ( n  =  4 9 ,  r  =  0 . 0 7 8 ) .  H o w e v e r ,  s e d i m e n t a t i o n  o f  t h e  4 S  f o r m  s h o w e d  a  
c o r r e l a t i o n  ( s i g n i f i c a n t  a t  1% l e v e l )  w i t h . p r o t e i n  c o n c e n t r a t i o n  ( n  =  4 9 ,  
r  =  0 . 3 8 9 ) .  T h e  l a t t e r  i s ,  h o w e v e r ,  s u b j e c t  t o  e r r o r  s i n c e  o n l y  6  v a l u e s  
w e r e  o b t a i n e d  a t  p r o t e i n  c o n c e n t r a t i o n  > 7 m g / m l  w h e r e  a  s l i g h t  r e l a t i o n s h i p  
w a s  s e e n  b e t w e e n  t h e  t w o ,  p r o b a b l y  a s  a  r e s u l t  o f  s e r u m  p r o t e i n s  s e d i m e n t i n g  
i n  t h e  s a m e  a r e a .
X}
<v
C N G
•H •H G
rH G O
03
CO +) P
G O a
03 cO G G
•H a Ü
en T) G
A c G Go (0 Æ
E- G
CQ
g g
33
C
0) G S
k •H (/] SZ
.0) a
Jh •G T3 G
Oh 03 C G
•H N G %
Û •H
B
G a G
03 <0 sz
O faO p
u O
e CJ G
o s: O
sz
q w T3I
•p 03 G
a G G P
03 0) G G
ü 5 ■H Ü
03 •P •H
tn CQ G "G
G a G
G G •H
0) O
W a G
0 3 G
Sh -P CM
+> G
en CM G
03 S3 CQ G
o 03 G CM 5
Oh
0)
fi G G T)
0 O 431 O G
U •H G
en G P ■H
03 fi G ü G
H •H S G P
•H 03 3 CO P
Oh ■P Æ O
O 0 G
Sh Sh G •H G
Oh Oh G
G T3l O
g O G G •H
> ■p G P P
■H a P G
+S fi G G G
cO 0 « Ü P
su G G
CO G G G
g, (0 G TJ ü
a H G G
0 03 43: G O
u CES El G O
>
0  
ü  
0 )  
Sh
S
CO
1
Ü
Sh<S)
Ou
Sh
O
+S
o ,
<ü
ü
0)
Sh
-ac(0
d
•H
<ü
O
k
g
mü)fH
o
a
c
•H
S:
0
•H+5
(0
Sh
1
Ü
Cg
I
•H
k
§
o
g
o
c
•H
C-o\
X)§
oen
TD
C
co
CQ
C
•H
LOCT\
1
cO
CT\
O
■=r
00
X)
c
cO
unc—
CM
CQg
S:
' H
O
O
co
u
c
•H
; C
T3
G
CO
PQ
'O
C
co
s :un
Sh£
S
S
>03
Sh
o
O
0
un
4 -
co
mg
g
•H
4-)
1
tO
03
03k=>
CO
"T
o
Cm
O
S :
o
•H
4 ^
•H
en
o
a
0 )
S
•HB
'H
CQg
G
Sh
< 0
Sh
O
o
Sh
0
m
1
ü
03
CQ
g
• H
03
O
Sh
Ou
Sh
03kii
Shg
un
CM
03
I
•H
- 133
U
O
3
CO
o
rH
ooo o
oo oo
CO
o
g
oo
c hû
o
o
CO
CO
tH
o
CM
o
A  -
O o ooooo
CM
o
CO
o
CM
o
00
o
u
<D
I
%
s
.2 
N
u
k
l - s
o
p. 5
O
o
o
o
oo oo oo
lO TP CO CM
2 a n .  mdo
- 134 -
3.1.2. Sedimentation Profile of Human Breast Tumour Oestrogen Receptor
(Low Salt Buffer)
A total of 118 sections from 74 tumours were analyzed by SDGA.
These comprised tumours obtained from pre- and post-menopausal patients.
Figure 26 demonstrates the major forms of sedimentation profiles obtained
The following were the profiles seen:-
(i) receptor negative cytosol (including one case from a women 
undergoing mammoplastic reduction) showed a profile as in 
Figure 26A.
(ii) tumour cytosol presenting a predominant 88 class of receptor 
(Figure 26B).
(iii) tumour cytosol presenting both 4S and 88 forms (Figure 26C)
(iv) Figure 26D represents tumour cytosol which displayed a higher
proportion of 48 form of receptor but 88 was still clearly 
observable.
(v) tumour cytosol showing predominantly (>70%) 48 form has been
presented in Figure 14.
(vi) Figure 26E is an example of a profile from an axillary node
showing the predominant 88 profile.
3.1.2.1 Distribution of the Molecular Forms
The relative distribution of the molecular forms observed is shown 
in Table 3.1; It must be pointed out that wherever possible only tumours with 
high receptor content were studied. However certain tumours showing low 
receptor concentrations were also included.
3.1.2.1.1 The 4S only ER^ Distribution
In contrast to several published results (Kute et al., 1978;
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Receptor 8pecies
Tumour Sections taken from both 
within a single tumour and from 
different tumours
dL
1. 48 11 (sections from 8 tumours) *
b
2 . 48 + 88 49 (sections from 36 tumours) **
3. 88 '" 19 (sections from 6 tumours)
4. D C C \ 8DG* 29 (sections from 20 tumours)***
5. DCC", 8DG" 10 (sections from 10 tumours)
118 sections from 74 tumours
* 4 tumours showed another section in 48 + 88 c lass
** Excluding the tumours from (1), two tumours showed 
two further sections in D C C \ 8DG^ class
*** D C C \ 8DG^ represents tumour section exhibiting receptor 
in one point DCC assay taut receptor could not tae quantified 
on 8DG.
b 6'^^ t  5
1 O'Sl G 
C  i  0 ,4 0 ^
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Wittliff et al., 1978) but in agreement with others (Jensen et al., 1975; 
Freedman and Hawkins, 1960), the 4S receptor was predominant in only a few 
tumours (Table 3.1), out of the % tumours which displayed predominant 4S 
receptor in one section, 4 tumours displayed a 48 + 88 profile in another 
section. An example is presented in Figure 28.1 (Section 3.1.3.3).
It is possible that aggregation of receptor could have resulted in a false 
distribution on the gradient (the 4S;8S ratio can only be calculated from 
the receptor sedimenting in the gradient fractions - aggregated receptor 
which may comprise a complex of one or both of these forms was not con­
sidered). One of the 8 tumours, with predominant 48 receptor, displayed 
a predominant 48 class of profile in all the four sections studied,
3.1.2.1.2 The 4S + 8S ER Distribution -------     o--------
A total of 49 sections from 36 tumours fell into this category 
(Table 3.1). From two tumours, however, further sections showed DCC com- 
petable counts but no clear sedimentation profile on the gradient (DCC^, 
8DG- class). In some other tumours when two or more sections were analyzed 
the molecular status of the tumour remained constant but the relative dis­
tribution of the ER^ between the molecular forms differed (further dis­
cussed in 8ection 3.1.3.2).
3.1.2.1.3 The Predominant 8S Profile
8ix tumours from which 19 sections were analyzed, all showed 
the predominant 88 profile (Table 3.1).
3.1.2.1.4 DCC'*', SPG- and DCC~, SDG~ ER^ Profile
Twenty nine sections taken from 21 tumours showed DCC”*', 8DG- 
type of sedimentation profile i.e. DCC assay showed significant competable 
counts, but these could not be quantitated under a defined 88 or 48 peak.
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An example is shown in Figure 16 where the specific counts can be seen to 
be distributed from 3-48 area and extending in an aggregated manner into 
the 8-98 region. This class most probably results from some modification 
of receptor structure during storage (8ection 3.1.1.7). The DCC , SDG 
type showed no competable counts in either one point assay or SDG.
3.1.2.2 Distribution of Molecular Forms Relative to Receptor Concentration
Table 3.2 illustrates that there does not appear to be any 
relationship between receptor concentration and the molecular form exhibited 
by the tumour cytosol. However, the mean receptor concentration for the 
predominant 88 profile was about 2-fold higher than predominantly 48 or 
48 + 88 class. Conversely, the mean value for DCC^, 8DG- class was 3-4 
fold lower than tumours exhibiting 48 or 48 + 88 forms. This could indicate 
a higher proteolytic damage to the receptor in the DCC*, 8DG- class, a 
lower tumour cell content of the biopsy or abnormal receptor. A similar 
form of classification, the + profile, was reported by lino et al. (1980).
3.1.3 Intratumoural Variation of both Oestrogen Receptor Concentration
and Molecular Form in Human Breast Cancer
3.1.3.1' Variability in Soluble and Nuclear Oestrogen Receptor Within a 
Single Tumour (Peripheral and Adjacent Sections)
Table 4 shows the variability obtained in both soluble and nuclear
oestrogen receptor across individual breast tumours. There appears to be a 
loss of both soluble and nuclear oestrogen receptor towards the centre of 
the tumour (tumour numbers 2 and 3). In tumour number 1, the section adjacent 
to the peripheral section showed a higher oestrogen receptor concentration 
and the same was found to be the case in five additional tumours, reported 
in Table 5. Further, tumour number 4 (Table 4) showed the peripheral section
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Table 4. Variability of Soluble and Nuclear Oestrogen Receptor 
Content across the same Breast Tumour
Scatchard analysis of Peripheral and Adjacent zones 
towards the centre of the tumour. The tumours were 
sectioned selectively as described in Figure 9. The 
processing of tumour and receptor content measurement 
was as described by Leake e^ a2. (1981) (Section 
2.2.2.3).
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Variability in Soluble and Nuclear Oestrogen Receptor 
across the same Breast Tumour. Scatchard analysis 
of Peripheral and Subsequent Adjacent Zones towards 
the Centre of the Tumour.
ER„ /  Krt X 10”
 ^ mg Pr ■ ^_________
Tumour Section 1 (Peripheral) Section 2 Section 3
1. JM ERc 155 /1 .0 * /  * 114 /0 .65
ER -3 6 3 9 /2 .0 4132/1 .37 3 9 0 5 /1 .9
2. SC 3 0 8 /1 .3
ND/ND
1 7 4 /4 .0
ND/ND
1 3 1 /1 .3
ND/ND
3. LK * / * 7 4 /1 .1 2 1 /1 .7* y * 4 7 3 0 /1 .1 1 7 4 6 /2 .8
4. MM 4 5 /1 .4
1754 /6 .6
0/0
0/0
0/0
0/0
5. MK 2 5 /3 .9
3 294 /3 .1
1 4 /2 .3
2014 /1 .0
1 9 /4 .6
1 882 /1 .4
6 . AK 3 4 /3 .9
0/0
4 6 /1 .5
3205 /6 .1
4 1 /3 .6
1 8 3 5 /1 .4
Three additional tumors were found negative for 
oestrogen r e a l t o r  in a ll sections.
* Receptor Concn. too high to attain equilibrium. 
ND - Not determined.
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to be positive for ER^ and ER^ (nuclear oestrogen receptor), but other 
sections were uniformly negative. Both tumours 5 and 6 showed relatively 
constant concentration of ER^ throughout. However, in tumour number 6 
only the soluble receptor was found in the peripheral section. Three 
additional tumours were found to be negative in all sections studied.
These results are in agreement with several published papers 
(Tilley et al., 1978; Silfversward et al., 1980) with respect to the 
soluble oestrogen receptor. The number of tumours reported in the present 
investigation is too small, however, to make any comments regarding the 
significance of dissociation constant changes observed in different 
sections. But the intratumoural variability of oestrogen receptor concentra-
tfj) ft. VI
tion (both ER and ER. ) and the decrease towards the centre approach/signi- 
ficance^ The loss of nuclear receptor towards the centre of the tumour 
was not observed by Silfversward et al.(1980)who reported the contrary . 
However, a similar loss towards the older part of the tumour has been recog­
nised in larger endometrial cancers (Castagnetta et al., 1983).
3.1.3.2 Variability in Soluble Oestrogen Receptor across the same
Breast Tumour relative to 4S;8S Ratios (Peripheral and 
Adjacent Sections)
Table 5 shows an intratumoural study of soluble oestrogen receptor concen' 
tration and the corresponding molecular forms. Where one molecular form 
of ER^ was detected, this was normally the predominant form found across 
the tumour, even when an additional random section was analyzed (tumour 
numbers 3 and 4). In tumour number 8, however, the peripheral section 
had predominantly the 48 form of ER^, the adjacent section was negative 
and a third section, chosen randomly, showed predominantly 88.
With respect to receptor concentration (Table 5), tumours
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number 1-5 all showed the peripheral section lower in ER^ (cf. tumour 
number 1 in Table 4) relative to adjacent section, but a fall towards the 
centre was evident (see Figure 27 for tumour number 1 reported in Table 5). 
In Figure 27 the Protein:DNA ratio indicated that, perhaps, the cell number 
is lower in the outside or peripheral section and this may be the reason for 
low receptor values recorded in this section. Table 5 further shows that 
tumours number 6-8 all indicated a drop of ER^ content from the periphery 
to the centre as detected using DCC single point assay prior to SDGA. 
However, no receptor could be detected on gradient in any of the three 
sections for tumour number 7 and for one section of tumour number 8. Again, 
tumour number 9 showed low receptor concentration of ER^ throughout as 
judged by DCC single point assay, but no receptor could be detected on 
the gradient. Finally, tumour number 10 was judged negative by both DCC 
and gradient analysis and is illustrated as an example of control.
When ER^ concentration was expressed per unit DNA, rather than 
per unit protein, individual tumours showed a reduction in variation (see 
tumour number 1 in Table 6’ and tumour number 6 in Table 6). However in 
the two axillary node tissues studied (tumour number 2 in Table 6 and the 
tumour reported in Table 7), the reverse was found to be the case i.e. 
variation increased when results were expressed per unit DNA. Once again, 
although the number of tumours analyzed was small, the possibility of 
lymph gland infiltration with leukocytes (Silfversward et al.,1980) might 
provide the answer for such variation. The possibility of having oestrogen 
receptor positive and negative cells in the same tumour should also be 
considered.
Wittliff and Savlov (1975) have presented evidence that two 
sections from the same tumour show the same distribution of molecular 
forms. This observation is confirmed and extended by the data in Table 5
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and 6. The recently published results of Izuo et al. (1982) show data 
similar to those presented here. However, the sedimentation patterns 
and associated changes in concentration of the molecular forms were not 
previously documented. The observation that, in a single tumour, one 
section was receptor positive whilst another receptor negative confirmed 
the results of Poulsen (1981). Such cases however, are rare.
3.1.3.3 Variability in Soluble Oestrogen Receptor across the same
Tumour (Random Sections)
Table 6 is an accumulation of data from 12 tumours in which two 
sections were randomized prior to analysis with respect to receptor concen­
tration and molecular form. A very similar pattern to that reported in 
Table 5 was found, i.e. tumour preserves its status with respect to the 
molecular form. However in one case, tumour number 8, the distribution 
of 48 and 88 concentration in Section A was predominantly 48 (>70%) whereas 
Section B was classed as containing both 48 (59%) and 88 (Figure 28.1).
This conclusion depends very much on the small amount of 88 recovered in 
Section A and may be of limited significance. Experimental artifacts, such 
as aggregation of receptor can result in false estimation of total receptor 
concentration from the gradient (see Section 3.1.1.8). However, in tumour 
number 8 (Table 6), there was total recovery of receptor concentration on 
the gradient and, therefore, no evidence of 88 being lost through aggre­
gation.
In keeping with Table 5, Table 6 also demonstrates the variation 
of 48 and 88 profile from two sections of the same tumour. Figure 28.2, 
representing tumour number 2 in Table 6, demonstrates another case of 
extreme variation where Section A can be classified as 48 + 88 type and 
Section B as predominantly 88 type.
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Figure 28.1. Intratumoural Variation in the Sedimentation Profile of 
Oestrogen Receptor from Human Breast Tumour Cytosol 
(Random Sections)
Two sections of human breast tumour were selected 
randomly for analysis. Cytosol was prepared, labelled, 
stripped of free steroid and analyzed as described in 
Section 2,2.2.1 (patient CB). Protein concentration 
was 8.2mg/ml in A and 3.2rag/ml in B. Receptor con­
centration in A was 76fmoles/rag protein and in B, 
115fmoles/mg protein. Percentage recovery was near 
100% in both A and B . Centrifugation was at 4°C for 
I4h at 45,000 rev/min in a Beckman SW 50.1 rotor.
- 147 -
ïntratumoral variation in the sedimentation profile of 
ER^ from human breast tumor cytosol (random selection)
1400-1
4.68
1200-
1000 -
800-
co
a
&
600-
400-
200 -
Top
10 20 30 40
— Total cpm
Nonspecific cpm
B
500-1
4.68
400-
200-
100
Top
10 20 30 40
Fraction Number
Figure 28.2. Intratumoural Variation in the Sedimentation Profile
of Oestrogen Receptor from Human Breast Tumour (Random
Sections)
Two sections of human breast tumour cytosol were selected 
randomly (Figure 9) for analysis. Cytosol preparation 
and SDGA was as described in Section 2.2.2.1. Details 
are given in Figure 24. Percentage recovery was 94% 
in A and 80% in B.
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Tumour number 7 in Table 6 was reported as ER^/ER^ clinically. 
This was based on one section analyzed. However for a further four sections, 
Scatchard analysis showed that two of these could be classified into 
ER^ /ER^ "** class (data provided by M. MoM&namin). When a further three sec­
tions were analyzed by both Scatchard and gradient analysis, all sections 
showed 4S + 8S profile, yet one of these sections proved to be ER^*^/ER^“ 
type. This implies that 8S was present in a +/o sample. This may question 
the validity of the idea that the presence of the 88 form predicts patients 
response (Wittliff and Savlov, 1975).
As previously indicated, some tumours showed a considerable 
proportion of ER^ sediraenting to the bottom of the tube (tumour number 
1 and 9 in Table 6). Receptor assays based only on SDGA could seriously 
underestimate total ER^ if the tube -bottom associated receptor were not 
taken into account.
Table 7 shows nine sections studied from a very large axillary 
node mass. The 8S form is predominant throughout. This result, in 
conjunction with that of tumour number 2 in Table 6, suggests that 
axillary nodes are more homogeneous than primary tumours in terms of 
malignant cell population.
3.1.3.4. Summary of Results of Intratumoural Study
Variation was found in receptor concentration across individual 
tumours. The peripheral and intermediate sections contained a higher 
proportion of receptor relative to the central sections. As judged from 
both selected and random sections, the molecular status of a tumour 
qualitatively was constant throughout. The 4S : 8S ratio, however, did 
show variation between sections from the same tumour. In only 4 cases 
out of 46 (9%) where both 4S and 8S could be detected was the intratumoural
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change large enough to have altered the actual classification of molecular
status e.g. 8S— >8S + 48 or 88 + 48---»48. This assumes that greater than
70% of one receptor species makes the tumour predominant in that species.
3.1.4 Effect of Mixing Breast Tumour Cytosol with Immature Rat Uterine
Cytosol
The previous section demonstrated that the 48 and 88 form of 
ER^ can co-exist in different proportions in different tumours and even 
within the same tumour. This most probably reflects an effect of variable 
levels of protease(s) acting on the 88 form (or the salt dissociated 48 
aggregatable type). Immature rat uterine ER^ sediments primarily as an 88 
complex. Advantage of this was taken to see if the human tumour protease(s) 
recognises and proteolyses rat receptor. Figure 29 shows that, indeed, 
such an effect was observed with a quantitative conversion of rat 88 
receptor into the 48 form. No loss of oestrogen binding capacity was 
observed suggesting a very specific site(s) for the protease action (a 
bifunctional domain of receptor aggregation site(s) and receptor oestrogen 
binding site, on the same receptor molecule, with considerable distance 
between them). It is not known if a complete conversion of 88 into the 
48 form would have taken place over a longer incubation period. Neither 
was the effect of a tumour cytosol containing mainly 88 receptor tested.
It is quite possible that tumours showing predominantly 88 complex may 
have a lower proteolytic effect. The tumour cytosol used in Figure 29 
was of the 48 + 88 type.
8orae preliminary data (not shown) indicated that mixing human 
breast tumour cytosol with immature rat uterine cytosol prevents the 
48— »58 conversion associated with immature rat uterine transformation 
reaction. This is in agreement with results presented by 8ato et al.
(19%1a, b) and lends further support to the alteration of receptor
Cvj
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structure by an activity present in tumour cytosol.
3.1.5. Sedimentation Profile of Mature Rat Uterine Oestrogen Receptor
at Various Stages of Oestrous Cycle
The previous observations of 8S— conversions as a proteo­
lytic sleavage step prompted an investigation of mature rat uterine soluble 
oestrogen receptor sedimentation profile at various stages of the oestrous 
cycle. It was possible that there might be a stage at which an exclusive 
4S form could be located. This would therefore provide a rich and a con­
venient source of protease activity for further characterization of its 
significance. Previous observations have indicated that a pro-oestrous, 
the DMBA induced mammary carcinoma lack the 8S form (Freedman and Hawkins,
1980). At pro-oestrous plasma oestradiol concentration is highest. Two 
possible explanations could, therefore, be that (i) all functional (8S) 
receptor is now present in the nuclear compartment leaving the non­
functional receptor (4S) in the cytoplasm or (ii) there is an abundance
of oestrogen induced protease-like activity (cytosol or nuclear) promoting 
8S— >4S conversion. An oestrogen induced trypsin-like activity has been 
reported (Katz et al., 1976). Muldoon (1977) has also related plasma 
oestradiol concentration to the 4S and 8S forms in mouse mammary tissue. 
Interconversion of 4S and 88 forms of oestrogen receptor is also found 
in normal rat mammary gland during pregnancy and lactation ( Mohla et al.,
1 9 8 1).
Figure 30 shows that in the rats, undergoing a 4 day oestrous 
cycle, uterine cytosols show the presence of 88 receptor at all stages.
The 48 form can also be detected at every stage but it seems to be minimal 
at dioestrous, the time at which oestrogen concentration is lowest, and 
highest at about oestrous, the time at which the uterus has just passed
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the maximal exposure to oestrogen. Once again this would favour the 
view that there is an oestrogen-induced enzyme capable of regulating 
receptor molecular form in vitro.
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3.2 ACTIYATION/TRANSFORMATIOH STUDY
3.2.1 Oestrogen Receptor Binding to DNA-Celluloae as a Measure of
Extent of Activation ^
3.2.1.1 Conditions for DNA-Gellulose Binding Assay
3.2.1.1.1 Influence of Non-Specific Proteins on Extraction of Steroid
from DNA-Cellulose
To measure the non-specific retention of tritiated oestradiol- 
17^ (^HEg) on the DNA-cellulose slurry, H D K . b u f f e r  was made 5 x 10"^M
3
with respect to HE^ in the presence or absence of receptor-free cytosol.
This cytosol was prepared from an ER^/ER^" tumour, thus providing 
approximately the same protein environment as when ER^^VER^^ cytosol was 
analyzed for receptor activation. The exact precedence described in 
Section 2.2.4.1.1 to measure receptor activation was then followed. After 
cooling to 4°C, 200ul aliquots of activated cytosol (or control) were 
introduced into a series of tubes containing increasing concentration of 
DNA-cellulose (DNA range 20-200ug). Table 8 demonstrates that, when using 
ER^ /ER^  tumour cytosol in HDK  ^^ , there is complete recovery of total 
counts, A small but insignificant retention of counts was noted with 
increasing DNA-cellulose concentration. Similar results were obtained 
if HDK was used in place of buffered cytosol, DNA-cellulose, under 
these conditions, does.not retain free steroid.
3.2.1,2 Studies with Immature Rat Uterine Soluble Oestrogen Receptor
3.2.1.2.1 The Effect of Washing DNA-Cellulose after Incubation with Cytosol 
Containing Activated and Non-activated Receptor
The effect of washing on binding of steroid-receptor complexes 
to DNA-cellulose was tested using both heated (30°, 30’) and control
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cytosol (Section 2.2.4.1,1). After each wash the supernatant obtained 
was checked for specific receptors, using the DCC assay. This was the 
method used by Park and Wittliff (1977) in their DNA-cellulose study 
of activation. However, Table 9.1 shows that the DCC treatment probably 
results in a gross underestimation of the total receptor bound to DNA.
(It was shown in Table 8 that free steroid is not retained by DNA-cellulose, 
therefore the 25,383 counts obtained from DNA cellulose slurry (Table 9.1) 
after incubation with activated cytosol most probably represent specific 
receptor. After incubation with DCC the salt extracted supernatant only 
registered 3,726 counts). Even so, activation does result in a greater 
proportion of receptor bound to DNA. As has been previously indicated 
both ionic strength and protein concentration can influence the DCC assay 
(Section 2.2.4.2). Table 9.1 also shows that most of the free counts 
were removed by Wash 5. Further washing was therefore not carried out, 
although employing an analogous procedure, Sato et al.(1981a) concluded 
that no loss of DNA-bound receptor occurs even after extensive washing.
Table 9.2 shows that, when using DES competitor, no significant 
counts are retained by the DNA cellulose slurry and, therefore, the salt 
extracted counts from incubation in the absence of competitor do represent 
specific receptor. Similarly alcohol failed to extract any further counts 
from incubation tubes containing competitor. However, there were alcohol 
extractable counts present in tubes incubated in the absence of DES 
competitor. This implies that a single extraction with 0.6M KCl-containing 
buffers fails to extract total receptor.
3-2.1.2.2 Sedimentation Properties of Receptor Recovered from DNA-Cellulose
To check that DNA-bound receptor did not represent aggregated
3material or non-specific retention of HE^, SDGA was carried out. After 
salt extraction of receptor from DNA-cellulose an aliquot (200ul from
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Table 9.2. Analysis of Salt Extracted DMA-celluloge Bound Counts
in the Presence of Competitor and in the Absence of any 
DCC Treatment of the Supernatant
The procedure was the same as that described for Table
9.1 except that there was no DCC treatment of supernatant 
obtained from washings or salt extraction. Aliquots from 
salt extracted receptor (40% of the counts shown) were 
loaded onto SDG (Figure 31).
— IS 0 —
Non-activated Cytosol 
4°, 30'
Activated Cytosol 
30°, 30'
3hE2 ^HEg +DES ®HE„ +DES
Wash 1 39,652 53,540 22,050 53,318
Wash 2 3,857 7,585 3,135 8, 230
Wash 3 1,392 1,915 1,315 1,872
Wash 4 978 560 1,018 597
Wash 5 782 208 997 256
Salt
Extract 9,673 405 25,634 487
Alcohol
Extract 4,766 393 10, 340 435
Total 61,100 64,606 64,489 65,195
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500ul total extraction volume - Table 9.2) was loaded onto a 5-20%
linear sucrose density gradient prepared in either HED or HEDK ^
(Figure 31). Salt extraction represents a relatively purified form
of receptor. The purified receptor is known to aggregate (Puca et al.,
1 9 8 0) and this was seen when the receptor was loaded onto the gradient
prepared in HED (Figure 31 A). There was also a trailing effect of free
steroid towards the top of the gradient. However when a high salt
gradient was used (Figure 3IB), the aggregation was retarded, although
there was still a trailing effect. In the high salt gradient, the bulk
of the receptor sediraented after the ^^C-BSA marker (4.68) as a broad
peak. No sedimentation peak was seen in the gradient containing salt
extracted material from tubes containing the competitor DES. The counts
observed at the top of the gradient could not be free HE^ which had been
trapped in the DNA-cellulose since, if this was the case, similar counts
would have been observed in the gradient of the DES competition control
(.... ) in Figure 31A and B . Further as is shown in Figure 32A and B,
the counts extracted from DNA-cellulose after incubation with activated
cytosol and washing (Section 2.2.4.1.1), will sediment as a sharp peak 
14
(after the C-BSA marker) if ovalbumin (Figure 32A) or BSA (Figure 32B) 
is included in the KCl extraction buffer (4mg/ml) and the centrifugation 
buffer (200ug/ml). The best results were obtained when BSA was included 
as the carrier protein both in the extraction and gradient buffers 
(Figure 32B - sedimentation peak 5.5S). This is probably because BSA 
provides the best protection of receptor in the 4-58 area, being a 
molecule of similar size. The recovery of counts from the gradient was 
low in the absence of added proteins but with the carrier protein in 
the gradient, recovery was increased to approximately 60%. If the whole 
centrifuge tube was extracted with alcohol after removal of the sucrose 
gradient, recovery could be increased to 75%.
Figure 31. Analysis of Salt-extracted Receptor from DNA-cellulose on 
Low and High Salt Gradients
The DNA-cellulose binding assay of immature rat uterine 
cytosol receptor was as described in Section 2.2.4.1 and 
2.2.4.1.1. After the binding assay, the receptor was 
extracted with HDK.^ from DNA-cellulose and 200ul aliquots 
were loaded onto 5-20% gradients prepared in either HED(A) 
or HDK.^ (B). Centrifugation was for I6h at 4°C at 45,000 
rev/rain in a Beckman SW 50.1 rotor. Profiles in the absence
(----) or presence (....) of DES are shown. The percentage
recovery of salt extracted counts in A (---- ) was 77% (com­
prising 34% within the gradient, 10% at the bottom of the 
tube and.33% from the walls of the tube extracted with
alcohol). The percentage recovery in B (---- ) was 85%
(comprising 44% within the gradient, 3% at the bottom of 
the tube and 38% attached to the walls of the tube). The 
sedimentation of receptor in B was as a broad 58 peak.
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An unexpected result was obtained when using human-#-globulins 
in the KCl extraction buffer and the gradient buffer. When the same 
cytosol incubation as that shown in Figure 32A and B was extracted with 
KCl buffer containing 4mg/ml of human-'jJ-globulins, a very low concen­
tration of receptor was solubilized (Figure 32C). The reason for this is 
not clear.
Thus the molecular form of receptor bound to DNA-cellulose is 
5S. Further, inclusion of non-specific (DES) values is unnecessary in 
DNA-cellulose binding experiments when only the level of activation is 
to be determined. However, an estimate of total and non-specific binding 
of the cytosol used for the assay is needed to quantitate the specific 
receptor present, bound to DNA. Exclusion of a DES value from the binding 
assay only applies when quantitating activated receptor from immature rat 
uterine cytosol. In the case of human breast tumour ER^ activation assay, 
the total DNA bound counts are relatively low (Section 3.2.1.3) and, 
therefore, DES values must be included.
3.2.1.2.3 Temperature Dependence of Activation of Oestradiol-Receptor
Complexes
Using a constant time of 30 min, the optimum temperature for 
maximum activation was determined, as measured by binding of activated
3
HEg-receptor complexes to DNA cellulose (Figure 33). It can be seen 
that when the cytosol was heated at 30^C for 30 rain (30°, 30') in the
3
presence of HEg, maximum binding to DNA-cellulose was obtained. Under 
these conditions approximately 90% of the specific counts were bound 
to DNA cellulose. Slight variation in maximum binding was obtained, 
as discussed later (3.2.1.2.7). A significant proportion (/v30%) of 
receptor was bound to DNA even from the non-heated control. This 
presumably reflects activation in HDK at 4°C. If the labelled
Figure 33- Effect of Temperature on Activation of Immature Rat 
Uterine Oestrogen Receptor
Immature rat uterine cytosol was prepared and labelled 
at 4°C for Ih as described in Section 2.2.4.1 (protein 
concentration 3.6mg/ml, receptor concentration 3.1nM). 
Aliquots of cytosol were then incubated at the indicated 
temperatures for 30 rain. These were then returned to 
4°C and kept for a further 5 minutes. The DNA-cellulose 
binding assay was then carried out as described in 
Section 2.2.4.1 and 2,2.4.1.1. (#— #  salt extracted 
receptor, (#...#) alcohol extracted receptor + salt 
extracted receptor.
- 16 5 -
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cytosol was heated to 37°C for 30 min. rather than 30^C for 30 min, 
then there was a fall in the number of receptor complexes bound to DNA 
cellulose. This most probably resulted from aggregation (37°C promotes 
rapid aggregation of receptor, data not shown) or destruction of receptor 
by masking or destroying the DNA binding site.
3.2.1.2.4 Time Course of Binding of Activated Receptor to DNA-Celluloae
Figure 34 shows that after activation (30°, 30'), maximum 
binding of activated receptor to DNA-cellulose was observed within Ih.
The alcohol extractable receptor binding population did not show time 
dependence indicating that certain sites on the DNA were rapidly filled. 
These may be the highest affinity binding sites (Spelsberg, 1976). The 
saturation of salt extractable counts possibly demonstrates the occupa­
tion of the lower affinity sites. Its quite possible that the lowest 
affinity receptor complex 'binding sites may dissociate during washing 
and perhaps explains why binding of 100% of receptor to DNA was not 
observed. Alternatively, there could be (i) an equilibrium between the 
activated and non-activated receptor (Atger and Milgrom, 1976) such that - 
there is always a proportion of non-activated receptor, (ii) loss of 
some DNA during washings, (iii) dissociation of activated into non- 
activated form during washing, (iv) lack of activation factor(s) limiting 
the extent of activated receptor and (v) presence of a form of receptor 
which cannot undergo activation. Further, heating the cytosol invariably 
leads to some aggregation which could mask the DNA binding site on indi­
vidual receptor molecules (Nishizawa et al., 1981, Sakly and Koch, 1982)
3.2.1.2.5 Binding of a Constant Amount of Receptor to an Increasing 
Concentration of DNA-Celluloae
It can be seen (Figure 35) that the use of lOOug DNA provided
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Figure 35. Influence of Increasing DMA Concentration on Binding of 
Activated Oestrogen Receptor from Immature Rat Uterine 
Cytosol
Immature rat uterine cytosol was prepared and labelled 
at 4°C for Ih as described in Section 2.2.4.1 (protein 
concentration 3.4mg/ml; receptor concentration 2.5nM)' 
Cytosol was then warmed to 30°C for 30 min, cooled to 
4°C for 5 min. and then incubated with increasing con­
centrations of DNA-cellulose (DNA 20-200ug). The DNA- 
cellulose binding assay was carried out as described in
Section 2.2,4,1 and 2,2,4.1.1 (#---#) salt extracted
receptor, (o***0) alcohol extractable receptor.
— 168 —
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3
the highest level of bound HE^-recepton complex after activation. Lower 
values of DNA also showed values close to maximum binding. The standard 
deviation obtained for each point within a single experiment was very low 
in all experiments using DNA-cellulose. Figure 35 further shows that 
saturation was obtained with the salt extractable counts, although 
binding began to drop when higher concentrations of DNA were used 
suggesting that the receptor was limiting. The alcohol extractable 
counts, however, seemed to increase with increasing concentration of 
DNA. The significance of this was not clear. However, if this was a 
genuine increase then it might further lend support to the concept that 
the high affinity receptor binding sites on the DNA are not salt extrac­
table (Clark and Peck, 1979; the concept of salt resistant receptor is 
mainly derived from studies with whole nuclei).
3.2.1.2.6 Binding of an Increasing Concentration of Activated Receptor
to a Fixed Amount of DNA
The optimum ratio of activated receptor to DNA-cellulose, should 
be the same whether it is the DNA or receptor concentration that is being • 
varied. This was found to be indeed the case (Figure 36). In Figure 
36(b) and (c), the concentration of activated receptor was adjusted with 
inactivated immature rat uterine cytosol (heated in the absence of steroid 
for 2h at 37^C) to give the same final volume and protein concentration.
In Figure 36(a), however, there was no dilution and the activated cytosol 
was simply mixed with the DNA-cellulose slurry. The binding in Figure 
3 6 (a) was of the same order of magnitude as in Figure 3 6 (b). The heated 
(37°C, 2h) immature rat uterine cytosol still showed /v 50% of the original 
counts intact. This, however, did not influence the linear relationship 
observed in Figure 36( (b), (c) and (d)). If the heated cytosol was 
exchanging any steroid for that from the activated cytosol then there
Figure 36. Influence of Increasing Activated Receptor Concentration 
on DNA-celulose Binding, (Immature Rat Uterine Cytosol)
Immature rat uterine cytosol was prepared and labelled at 
for Ih as described in Section 2.2,4.1 (protein con­
centration 3.4mg/ml; receptor concentration 3nM). Cytosol 
was then warmed to 30^0 for 30 min, cooled to 4°C for 5 
min. and then increasing concentrations of cytosol were 
incubated with lOOug DNA cellulose. In (a) there was 
no dilution of cytosol while in (b), (c) and (d) the 
volume was adjusted to 600ul with either the same cytosol 
which had been previously heated to 37°C for 2h in the 
absence of steroid, or with buffer, as shown. The DNA- 
cellulose binding assay was carried out a s  described in 
Sections 2 . 2 . 4 . 1  a n d  2 . 2 . 4 . 1 . 1 .  ( # — #)  s a l t  e x t r a c t e d  
r e c e p t o r ,  (O-— O) a l c o h o l  e x t r a c t e d  r e c e p t o r .
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should have been a difference in the extent of binding between Figure 3 6 (a) 
and (b). This would have been the case if the heated cytosol contained 
any activated receptor (it should not since the heating was done in the 
absence of steroid). In addition, heating at 37°C leads to receptor 
aggregation (data not shown) and most probably loss or masking of the 
DNA binding site (Sakly and Koch, 1982). Thus heated cytosol (37°C, 2h) 
is inactive and not influencing DNA-binding of activated receptor 
(activated cytosol - 30°, 30’), when the two are mixed. It is further 
shown in Figure 36 that alcohol extractable counts also increase with 
increasing activated cytosol incubation with a fixed amount of DNA- 
cellulose (of. Fig.35)-
3 .2 .1.2 . 7  Percentage Binding of Soluble Receptor from Activated and
Non-activated Cytosol and Extent of Salt and Alcohol Extraction
Table 10 shows the total binding obtainable with the activated 
receptor from three different experiments. A higher proportion (rv 80%) 
of receptor from the activated cytosol binds to DNA when compared to 
control (28%). Approximately 70% of the DNA-bound receptor was salt 
extractable, using a single extraction. This is in agreement with 
published results of Katzenellenbogen et al. (1980) using intact immature 
rat uteri nuclei. Variation between experiments was obtained in the total 
amount of receptor bound to DNA-cellulose from the activated and non- 
activated cytosol, yet the ratio of salt and alcohol extractable receptor 
was always similar for both conditions. This implies that non-activated 
cytosol contains a proportion of activated receptor which can bind DNA 
without prior warming. This observation is documented (Le Fevre et al., 
1 9 7 9) and could be the result of inclusion of 0.15M KCl and exclusion 
of EDTA from the homogenization and incubation buffers. Salt is known 
to induce activation (Notides, 1978). Table 11 shows accumulated results
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from 9 experiments with HDK ^^  buffer. It confirms the data in Table 10 
showing that approximately 80% of the total receptor from activated cytosol 
is capable of binding to DNA-cellulose and about 70-80% of this is released 
on one salt extraction.
3.2,1.2,8 The Effect of Sodium Molybdate on Receptor Activation
The effect of sodium molybdate in inhibiting receptor activa­
tion is well documented (Section 1.1.5.3.2). This effect was confirmed 
(Figure 37). However, inclusion of 20mM sodium molybdate, still left 
^20% of the receptor whose activation could not be inhibited when 
compared to the 4°C control. A similar level of DNA-bound receptor 
was observed whether sodium molybdate was added just prior to activation 
or at the start of incubation with HE^. The same cytosol without sodium 
molybdate, showed a much greater proportion (90%) of receptor bound to 
DNA cellulose after activation (Figure 37). In addition, if sodium 
molybdate was added to the homogenization buffer (HDK + 20mM sodium 
molybdate) and the incubation and activation performed as before, again 
rs/20% of the receptor was bound to the DNA cellulose (Figure 38).
However, interestingly, in this experiment, activation in the 4° control 
was completely absent (Figure 38). It appears, therefore, that A,20% of 
the receptor population normally activated by 30°, 30' incubation is not 
sensitive to sodium molybdate under the present experimental conditions.
The optimum time of exposure to sodium molybdate was not specifically 
established. Data in Figure 37 might suggest that exposure time to 
sodium molybdate was inadequate but Figure 38 was drawn from experi­
ments in which the sodium molybdate was present throughout. This shows 
the same level of molybdate-resistant binding suggesting that the 
observation is real.
Figure 37. Effect of Sodium Molybdate on Activation of Immature 
Rat Uterine Cytosol Oestrogen Receptor
Immature rat uterine cytosol was prepared and labelled 
at 4°C for Ih as described in Section 2.2.4.1 (protein 
concentration 3.6mg/ml; receptor concentration S.lnM).
3
At the start of incubation with HE^ one set of aliquots 
was made 20mM with respect to sodium molybdate (D). A 
second set of aliquots were similarly treated with sodium 
molybdate just before the heat activation step (C). Two 
further sets were kept sodium molybdate free. One set of 
sodium molybdate free cytosol (A) was retained at 4*^ 0, 
all other cytosols were warmed to 30^C for 30 min. includ­
ing a sodium molybdate free cytysol (B). The warmed 
cytosol aliquots were cooled to 4°C for 5 min. DNA- 
cellulose binding assay of all the aliquots was as 
described in Section 2.2.4.1 and 2.2.4.1.1 ( ®  ) salt
extracted receptor, ( D  ) alcohol extracted receptor.
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Figure 38. Influence of addition of Sodium Molybdate to the 
Homogenization Medium on Receptor Activation
Immature rat uterine cytosol was prepared in 
containing 20mM sodium molybdate and labelled for Ih 
at 4°C as described in Section 2.2.4.1 (protein con­
centration 3.4mg/ml; receptor concentration 2.5nM).
While keeping one set of aliquots at 4°C, another set 
was warmed to 30°C for 30 min. Warmed cytosol was then 
cooled to 4^C for 5 min. Both sets were then incubated 
with DMA-cellulose and the binding assay carried out 
as described in Section 2.2.4.1 and 2.2.4.1.1 (13) salt 
extracted receptor, ( O ) alcohol extracted receptor.
Figure represents the percent specifically bound steroid 
retained by the DNA (Salt soluble + salt resistant counts) 
at the end of the extraction procedure. After a second 
experiment corresponding mean values were 2 and 25 
respectively.
- 176 -
100
Q
Bo
k,«4H
73
O
k,
>
O
o
(U
k,
CM
a
CO
73
C
P
O
,o
o
CD
a
CO
>
20 -
16 —
12 -
8 -
4 -
Salt extracted receptor 
I I Alcohol extracted receptor
30'
Percent retained
30°, 30' 
28
177 -
3.2.1.3 DNA-Cellulose Binding of Soluble Oestrogen Receptor from 
Human Breast Cancer
Early attempts to show binding of the activated receptor (ER^) 
from human breast tumour to crude nuclear pellets, derived from the same 
tumour, were unsuccessful (data not shown). Park and Wittliff (1977) 
have commented on similar problems associated with nuclear preparations 
from mammary tissues. The failure of the earlier reconstitution experi­
ments was probably due to the following reasons
a) the human breast tumour cytosol, when heated for activation, 
resulted in the degradation of receptor to the 48 form (Figure 15) 
probably through the proteolysis of the 48 form (the form which can 
aggregate to 88 form in low salt)
b) this protease effect can be inhibited with OFF (Figure 51) 
which was not used in earlier experiments
c) the proteolyzed 4S form probably does not bind to DNA 
(Figure 43).
3.2.1.3.1 Activation and DNA-celluloae Binding of Human Breast Tumour 
Soluble Oestrogen Receptor in the Absence or Presence of DFP
Figure 39 shows that the human breast tumour receptor, like 
that from the rat, showed temperature dependent binding to DNA-cellulose 
However, the maximum binding obtained (only 18% of total receptor) was 
strikingly in contrast to the 90% or so binding obtained with immature 
rat uterine activated receptor (Figure 33). The results presented in 
Figure 40 and Table 12 show that, in the presence of DFP, significantly 
more receptor was bound to DNA-oellulose after activation compared to 
control. Comparison of Figure 39 and 40 shows the variability that can 
be obtained in DNA-cellulose binding of human activated receptor in the
Figure 39. Effect of T«nperature on Human Breast Carcinoma Cytosol 
Oestrogen Receptor Activation
Human breast tumour cytosol was prepared in HDK.^^ as 
described in Section 2.2.3.2 (patient SN; protein con­
centration 8.2mg/ml). The DNA-cellulose binding assay 
was as described in Section 2.2.4.2. Receptor concentra 
tion of the cytosol preparation was 4l6fmoles/mg protein, 
(Q) Salt extractable receptor, (■) alcohol extractable 
receptor.
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Figure 40. Effect of DFP on Termperature-dependent Activation of 
Receptor from Human Breast Cancer
After homogenization of tumour cytosol in HDK.^^ (Section 
2.2.3-2) one portion of the horaogenate was made lOraM with 
respect to DFP. Cytosol was prepared as described in 
Section 2.2.2.1 and DNA-cellulose binding was as described 
in Section 2.2.4.2 except that both the cytosols in the 
absence and presence of DFP were heat activated at 30°C 
for 30 min. (Q) receptor bound in the absence of DFP,
( D  receptor bound in the presence of DFP. The recover­
able receptor shown is the sum of salt extracted and 
alcohol extracted receptor. The receptor concentration 
for Tumour 1 (patient SC), was l46fmoles/mg protein (pro­
tein concentration 2.2mg/ml) in the absence of DFP and 123 
fmoles/mg protein (protein concentration 2.6mg/ml) in the 
presence of DFP, The receptor concentration for Tumour 2 
(patient FM) was 136fmoles/mg protein (protein concentra­
tion 8.6mg/ml) in the absence of DFP and 101fmoles/mg 
protein(protein concentration 9.2mg/ml)in the presence 
of DFP .
- 179
TD
CD
L_
CD
>
O
CJ
CD
CNJ
E f f e c t  o f  DFP on Human Tumour
O
o
CJ
CD
Q.
CO
ERc
100 -,
35 -
30 -
25 -
<czo 20 -
EoL_ 15 -4-
10 -
5 -
DFP
n
Tumour 1 Tumour 2
Table 12. Influence of DFP on Recovery of* Receptor from DNA- 
Cellulose
Human breast tumour was homogenized in HDK.^^ and 
immediately divided into two halves. To one half 
DFP was added to a final concentration of 1OmM and 
both DFP containing and DFP free cytosols prepared 
as described in Section 2.2.3.2. After heat activa 
tion at 30°C for 30 min, the cytosol was incubated 
with DNA-cellulose and the binding assay and salt 
and alcohol extraction carried out as described in 
Section 2.2.4.2.
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Activated Cytosol 30^, 30'
- DFP + DFP
^HEg +DES ^HEg +DES
Wash 1 39635 44970 43440 42535
Wash 2 4700 6300 5915 6345
Wash 3 832 1487 1122 1322
Wash 4 222 412 382 372
Wash 5 65 95 115 120
Salt Extracted 186 133 581 124
Alcohol
Extracted 532 197 1477 248
Total 46172* 53594 53032 51069
Recovery Of cpm throughout was ^90% except in this case 
(recovery 84%).
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absence of DFP (3-18%), confirming the data of Sato et al. (198la),
Table 12 shows the effect of washing DNA-oellulose after the receptor 
binding reaction, indicating that the problem is not due to loss of 
counts during the experiment. DFP was used in these experiments since 
it is known to be the most potent inhibitor of the trypsin-like activity 
encountered in human tissue (Notides et al., 1976; Lukola et al., 1980; 
Lukola and Punnonen, 1982). The results presented in Figure 40 show 
that a greater proportion of receptor (about 5-fold more) bound to DNA- 
cellulose in the presence of DFP. When Park and Wittliff (1977) noted 
the lower binding obtained with human breast tumour ER^, their experi­
ments, like those of Sato et al. (198la),were conducted in the absence 
of protease inhibitors. However, even in the presence of DFP the 
extent of binding of human breast tumour activated ER^ was much lower
than that obtained with immature rat uterine activated ER in the
c
absence of DFP. Nevertheless, the binding was more in the presence 
than in the absence of protease inhibitor in human tumour cytosol. It 
was also noted that in the presence of DFP, the total specific counts 
obtained (by DCC method) were lower than from the same cytosol in the 
absence of DFP. This is in agreement with results published by Notides 
et al. (1 9 7 6) and Lukola et al. (1979).
Finally, Table 13 shows that, in contrast to the immature 
rat uterine activated ER^ binding (Table 11), the human breast tumour 
receptor is less easily extracted with salt from the DNA-cellulose and 
a greater proportion is, correspondingly, only extractable in alcohol. 
However, the actual counts obtained were too low (see Table 12) to be 
resolved on SDGA. The difference in salt extractability of human and 
rat receptor may indicate different types of interaction of receptor 
with DNA from two different sources. Such differences in salt
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extractability of receptor are documented (Katzenellenbogen et al., 1980 
where tissue under investigation was human endometrium and immature rat 
uteri).
3 .2 . 2 Analysis of DNA Oeatrogen-receptor Interaction using Low
Salt SDGA
It has been suggested that the proteolyzed receptor, which 
sediments at 3-48, fails to bind to DNA (Andre and Rochefort, 1973; 
Rochefort et al., 1980). Nevertheless, the appearance of 48 receptor 
in low salt cannot be ascribed solely to proteolysis since, it is known 
that the 88 form may dissociate reversibly into the 48 form (Wittliff 
et al., 1972 - cited in Leake, 1981b). However, it has recently been 
suggested (Park and Wittliff, 1980) that human breast tumour 48 receptor 
fails to bind to DNA, reflecting the proposal that patients, whose 
tumours contained only the 48 form of receptor, failed to show sub­
sequent response to endocrine therapy (Wittliff and Savlov, 1975). In 
contrast, the results reported below show that, for some tumours at 
least, a large proportion of 48 as well as 88 was removed from the 
gradient by the soluble calf thymus DNA.
3 .2 .2 .1 Interaction of Immature Rat Uterine Soluble Oestrogen
Receptor with Calf Thymus D M
To check the validity of the assay system (8ection 2.2.5), 
immature rat uterine soluble receptor, known to sediment at 88 under 
low salt conditions was used. In accordance with published results of 
Toft (1973), the 88 receptor complex was shown (Figure 4lA and B) to 
bind to calf thymus DNA and sediment to the bottom of the tube. This 
result confirmed that the 20 minute incubation with DNA prior to sedi­
mentation, removed most activated receptor from the cytosol. One
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further effect, reported in Figure 41(C) was that in the presence of 
excess protein (lOmg/inl BSA added to the cytosol at the time of incuba-
3
tion with HE^) the profile was effectively unaltered, although a small 
additional peak at 4.68 was observed. This most probably represents the
3
HE^ non-specifically associated with the BSA. This latter experiment 
was included to check the effect of protein concentration on DNA binding 
since breast tumour cytosol preparations had a higher protein concentra­
tion range than that generally used with the immature rat uterine cytosol. 
This does not exclude the possibility that the breast tumour cytosol may 
provide additional DNA binding proteins.
3.2.2.2 Interaction of Human Breast Tumour Soluble Oestrogen Receptor 
with Calf Thymus DNA
Analogous to the results reported in Figure 41, Figure 42
shows that the 88 form of human breast tumour ER bound to DNA andc
sedimented to the bottom of the tube in association with it. The small but 
sharp 48 peak observed in this low salt gradient became more disperse when 
the incubation was carried out in the presence of DNA. However, this is 
unlikely to represent a specific effect of the DNA. In addition Figure 
43 shows that in accordance with the proposed model of Wittliff, most of 
the 88 form of the receptor bound to the DNA, leaving behind most of 
the 4S form. i.e. the 48 form is less efficient in binding to DNA than 
is the 88 form. However, Figure 44 clearly demonstrates that in certain 
tissues 48 receptor bound to DNA equally efficiently. This latter 
observation indicates that some of the 48 form can exist with an intact 
DNA binding site. Most probably this 48 represents the disaggregated 88 
receptor rather than the proteolyzed form detected in Figure 43* It 
should be mentioned that these studies did not involve the warming
Figure 42. Influence of Addition of DNA on the Sedimentation Profile 
of Oestrogen Receptor from Human Breast Tumour Cytosol
Cytosol was prepared as described in Section 2.2.5 (patient 
DM ; protein concentration 4.4mg/ml). Aliquots were 
then incubated for 3h at 4°C with 5 x 10~^M in the
absence (----) or presence of DES (....). One set was
then made Img/ml (final concentration) with respect to 
DNA. Aliquots were further incubated for 20 min at 4°C, 
Following removal of unbound steroid with DCC, oestrogen 
receptor was separated on linear 5-20% sucrose density 
gradients at 50,000 rev/rain for l4h at 4*^ C in a Beckman 
SW 50.1 rotor.
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Influence of addition of DNA on sedimentation profile 
of oestrogen receptor from human breast tumor cytosol
260-1
No DNA
220
180- 4.63
eg
W
W 140 —
I -
100-
60 -
20-
Top
10 20 30 40
DNA Im g/m l.
-Total cpm 
• Nonspecific cpm
4.63
I%
Top
 1------ 1---1---1
10 20 30 40 
Fraction Number ^
Figure 43. Selective Binding of Human Breast Tumour Cytosol 8S 
Receptor to Calf Thymus DNA.
Human breast tumour cytosol was prepared as described
in Section 2.2.5. (protein concentration 8.2mg/ml; patient
IH). Aliquots were then labelled with 5 x 10"^M ^HE^ -1000
fold excess DES for Ih at This was followed by the
addition of DNA to a final concentration of Img/ml to one
set (,...) while keeping the other set DNA free (--- ).
Incubation was then continued for a further 20 min. at 4°C.
Following removal of unbound steroid by DCC, receptor was
separated on linear 5-20% gradients at 45,000 rev/min for
l4.5h in a SW 50.1 rotor at 4°C. Arrow indicates the posi- 
14
tion of C-labelled marker protein. The receptor concen­
tration, as determined by DCC analysis, was 93fnioles/rag 
protein . Percentage recovery in the absence of DNA was 
95%. In the presence of DNA total recovery of receptor 
including the counts determined at the bottom of the tube 
approximated to 96%.
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Figure 44. Binding of both 8S and 48 Oestrogen Receptor to Calf 
Thymus DNA
Cytosol was prepared in HED as described in Section 2.2.5 
(_A, patient CM, protein concentration 6.2mg/ml; B, patient 
IH, protein concentration 6.2mg/ml). All procedures were 
as described in the legend to Figure 43. The receptor concen 
tration in fraoles/mg protein as determined by DCC was 70
(---- ) and 65 (....) in A and 116 (---- ) and 112 (.___) in B,
Percentage recovery of specific counts in A was 95% in the 
absence of exogenous DNA and 103% in the presence of DNA 
including the counts sedimenting to the bottom. Percentage 
recovery in B was 84% in the absence of exogenous DNA. In 
B , counts at the bottom of the tube were not determined 
but recovery in the gradient in the presence of DNA was 49%.
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procedure for activation (30°, 30') since the heating process resulted 
in either degradation of receptor to 4S form or formation of high mole­
cular weight aggregates (Section 3.2.3.2.7).
The DNA binding observed in low salt conditions may represent 
non-specific interactions but when these studies were repeated in the 
presence of 0.15M KCl the similar proportion of binding was obtained (data not 
shown) although under these conditions 4S and 88 forms do not exist as 
separate entities.
Finally, one tumour was obtained from which both 4S and 8S 
ER^ bound to the DNA (Figure 45) but, in each case, to only a limited 
extent. The high protein concentration (10.4mg/ml) of the cytosol might 
account for such a result, since the acceptor sites on the DNA may be 
masked by other DNA Binding proteins or that an excess of an inhibitor(s) 
(Section 1.1.5.3.2), may reduce activation of ER^. As shown in Figure 4lC 
where lOmg/ml BSA was added to block receptor binding to DNA, this block­
ing effect was not a non-specific effect of increased protein content.
3.2.2.3 Conclusions Drawn from the DNA-binding Studies
The 4S form of receptor, seen at 4°C in low salt conditions, 
is generally less efficient in DNA binding than the 8S form. The 4S 
population of receptor may comprise not only proteolyzed 8S complex 
(or proteolyzed 48 receptor not able to form 8S complex) but also 
reversibly dissociated 8S complex (or intact 48 receptor which under 
optimum conditions will form 88 complex). Thus 48 receptor observed 
in vitro is probably a heterogeneous population. It appears that by 
heating the cytosol or during the storage period (8ection 3-1.1.4 and 
Section 3.1.1.7 respectively), some of the receptor is proteolyzed to 
the inactive 48 form, since even the immature rat uterus stored for
Figure 45. Partial Binding of both 8S and 4S Receptor from Human 
Breast Tumour Cytosol to Calf Thymus DNA
Cytosol was prepared in HED as described in Section 2.2.5 
(patient HE; protein concentration 10.4mg/ml). All pro­
cedures were as described in the legend to Figure 43. 
Receptor concentration as determined by DCC prior to 
SDGA was 280fraoles/mg protein. Percentage recovery of 
specific counts in DNA free tube was 104% and in DNA 
containing tube, including the receptor sedimenting to 
the bottom of the tube was 91%.
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24h in sucrose/glycerol buffer possesses receptor which has lost its 
ability to transform to 5S (Figure . Thus presence of intact 4S
seems essential for formation of 88 complex and also for binding to DNA.
3 .2 . 3 In Vitro Transformation Studies
Transformation is the hormone and temperature dependent 
event reflected by an increase in the sedimentation value from 4SH^5S 
for soluble immature rat uterine oestrogen receptor on SDGA containing 
0.4m KCl (Section 1.1.5.3).
3 .2 .3 .1 The 4S— »5S Transition of Soluble Oestrogen Receptor from 
Immature Rat Uterine Tissue
3 .2.3 .1.1 The Effect of Warming at 30^C for 30 min, prior to Analysis
The 4S—>5S transition observed with immature rat uterine ER
c
is shown in Figure 46, The receptor from non-activated cytosol sedi- 
mented at 4.6S (Figure 46A). After activation only the 5.6S peak was 
observed (Figure 46C). The latter has been presumed to be the form 
binding to DNA (Section 1.1.5.3). Figure 46B shows that the appearance 
of the 5 .6s peak was a time and temperature dependent process. Warming 
the cytosol at 30^C for 5 min. leads to only a minimal increase in the 
5 .6s peak (Figure 46B) whilst complete conversion to 5.68 was seen after 
30°C for 30 min. warming (Figure 460. In fact the complete conversion 
to 5 .6s form may occur earlier followed by the formation of salt resistant 
aggregation as indicated by only an 89% recovery of specific counts on 
the gradient in Figure 46C, It can also be seen that there was a slight 
shoulder present in the 5.68 area even in the absence of any warming 
procedure (non-activated cytosol - Figure 46A). This probably accounts 
for the 20-30% receptor bound to DNA-cellulose in the absence of any 
warming procedure (Section 3.2.1.2) indicating that some activated
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receptor can be found even at 4°C in the present experimental conditions
It was also observed that the presence of EDTA retarded the 
4S— >5S transition (data not shown), supporting the observation of 
Sato et al. ( 1978a). It should also be mentioned that 4S —> 5S transition 
was observed in HDK  ^whether the initial homogenization buffer was HD
or HDK .
.15
3 .2 .3 .1.2 The Effect of Dilution on 4S— »5S Transition
Figure 4?A shows that, in agreement with results presented 
in Figure 46, the heat activated receptor sediments at 53. Figure 47B 
further shows the effect of dilution of the same cytosol after activation. 
With increasing dilution, an increasing tendency for the HE^ to dissociate 
during the centrifugation run was observed. There was also a slight 
shift of the 5.68 form towards the BSA marker. This most probably 
resulted from the relatively low concentration of (bound) receptor and its 
effect on the 48— >58 equilibrium. Figure 47C illustrates that on further 
dilution 58 could no longer be detected. However, since the HE^ had 
all dissociated to the top of the gradient, it is only possible to say 
that steroid was no longer bound to receptor. The molecular size of 
the empty receptor under these conditions was unknown.
The reason for investigating the effect of dilution resulted 
from the observations that this process resulted in little or no tempera-, 
ture dependent binding to either DNA-cellulose or to nuclei prepared 
from crude pellets after several (X 3) pellet washings (data not shown).
It was subsequently found that dilution followed by heat activation 
also prevented the formation of the 58 peak giving instead a broad peak 
at 4.6s, with loss of radioactivity towards the top of the gradient.
This contrasted with the reported increase in activation on dilution
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(Notides, 1978). However, it must be emphasized that in the results 
reported above, the dilution process was followed by warming. The sedi­
mentation profile of diluted cytosol, in the absence of heating to promote 
activation, was not determined. Dilution may simply be affecting the 
association of receptor activation factor ( Thampan and Clark, 1981) or 
might involve some protease activity. As a result of such experiments 
it was concluded that at least 2rag/ml cytosol protein concentration is 
essential for studying 4S— ^5S transformation. The effect of receptor 
concentration was not investigated but results in the literature suggest 
that at least InM receptor concentration is required for efficient acti­
vation (Notides et al., 1981). The receptor concentration effect however, 
may be different in test tube assays and in non-equilibrium sucrose 
density gradients.
3.2.3.2 The 4S— »5S Transition of the Soluble Oestrogen Receptor
from Human Breast Tumours
3.2.3.2.1 The Effect of Warming at 30°C for 30 min. prior to Analysis
Figure 48.1 and 48.2 show that, in contrast to the 48— »5S 
change generated in immature rat uterine cytosol, no such conversion was 
observed with human breast soluble oestrogen receptor. The receptor sedi- 
raented in the 43 area either at 4°C or after activation at 30°, 30’
(Figure 48.1 A and B, Figure 48.2A and B). Further, activation resulted 
in a decrease of total binding capacity. Dilution of the activated 
cytosol, to reduce receptor concentration showed the presence of a 
3-48 peak (Figure 48.1C). In another tumour cytosol a split in the 
equivalent peak was evident (Figure 48.20). The latter observation 
suggested the presence of mero-receptor (8herman et al., 1980) arising 
as a result of receptor degradation.
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The above results were from ER ’*'/ER ^ tissues which shouldc n
possess the functional receptor. The object of these experiments was
to show whether ER ^/ER " receptor was different from the ER *VERc n c n
receptor in terms of transformation. Three ER ^/ER tumours were  ^ c n
analyzed, one of which showed results analogous to those shown in
Figure 48.1 and 48.2, (i.e. no 4S —► 5S transition) but the other two 
tumour cytosols showed complete loss of binding activity on activation 
(data not shown). This loss could result from the high proteolytic 
content of ER^*/ER^" tumours or, less likely, the absence of other 
subunit(s) involved in stabilization of receptor during transformation.
3.2.3.2.2 The Influence of Salt Concentration
The transformation experiments were performed in gradients 
containing 0.4M KCl. It was, therefore, possible that salt shifted the 
4S— >5S equilibrium in favour of the 4S form of human breast tumour ER^.
However, similar results were obtained in 0.15M KCl containing gradients
(data not shown) suggesting that salt was not responsible for the failure 
to detect the 58 form.
3.2.3.2.3 The Influence of Time and Equilibration
It was possible that in the previous experiments the 48—> 58 
reaction did not reach equilibrium within the incubation time period. It 
was therefore decided to label the cytosol overnight at 4^C with 5 x 10”^M 
^HE^ + 5 X lOT^M DES. This should promote 58 promotion if the 48—4 5S 
transition resembled the rat uterine ER^ reaction (Traish et al., 1979). 
However the results obtained were identical to those shown in Figure 48.1 
and 48.2 (data not shown). In fact it is probable that such a pre­
incubation caused 8S— > 48 conversion through a proteolytic effect (see 
Figures 12.1 and 12.2). Proteolytic activity within the gradient may
- 19 9 -
also occur.
3.2.3.2.4 Effect of Centrifugation Temperature
The 48— >58 transformation might take place but temperature and 
ionic strength might promote dissociation back to the 48 form during the 
centrifugation run. To test this hypothesis the following experiments were 
run.
The results shown in Figure 49 permit a direct comparison of 
immature rat uterine and human breast tumour ER^ sedimentation profile at 
different temperatures. In the human breast tumour experiment (Figure 49A 
and B) the receptor, when centrifuged at 4^C without a previous warming 
step, sedimented as a 3-48 peak. This was shifted to 4.68 when centrifu­
gation was performed at 20^C (without prior warming of the cytosol). The 
same 4.6S peak was dominant in other breast tumour cytosols run under 
these conditions. This 4.68 molecule may represent a specific interaction 
of the receptor with another molecule(s) or a conformational change in
receptor protein, increasing its sedimentation value. A change in sedi-
14mentation value of C-B8A marker itself is ruled out since a linear
14relationship between it and the C ^-globulins marker was observed under 
all conditions used. Further, in all the human breast ER^ analysis, there 
was almost 100% recovery of radioactivity indicating that receptor was 
not lost through aggregation or proteolysis. Immature rat uterine ER^, 
while showing a sharp peak at approximately 4.48 during centrifugation 
at 4°C, failed to retain bound steroid during the 20°C run (Figure 49C 
and D) either due to protease activity and/or due to lack of protein 
environment in the 4—58 area (homogenization was at 2 uteri/ml giving 
the indicated protein concentration). Up to 50% of the receptor aggre­
gated to the bottom of the tube suggesting that both proteolysis of 
receptor to non-aggregating form and aggregation of receptor must have
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occurred at the start of the centrifugation. These results were most 
unexpected since human breast tumour tissues is more rich in protease 
activity (Sherman et al., 1980). One possibility is that the rat and 
human receptor degrading proteolytic enzyrae(s) (or cofactors) are 
separated from the receptor to differing extents during centrifugation.
Figure 50 shows that DFP failed to sustain the 5S form of 
immature rat uterine ER^ when centrifugation was performed at 20°C. In 
addition ^/50% of the receptor still sedimented to the bottom of the tube.
Interestingly, there was no dissociation of counts towards the top of the
gradient under these conditions (cf Figure 49D). In the experiments shown 
in Figure 50, rat uterine cytosol was prepared from homogenization of 
4 uteri/ml, whereas for results shown in Figure 49C and D, homogenization 
was at 2 uteri/ml (it was decided only later to perform experiments at 
4-5 uteri/ml of buffer since such preparations yielded optimum trans­
formation, See Section 3.2.3.1.2). It therefore seems that the protection 
provided by the protein environment in Figure 50 prevented the dissociation 
of steroid seen in Figure 49C and D. It is concluded that DFP fails to 
protect the rat uterine 5S receptor form during centrifugation at elevated 
temperature, the 5S form being aggregating to high molecular weight
complex and/or dissociating to the 4.6S form.
3.2.3.2.5 Effect of Receptor Concentration
It is possible that tumour cytosol receptor concentration 
could play an important role in the final conformation. Table 14 shows 
that, in the absence of protease inhibitors, receptor concentration up to 
/V 1000fmoles/ml failed to induce formation of 5S receptor although 
increasing receptor concentration did lead to a small increase in the 
sedimentation value of the 4S moiety. This increase appears to be
Figure 50. Effect of DFP on Immature Rat Uterine Oestrogen Receptor 
Transformation (20°C Centrifugation)
Immature rat uteri were homogenized in H D K . a s  described
in Section 2.2.3-1 (4 uteri/ml; protein concentration 4.0rag/ml)<
One portion of the homogenate was then made lOmM with respect
to DFP. Homogenate was then centrifuged at 50,000 rev/min for
30 min in a Beckman 50 Ti rotor at 4°C. Aliquots of cytosol
were then labelled with 5 x 10 ^HE^ in the absence (---- )
or presence (....) of 5 x 10"^M DES at 4°C. Unbound steroid
was then stripped with DCC (0.25% w/v, final concentration)
and 200ul aliquots were then loaded onto 5 -20% linear sucrose
density gradients prepared in H D K .C en tr if ug at io n  was
performed at 45,000 rev/min for 7h in a Beckman SW 50.1 rotor 
o 14at 20 C. C-BSA (4.6S) used as marker protein is shown as 
the pointed arrow. The receptor concentration in the absence 
of DFP was 480fmoles/mg protein with 52% recovery in the 
gradient and the receptor concentration in the presence of 
DFP k>as 531fmoles/rag protein with 54% recovery in the gradient
- 202 -
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Table 14. Sedimetation Profile of Oestrogen Receptor from Human 
Breast Tumours in the Absence of Protease Inhibitors - 
CentrifugationjTemperature 20^C
^ l a v  —  '2 - 1 3 0 f ^
Human breast tumour cytosol^was prepared in HDK.  ^as 
described in Section 2.2.3.2, After incubation with 
5 X 1 0 ^HEg t 1000 fold excess DES for 1h at 4°C 
unbound steroid was removed with DCC (0.25% w/v final 
concentration). Cytosol was loaded on 5-20% sucrose 
density gradients prepared in HDK.  ^^ and centrifuged 
as described in Section 2.2.3.2 at 20°C.
- 203 -
Tumour Protein Concentration 
m g/m l
ERc^
fm o les/m l
Sedimentation
Coefficient
1 2.8 261 Not detectable
2 4.1 341 3.58
3 2.3 585 3.28
4 4.0 656 4.08
5 4 .2 946 4.68
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independant of total protein concentration, although the number of 
tumours studied is small. The maximum sedimentation value obtained 
under these conditions with cytosol from any tumour was 4.8S.
3.2.3*2.6 Effect of Protease Inhibitors and Salt Concentration on
Receptor Sedimentation Profile at a Centrifugation Temperature 
of 20°C
It was possible that in the previous experiments either the 
receptor was undergoing mild proteolysis or that the other factor(s) 
required for promoting the higher sedimentation form (analogous perhaps 
to the activated receptor of the rat uterus), was being degraded. Inclusion 
of protease inhibitors in tumour cytosols was therefore investigated. The 
ineffectiveness of PMSF in the analysis of receptors from human sources 
is recognized (Lukola and Punnonen, 1982). Therefore, another potent 
inhibitor of serine proteases, DFP, was used. Notides et al. (1976) 
have already established the use of DFP in elevated temperature centri­
fugation studies of human ER^ from myométrial tissue.
Figure 51A shows that in the presence of DFP the receptor 
sedimented at 6S (5.78) at 20°C centrifugation in physiological ionic 
strength buffer (0.15M KCl). This is in contrast to the 4.68 value seen 
for the same cytosol preparation in the absence of DFP [Figure 51 A(...)]. 
Thus DFP prevents proteolysis of the receptor (or some other factor(s) 
required for the formation of transformed ER^). Almost 100% recovery of 
radioactivity was seen in the absence of DFP, whereas in the presence 
of DFP the recovery was only 66% with receptor showing a tendency to 
aggregate and sediment to the bottom of the tube. Thus, factors involved 
in the aggregation of the intact receptor must be very protease sensitive. 
In five tumour cytosols studiedjfor transformation at 20°C in the presence
Figure 51. Effect of DFP and Salt Concentration on the Transformation 
of Oestrogen Receptor from Human Breast Cancer
In (A) cytosol was prepared in the absence (....) or presence
(---- ) of lOmM DFP as described in Section 2.2.3-2 (patient
AP; protein concentration was 7.3mg/ml in the absence of DFP
and 7.9mg/ml in the presence of DFP), Cytosol was labelled
with 5 X 10 t 1000-fold excess DES at 4°C for 1h.
After removal of free steroid with DCC (Section 2.2,3.2) 200ul
aliquots were loaded onto 5-20% gradients prepared in HDK.^^.
Centrifugation was for 7h at 45,000 rev/min in Beckman SW 50.1 
o 14rotor at 20 C. C-labelled BSA was added as marker protein.
The receptor concentration in the absence of DFP was 347fmoles/ 
mg protein with 93% recovery in the gradient. In the presence 
of DFP, the receptor concentration was 3l4fmoles/mg protein 
with 66% recovery of receptor in the gradient.
In (B) cytosol was prepared in the presence of lOmM DFP as 
described in Section 2.2.3*2 (patient SC, protein concentra­
tion 7.Img/ml). The labelling of cytosol and DCC treatment 
were as above. 200ul aliquots were then loaded onto 5-20%
gradients prepared in either HDK. (---- ) or HDK. (....).
Centrifugation was for 11h at 43,000 rev/min in Beckman SW 50.1
Q 1
rotor at 20 C. C-labelled BSA was added as marker protein. 
The receptor concentration was 28lfmoles/mg protein. The 
recovery of receptor in 0.15M KCl gradient was 61% and in 
0.4M KCl gradient was 93%.
14The sedimentation peak after C-BSA marker is at 5.78 (/v6S) 
in both A and B.
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of DFP and in gradients containing 0.15M KCl, the average sedimentation 
value obtained was 5.98 + 0.2S (n = 10).
Formation of 4.6S receptor, seen in the absence of DFP, can 
also be induced by the presence of 0.4M KCl in the gradients in the 
presence of DFP (Figure 51B) suggesting that the 4S— > 6S transition was 
salt sensitive. As in Figure 51A (profile in the absence of DFP), the 
presence of 0.4M KCl also leads to the loss of aggregation and full 
recovery of all radioactivity on the gradients. It is not known if 
0.4M salt may in fact make DFP ineffective.
Both tumours used for the experiments illustrated in Figure 51A 
and B had been analyzed previously in low salt gradients (cytosol prepared 
from different sections) and were found to contain principally the 8S ER^.
Table 15 relates the sedimentation profile obtained at 20°C 
centrifugation with various parameters. A comparison with Table 14 shows 
that the protein concentration used was higher. As seen from Table 15, 
tumours with only an 88 peak at low ionic strength (centrifugation 
conducted at 4^C) yielded a single peak at /v68 in 0,15M KCl gradients 
in the presence of DFP (centrifugation conducted at 20°C). The presence 
of both 43 and 83 peaks in low ionic strength led to a broad peak
sedimenting after the 4.63 marker in gradients run at 20°C at physiological
ionic strength. The formation of the broad peak (after 4.63) apparently 
depended on the 4S + 83 distribution, obtained in low salt and may also 
depend on the 83 receptor concentration since tumour number 1 in Table 15 
failed to show a distinct, 63 peak in 0.15M KCl gradients although con­
taining 83 form (at a relatively low concentration) in low salt conditions. 
Figure 52 on the other hand shows the sedimentation profiles obtained 
from tumour number 5 (Table 15). It can be seen that (Figure 52A) both
4.63 and 63 peaks are resolved. The low salt gradient of the same tumour
Table 15. Sedimentation Profile of Oestrogen Receptor from 
Human Breast Tumour in the Presence of Protease
Inhibitors - Centrifugation Temperature 20°C
(-too *^5 I ^
Preparation of tumour cytosol^was as described in 
legend 14 except that DFP was introduced immediately 
on homogenization (see Section 2.2.3.2). Centrifuga­
tion was in 5-20% gradients prepared in HDK.^^ and 
centrifugation was as described in Section 2.2,3.2 
at 20°C. Also included is the low salt profile of 
receptor obtained from another section of the tumour 
which was processed and analyzed as described in 
Section 2.2.2.1.
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Tumour
Protein Concn. 
m g/m l
ER concn. c
f m ole/ral
8edimentation 
Coefficient 
(0.15MKC1, 20^0
Low 8 alt 
Profile (4°C)
1 8.4 124 BPA 4.68* 88
2 6 .4 273 BP A 4. 68* 48 + 88
3 6 .0 455 BPA 4.68* 48 + 88
4 8,3 688 BPA 4.68* 48 + 88
5 6 .2 1028 48 + 68 48 + 88
6 7.0 1996 5.78 88
7 8.0 2478 5.78 88
8 11.4 2829 48 - 88 48 + 88
9 7.6 2977 68 88
* BP A 4.68 = Broad peak after 4.68 marker
Figure 52. Effect of Protease Inhibitor (Leupeptin) on the Sedimenta­
tion Profile of Human Breast Tumour Cytosol Oestrogen Receptor
The profiles shown are from two different sections of a single 
tumour (patient IT). Leupeptin was only used in A. In (A) 
tumour was homogenized in HDK.^^ as described in Section 
2.2.3.2. Immediately on homogenization, Leupeptin was added 
to a final concentration of lOmM. Cytosol prepared (protein
_Q O
concentration 6.2rag/ml) was then labelled with 5 x 10 M HE^
in the absence (---- ) or presence (....) of 5 x 1 0 DES for
1h at 4°C. Free steroid was then removed with 0.25% w/v final 
concnetration of DCC and 200ul aliquots loaded onto 5-20% lin­
ear sucrose density gradients prepared in HDK.^^. Centrifuga­
tion was for 8h at 45,000 rev/min at 20°C in a Beckman SW 50.1
14rotor. Arrow indicates the position of C-labelled marker 
protein. The receptor concentration was l66fmoles/rag protein 
and the recovery in the gradient was 78%. The two peaks shown 
represent 4.6S and rv 6S values.
In B cytosol (protein concentration 4.8mg/ral) was prepared 
in low salt, then analyzed as described in Section 2.2.2.1. 
Receptor concentration was 330fmoles/mg protein with 79% re­
covery in the gradient. The gradients were centrifuged for 
14h at 45,000 rev/min in a Beckman SW 50.1 rotor at 4°C.
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( a  d i f f e r e n t  s e c t i o n )  s h o w e d  t h e  4 S  +  8 S  p r o f i l e  ( F i g u r e  5 2 B ) .  I t  
t h e r e f o r e  s e e m s  t h a t  t h e  r e c e p t o r  o b t a i n e d  f r o m  8 S  p e a k  i n  l o w  s a l t  
y i e l d e d  t h e  6 S  f o r m  i n  0 . 1 5 M  K C l  c o n t a i n i n g  g r a d i e n t s .  T h e  4 . 6  v a l u e  
w a s  m o s t  p r o b a b l y  d e r i v e d  f r o m  t h e  l o w  s a l t  4 S  p e a k .  A  d i r e c t  c o m p a r i ­
s o n  o f  l o w  s a l t  g r a d i e n t s  a n d  0 . 1 5 M  K C l  c o n t a i n i n g  g r a d i e n t s  c a n n o t  b e  
m a d e  s i n c e  t h e s e  r e p r e s e n t  p r o f i l e s  f r o m  t w o  d i f f e r e n t  s e c t i o n s  o f  t h e  
t u m o u r  a n d  a n a l y s i s  a t  t w o  d i f f e r e n t  t e m p e r a t u r e s .
T u m o u r  n u m b e r  8  i n  T a b l e  1 5  s h o w e d  a  4 8  +  8 S  p r o f i l e  i n  
l o w  s a l t .  I n  0 . 1 5 M  K C l  g r a d i e n t s  ( a n d  h o m o g e n i z a t i o n  b u f f e r  H D K . ^ ^ ) ,  
t h i s  p r o f i l e  d i d  n o t  c h a n g e  w h e n  t h e  c y t o s o l  w a s  c e n t r i f u g e d  a t  4 ° C  
( F i g u r e  5 3 A ) . T h e r e  w a s  a n  a d d i t i o n a l  p e a k  a t  6 8  w h e n  t h e  c e n t r i ­
f u g a t i o n  w a s  p e r f o r m e d  a t  2 0 ° C  ( F i g u r e  5 3 C ) .  T h i s  m o s t  p r o b a b l y  
r e p r e s e n t s  a  p r o t e i n  c o n c e n t r a t i o n  e f f e c t  ( p r o t e i n  c o n c e n t r a t i o n  
1 1 . 4 m g / m l ) .  T h i s  s a m e  t u m o u r  ( n u m b e r  8  i n  T a b l e  1 5 )  h a d  f a i l e d  t o  
s h o w  a n y  s i g n i f i c a n t  D N A  b i n d i n g  ( F i g u r e  4 5 ) .  P e r h a p s  t h i s  l a c k  o f  
d i s a g g r e g a t i o n  o f  t h e  r e c e p t o r  w a s  r e s p o n s i b l e  f o r  s u c h  a n  e f f e c t  
s i n c e  s o d i u m  m o l y b d a t e  i s  a l s o  t h o u g h t  t o  p r e v e n t  D N A  b i n d i n g  b y  
p r e v e n t i n g  d i s a g g r e g a t i o n  o f  r e c e p t o r  ( R e d e u i l h  e t  a l ., 1 9 8 1 ) .  T h u s  
t h e  D N A  b i n d i n g  s i t e  c o u l d  b e  m a s k e d  w h e t h e r  i n  l o w  s a l t  o r  i n  t h e  
p r e s e n c e  o f  0 . 1 5 M  K C l .
3.2.3.2.7 Effect of Warming the Cytosol in the Presence of Protease 
Inhibitors Prior to the Analysis of Receptor at 4°C
E a r l i e r  e x p e r i m e n t s  s h o w e d  t h a t  a c t i v a t i o n  ( 3 0  , 3 0 ’ ) i n  
t h e  p r e s e n c e  o f  t h e  p r o t e a s e  i n h i b i t o r  D F P  r e s u l t e d  i n  a g g r e g a t i o n  o f  
r e c e p t o r .  T o  t e s t  w h e t h e r  0 . 4 M  K O I  c o n t a i n i n g  g r a d i e n t s  w o u l d  p r o m o t e  
d i s a g g r e g a t i o n  o f  t h e  a g g r e g a t e d  r e c e p t o r  t o  a  f o r m  d i s t i n c t  f r o m
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non-activated receptor, the following experiment was conducted. Tumour 
cytosol was heat activated and loaded onto 0.4M KCl gradients (Figure 
54b ) and centrifuged at 4^C.
In addition non-activated cytosol was loaded onto 0.15M KCl
gradient and centrifuged at 4°C (Figure 54A), In Figure 54A, the 6S
peak can be seen in addition to the 4S and 8S shoulders. It should be
pointed out that homogenization was performed in HDK , rather than
HED as in Figure 22 where only a 4S peak was demonstrated. Figure 543 
shows the effect of heating the cytosol to 30°C for 30 min. followed 
by centrifugation at 4^0 in 0.4M KCl containing gradients, an experimental 
situation analogous to that showing the transformed 58 receptor from rat 
uteri. This experiment was conducted in the presence of protease inhibitor 
DFP. There appears to be a considerable loss of radioactive counts towards 
the top of the gradient. The specific counts on the gradient (not 
necessarily receptor bound) only account for 78% of the total counts 
loaded. It is probable that aggregation (as a result of warming in 
the presence of protease inhibitor) followed by disaggregation on gradients 
is releasing a form of receptor with a modified structure giving a lower 
value and, as a result, loss of free steroid, seen towards the top of 
the gradient. This possibility is further strengthened by the result 
shown in Figure 54C where centrifugation of the cytosol at 20°C (without 
previous heating step) resulted in 78% recovery of counts on the gradient 
with a 63 peak. When the centrifugation of the same cytosol was performed 
at 20°C in a 0.4M KCl containing gradient (Figure 54D), only the 4.68 
form of the receptor was observed with 96% recovery of specific counts 
under the peak. The most likely explanations, therefore, for the situation 
observed in Figure 543 are that either, when once aggregated, the receptor 
cannot revert to the original 4S form in 0.4M KCl or that certain enzymes
873
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present in some tumour cytosols may hydrolyze DFP at high temperatures. 
Perhaps during the 20°C centrifugation, an early separation of such an 
enzyme has taken place or else that the enzyme has preferential activity 
against the aggregated protein.
Heating the cytosol to 30°, 30’ followed by centrifugation in 
0.15M KCl at 4°C (Figure 53B) resulted in a very broad sedimentation 
profile extending from 4S to 8S with only 72% receptor recovery on the 
gradient. 26% of the specific counts were located at the bottom of the 
tube and, therefore, represented aggregation even in the presence of 
0.15M KCl. The unusual properties of the cytosol from this tumour have 
already been noted in the previous section. The low salt gradient of 
this tumour showed a 48 + 88 profile. Again, another tumour which showed 
the low salt profile of 48 + 88 forms also showed both 48 + 68 forms on 
0.15M KCl gradients at 4°C (Figure 55A). Heating at 30°C, 30’ of the 
same cytosol resulted in conversion of the 68 form to the 48 form 
(Figure 55B) with some aggregation to the bottom of the tube (% recovery 
of specific counts was 85% in Figure 55B compared to 100% in Figure 55A). 
The 20°C centrifugation of the same cytosol in 0.15M KCl (Figure 55C) 
showed complete recovery of counts (98%) but the broadness of the peak 
after the 4.68 marker is characteristic of 48 + 88 low salt type tumour 
cytosol (Table 15).
It appears from the foregoing that two simultaneous processes 
can occur when tumour cytosol is prepared in HDK  ^^ in the presence of 
protease inhibitors and, subsequently, subjected to activation conditions 
(Scheme 1).
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Scheme 1 ( 1 ) (2)
Proteaset ProteaseV
48 < ----------  48 ^ — Z" 68---------- > Aggregate
Comprising 48 comprising 48 possibly 48 comprising 88
proteolyzed form aggregating type dimer + higher molecular
weight species
Depending on the protease content of the tumour cytosol, mechanism (1) 
and/or (2) shown in Scheme 1, is dominant.
In Figure 54A non-activated cytosol in 0.15M KCl at 4°C 
showed a clear 88 shoulder, together with the suggestion of a 48 shoulder, 
in addition to the major 68 peak. However activation conditions led to 
the disappearance of the 88 shoulder (Figure 548, similar to the dis­
appearance of the 68 form in Figure 558). After activation conditions, 
therefore, there is a clear increase in the amount of 4S but the 68 and 
88 peaks are lost. A proportion of receptor is aggregated to the bottom 
of the tube and a large proportion of radioactivity appears to have been 
released from the receptor specially, as shown in Figure 548, in the 
presence of 0.4M KCl gradients. It is possible that the 48 form of 
receptor, extracted initially in HDK ^^, is possibly aggregated to the 
68 form and further aggregated to the higher molecular weight species 
or is proteolyzed to the 48 non-aggregating type (Scheme 1, Figure 54 
and 55). It was therefore decided to see if aggregation could be 
accelerated by homogenizing tumours in low salt rather than in buffers 
containing 0.15M salt.
For the experiment illustrated in Figure 56, the tumour 
was homogenized in HD buffer instead of HDK DFP was then introduced.
Figure 56A shows that again a 68 + 88 profile ( with a shoulder at rv 4S) 
could be observed when centrifugation was carried out in 0.15M KCl at
Figure 56. Effect of Salt Concentration and Temperature on the Sedimenta­
tion Profile of Oestrogen Receptor from Human Breast Cancer 
Cytosol
Human breast tumour cytosol was homogenized in HD (patient SN) 
as described in Section 2,2.3-2. Immediately after homogenisation 
DFP was added to a final concentration of lOmM. Cytosol (protein 
concnetration 4.8mg/ml) was labelled with 5 x 10”^ M ^HE^ - 1000- 
fold excess DES for 1h at 4^C. Free steroid was then removed with 
DCC (0.25% w/v, final concentration). Two sets were then immedia­
tely loaded onto 5-20% gradients prepared in either HDK.^^ (B) 
or HDK.j^  (E) and centrifuged at 42,000 rev/min for 11h at 20°C 
in a Beckman SW 50.1 rotor. Two further sets were heat activated 
at 30^ C for 20 minutes, cooled to 4^C for 5 minutes and then 
loaded onto 5-20% gradients prepared in either H D K . ( C )  or 
HDK.2^ (F). Control aliquots at 4°C were also loaded onto 5-20% 
gradients prepared in either H D K . ( A )  or HDK.^ (D). These 
gradients (A, C , D and F) were then centrifuged at 50,000 rev/min 
for 11h at 4°C in a Beckman SW 50.1 rotor. Arrows indicate the 
position of ^^C-labelled marker proteins. The peak position 
between the sedimentation markers in A and C is at r<j 6S. The 
receptor concentration of the cytosol preparation as determined 
by taking aliquots after DCC treatment was 587fmoles/mg protein 
with recovery of specific counts in the gradient representing 
96% in A, 85% in J, 88% in_C, 103% inj, 97% in JE_and 100% in__F.
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4°C. Now, in contrast to the previous results, centrifugation at 
20^C led to a 7-88 peak (Figure 56B) suggesting that the 4S and 6S 
are present in the aggregated form. Surprisingly however, warming 
cytosol to 30°, 30* prior to centrifugation in 0.15M KCl containing 
gradients at 4°C, yielded a dominant 6S profile with a 4S shoulder 
(Figure 560). This result contrasts with the previously observed aggrega­
tion plus conversion to the 4-4.6S form under such conditions (Figures 
53-55). It therefore appears that, in the low salt conditions, heating 
this tumour cytosol to 30°, 30* prior to analysis in 0.15M KCl gradients
at 4°C, led to the formation of 6S form. This suggests that either there
was no aggregation to high molecular state or that the aggregation is 
reversible under these conditions. The same cytosol used in Figure 56A,
B and C, when subjected to 0.4M KOI gradient following various conditions 
yielded only the 4.68 state (Figure 56D, E and F) although in Figure 56F
there was a shoulder present at /v5S and there was no loss of counts seen
towards the top of the gradient. It is essential, therefore, to establish 
if the 68 form represents the active form, that is to say if the 68 form 
observed in 0.15M KCl gradients represents the same type as the two 
subunit structures of progesterone receptor. The formation of 6S at 
4°C for the oestrogen receptor (as indeed is the case for progestoner 
receptor) may take place as a result of removal of low or macromolecular 
weight inhibitors during centrifugation.
3.2.3.3 The 4S >5S Transition of the Soluble Oestrogen Receptor
from the Human Endometrial Tissue
3.2.3.3.1 Effect of Warming to 30°C for 30 min. prior to Analysis
Warming human endometrial cytosol to 30°C for 30 min followed 
by analyzing the cytosol in 0.4M KCl gradients (Figure 57A and B), led to
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an increase in the total binding capacity. This is in contrast to the 
results presented under the same conditions for breast tumour tissue 
cytosol (Figure 48.1 + 48.2). However, there was no change in the sedi­
mentation value from 4S— »5S, confirming the situlation with the human 
breast tumour cytosol and in contrast to the results obtained with immature 
rat uterine cytosol included in Figure 57 (C). In contrast to the v100%
5S conversion obtained from fresh immature rat uteri, only /V50% of sucrose/ 
glycerol stored uteri could be transformed to the 58 form. The sucrose/ 
glycerol storage procedure is known to affect the stability of rat uteri 
ER^ (Figure 21). However, both fresh and stored endometrial ER^ showed 
no such transition. In some cases of human endometrial cytosol, the 
receptor, after activation, sedimented as a single peak at ^38, implying 
a different proteolytic content of different cytosols. 8imilar findings 
are reported by Notides et al. (1976) for human myométrial tissue.
Figure 58 shows the effect of temperature of activation on 
the sedimentation profile of human endometrial cytosol, under 0.4M KCl 
and 4^C centrifugation conditions. The purpose of this experiment was 
to find out if the 30 ,^ 30’ heating procedure was longer than needed to 
activate or transform (4S—» 58) the receptor and might even be promoting 
a 58— * 48 degradation. A reduced temperature of 20°C was, therefore, 
used with no difference in sedimentation value (Figure 58). A similar 
temperature-dependent rise in total binding capacity (as seen in Figure 
57) was obtained.
3.2.3.3.2 Effect of Elevated Centrifugation Temperature, Inclusion of
Protease Inhibitors and Salt Concentration
Figure 59 shows that only in the presence of a protease 
inhibitor (Leupeptin) can the 68 be maintained during elevated temperature 
centrifugation run. Inclusion of DFP also showed a similar effect. As
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Figure 59. Effect of Protease Inhibitor Leupeptin on the Sedimentation 
Profile of Oestrogen Receptor from Human Endometrial Cytosol
Two different endometrial samples were used. In (A) human endo­
metrium was homogenized in T D K . a s  described in Section 
2,2.2.6. Cytosol was prepared (Section 2.2.2.1) and the protein
concentration obtained was 6.8rag/ral. It was then labelled with 
-9 15 X 10 M HEg in the absence (---- ) or presence (....) of 5 x
10”^ M DES for 1h at 4^0. Free steroid was removed with DCC 
(0.25% w/v, final concentration) and 200ul aliquots loaded 
onto 5-20% linear sucrose density gradients prepared in TDK.^^.
Centrifugation was for 8h at 50,000 rev/min in a Beckman SW
o 14
50.1 rotor at 20 C. Arrow indicates the position of C-^SA
(4.6s). Receptor concentration was 209fmoles/mg protein and
recovery of specific counts in the gradient was 84%. Receptor
peak is at 4.8S.
In (B), endometrial sample was homogenized in HDK.^^ as des­
cribed above. Cytosol preparation (protein concentration 
6.2mg/ml) was labelled with 2 x 1 0 ^HE^ in the absence
(----) or presence (....) of.2 x 10~^M DES for 1h at 4^C.
Free steroid was removed and aliquots loaded onto gradients 
prepared in HDK.  ^as described above. Centrifugation was for
10h at 45,000 rev/min at 20°C in Beckman SW 50.1 rotor. Arrow
14indicates the position of C-labelled marker protein. Recep­
tor concentration was 137fmoles/rag protein and recovery of 
specific counts in the gradient was 77%. The position of 
receptor peak is at r/ 6S (5.8S).
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for the breast tissue cytosol, these protease inhibitors protect the 
aggregation property of the receptor.
Figure 60 demonstrates the effect of salt concentration on 
the sedimentation profile of human endometrial ER^ where 0.4M fCCl is 
once again shown to inhibit the formation of the 68 peak even though 
DFP is present in the cytosol. This result is very similar to the one 
already presented for human breast tissue ER^ (Figure 51) and implies 
ionic interactions in the 68 formation.
Leupeptin concentration below ImM were found to be ineffective 
and studies, therefore, were routinely conducted at 5mM. Optimum DFP 
concentration was not determined and the lOraM concentration used by 
other workers (Daxenbichler et al., 1980) was adopted. These inhibitors 
caused reduction in the binding capacity of the cytosol, as also observed 
by Lukola et al. (1980). Leupeptin if present during homogenization 
caused frothing, an observation in agreement with 8herman et al. (1980), 
with an adverse effect on receptor binding capacity. Its not known if 
inclusion of DFP during homogenization would have made any difference.
The inhibitors were added immediately after homogenization.
3.2.3.3.3 Effect of Receptor Concentration
It was observed that at low receptor concentration, 157 - 485 
fraoles/ml, Leupeptin or DFP failed to protect the receptor aggregation 
site and the receptor sedimented at 4.0 - 4.88. It is possible, however, 
that for other reasons the receptor may be initially in the 48 state. The 
4.0 - 4.8s value observed with low receptor concentration is similar to 
that observed with high receptor concentration in the absence of protease 
inhibitors (Figure 59A - receptor concentration I4l8 fraoles/ml). However 
lack of aggregation could also be due to (a) receptor concentration being 
below a certain critical level or (b) absence of other aggregating molecules
I
î
î
u
o
I
I
s
3
g
i
g
%
I
s: •
4J en tu
ü 1 Sh m su tu
tu O « tu o bO
(X tu S p td
ta P o p
tu X (X 03 Sh S3
(\j t. <u P Uü tu
iTi O Q tu
on x: es X su
X tu* o tu
C\J •H P u •H Sh LO a
•H o rH o
CM :3 Cd tu
z cy] •H
C s X P rH <t! Cm
O o tu Cd es S3 «H
•H p o td tu
+3 cd X o LO S tu
ü tu X CM es: a
tu 73 es ü ta
00 cd ü "4 Ud tu
B $3 D A m X
c •H u S3 X S3
•H 03 O S3 cd
(d 03 CO •H SU •H
n s Cd W P tu S3
tu S Q Cd X X 'H
Xi tu su p LO tu
•H -p X S P •H P
k cd tu vo C tu C37 O
Ü c S3 1 tu SU
w tu •H o ü S3 SU a
tu bO Cd 53 •H o
tu O p O Cm bO
E X X ü X E
ta O o tu C
ttS Xî m rH £h •H 03 m
Cd td E tu
ir t tu rH Cm S3 (X iH S3
X E O •(H tu > O •H
X Cm u tu E
w SX SU Cm
o S3 E -=J-
nn O CM > 03 O CM CT\
•H P O
c P X 13 S3 O X
•H Cd tu 03 S3
N S3 ■5S. •H CM td cd
73 O tu LO X a - >
tu S3 'H ü CM Cd
SU tu P X P S3
fd faO Cd tu O bû Cd O 53
a O SU 03 ■iH •H
tu E p tu î>i X P
su O S3 !U U P tu td
eu X tu X O ■H bO SU CM
ü Q 03 es p X
03 03 S3 e. 53 Cm S3
tlJ 03 O o X tu •H tu 03
:s Cd (3 P X u ü Cd
rH •H p S3 3
1—1 bO S3 S tu S3 Oo •H 03 tu ü P
03 03 tu X O Ü 53
O 03 P •H SU SU tu
4J Cd O O ü C o •H1— 1 iU su es tu p X
Ü bO SX tu tu 03 X a Cd
tu p P tu su
1— 1 u S3 03 ü bO
cd tu rH tu o 03 tu
•H P O 03 tu c\j td su tusu 03 X tu 1 S: X
4J Cd O cd Sh LO tu p
tu P Cm P XB >1 >, tu O S3 E-t S3o fH t_) X Cm p tu •H
73 tu p O S3 •H
S3 P O X >ï
tu Cd 1 rH Cd O X
•H PL. H td X Sh O tu
c TJ PlH > tu bO o t>
(d tu Q CM o X CM o
S E sa S cd tu ües S O X tu o X P tuffi H P r o Shi e-r Cd u
ovO
.1(Xh
- 223 -
C
<1)1
bû
O
k
- w
C/3
03
O
2
A
C
o
"cd
4-*
§
S
'i
m
<D
JC
c
o
§
k4U
C
0
U
C
o
U
0
B
€
C
M
(d
CO
0
ië
M
S
K
S
o*4
«♦H
k,
O
a
0
0
0
0^
PQ
0 m
O
Occ
oM
_ O
CO
o
CO
CO
<
o
COCO M
O
55
c
4-J
0
CTj
k
CO
O
CVI
-2
cüdo ioipBj}S0o-H
- 224 -
Further* results are required to correlate the presence of 8S in low salt 
with the amount of 68 formed, and with DNA binding. The two determinations 
performed at 753 fmoles/ml (12.4 mg/ml protein concentration) and 852 
fmoles/ml (6.2 rag/ml protein concentration) resulted in sharp 6S peak.
The appearance of the 68 form, therefore, seems to be less dependent 
on high receptor content, in contrast to that observed with human breast 
tissue (Table 15) and may be related to the total concentration of ER^ 
being present in the 88 form in low salt conditions in the human endometrial 
cytosol.
3.2.3.3.4 Effect of Sodium Molybdate
8odium molybdate is known to stabilize steroid receptors 
(8ection 1.1.5.3-2) but it also inhibits transformation of the rat ER
c
(8hyamala and Leonard, 1980). It was, therefore, decided to test this 
agent in human endometrial cytosol, in the transformation studies, in 
case the mode of action of sodium molybdate is different in different 
target tissues or under different experimental conditions. 8odium 
molybdate may protect the activated oestrogen receptor (68) in a manner 
anaolgous to pyridoxal-5-phosphate, which activates glucocorticoid 
receptor but inhibits its DNA binding properties (8chmidt and Litwack,
1982).
Figure 61.1 and 61.2 show the effect of inclusion of sodium 
molybdate prior to centrifugation at 20°C. No 68 could be demonstrated 
under these conditions, presumably because of the inhibition of trans­
formation. If sodium molybdate prevented receptor disaggregation, a 
prerequisite to transformation, then an 88 peak or higher aggregates 
should have been seen. Unless the original cytosol contained only the 
48 non-aggregating receptor, sodium molybdate did not prevent proteolysis
Figure 61.1. Effect of Sodium Molybdate on the Sedimentation Profile of 
Oestrogen Receptor from Human Endometrial Cytosol
Human endometrial cytosol was homogenized in HED as des - 
cribed in Section 2.2.2.6. The horaogenate was immediately 
divided into two portions and one was made lOmM with respect 
to sodium molybdate. Cytosol was then prepared (Section 
2.2.2.6; protein concentration 5.0rag/ml) and labelled with 
5 X 1 0 ^HE^ - 1000-fold excess DES for 1h at 4°C. After 
removal of free steroid with DCC (0.5% w/v, final concentra­
tion), 200ul aliquots were loaded onto 5-20% linear sucrose 
density gradients prepared in HDK.^^. Centrifugation was
at 20^C for 7.5h at 50,000 rev/min in a Beckman SW 50.1
14rotor. Arrows indicate the position of C-labelled marker 
proteins. The receptor concentration obtained was 128fmoles/ 
mg protein with 56% recovery in the gradient for sodium 
molybdate free cytosol and l64fmoles/rag protein with 73% 
recovery in gradient for sodium molybdate containing 
cytosol.
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Effect of sodium molybdate on the sedimentation profile of 
human endometrium ER^. Centrifugation temp. 20^0. SDG 
containing 0 . 15M Kcl. Profiles obtained from same cytosol
preparation
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Figure 61.2. Effect of Sodium Molybdate on the Sedimentation Profile 
of Soluble Oestrogen Receptor from Different Sections of 
Human Endometrium
Two different portions of the same endometrial sample were
homogenized in as described in Section 2.2.2.6 in
the absence (A) or presence (B) of 20mM sodium molybdate.
Cytosol was prepared as described in Section 2.2,2.6.
(protein concentration 5.9mg/ml in the absence and 6.2mg/ml
in the presence of sodium molybdate). Aliquots were
labelled with 5 x 10"^M in the absence (----) or
presence of 5 x 10~^M DES (....). After removal of free
steroid with DCC (0.25% w/v, final concentration), 200ul
aliquots were loaded onto 5-20% sucrose density gradients
at
prepared in HDK.^^. Centrifugation was^50,000 rev/min
for 8h at 20^C in a Beckman SW 50.1 rotor. Arrow indicates 
14the position of C-labelled marker protein. The receptor 
concentration in A was 51fmoles/mg protein with percentage 
recovery of 80% and the receptor concentration in B was 
96fmoles/mg protein with percentage recovery of 80%'
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or dissociation of 88 form at 20°C. However, sodium molybdate does 
protect or even increase the binding capacity of the cytosol preparations 
(Figure 61.1 and 61.2). It is also possible that the 4.68 receptor in 
the Figures 61.1 and 61.2 has its aggregation site preserved but that 
sodium molybdate specifically inhibits aggregation. 8odium molybdate 
may also interact with other components required for transformation.
A further consideration for inclusion of sodium molybdate was the 
possibility that it may interact with certain proteases or phosphatases, 
separating them on the gradient and permitting receptor to form the 68 
complex (assuming that all necessary components for 68 formation co­
sediment with the receptor).
3.2.3.3.5 Effect of DCC Treatment
It was found that DCC treatment of the labelled cytosol 
did not alter the formation of 68 complex when the cytosol, in the 
presence of DFP, was analyzed at 20°C in 0.15M KCl gradients. That 
is to say that DCC was not removing any factors required for the formation 
of 68 complex (data not shown).
In conclusion, human endometrial cytosol shows similar 
sensitivity to protease inhibitors for the formation of 68 complex as 
does human breast tumour cytosol ER^. These proteases do not seem to 
be sensitive to sodium molybdate since elevated centrifugation runs 
yielded a 48 peak rather than higher 8 values and/or aggregation of 
receptor.
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4. DISCUSSION
Despite several years of research into the cellular biochemistry 
of steroid receptors, the molecular mechanisms involved in steroid hormone 
action remain unclear. As yet, it is not even known as to exactly where 
in the cell the soluble empty receptor resides (Leake, 1976; Sheridan et al- ,
1979). It has, nevertheless, been shown that the genomic interaction of 
filled receptor leads to the differentiation of the target cells (Clark 
and Peck, 1979). It is the latter concept which has proved useful in 
selecting human breast cancer patients for endocrine therapy (Jensen, 1981). 
Sex steroid hormone receptor determinations have acquired an established 
position in the selection of such patients (there are also indications for 
the usefulness of this approach in the management of patients with other 
endocrine related diseases (Leake, 1981b)). However, several studies 
measure only the soluble receptor with the inherent assumption of measuring 
total functional receptor. Such methodology has resulted in the selection 
of receptor positive patients only 50% of whom respond to endocrine therapy 
(Hawkins ^  , 1980). To circumvent the problem of 'false positive'
patients, Wittliff and Savlov (1975) proposed analysis of the molecular 
forms of soluble oestrogen receptor (ER^) on sucrose density gradient 
(SDG). They have proposed that it is the 83 ER^ complex which indicates 
functional receptor and that only those patients exhibiting this form of 
receptor in the tumour biopsy should be considered for endocrine manipulation. 
This proposal has been criticized (Freedman and Hawkins, 1980) and several 
investigators have been unable to demonstrate any relationship between the 
molecular form of receptor and response (Westerberg £t ^ . , 1978; Dao and 
Nemoto, 1980). The general consensus is that the 48 and 88 forms to not 
serve as individual independent prognostic parameters.
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The work presented in this thesis was directed in part towards 
elucidating some of the reasons why such contradictory results are to be 
found in the literature. Some of the findings observed in cancerous tissue 
were related to those which are found in normal tissue, particularly the 
immature rat uterus, since this tissue is the best characterized with 
respect to oestrogen-receptor interaction (Figure 5). This work is 
presented in Section 4.1 below.
Another concept put forward by Wittliff e^ (1976) is that
the reason why 48 containing tumours do not respond to hormone therapy is 
because they lack a second subunit. The second subunit combines with the
48 form to give the 68 complex which is claimed to be the active form of
the receptor vivo. This proposal was based on the fact that in physio­
logical ionic strength only the 88 containing tumours yield a 68 complex.
However Wittliff (1978) have failed to detect such a form after
heat activation. It is suggested in Section 4.2. that whereas Wittliff's 
view may be correct, the way it is presented in the literature is misleading, 
In vitro 48 can originate as a result of proteolysis, and several factors 
influence 88— >48 proteolysis (Section 4.1). Therefore, in vitro the 48 
receptor may lose its ability to bind to the other subunit. The proteolytic 
activity of individual tumours (reflected in 88— > 48) may, however, be an 
indicator of tumour growth potential. It is shown in Section 4.2. that the 
68 complex can be determined at higher temperatures but only in the presence 
of protease inhibitors and in 0.15M KCl gradients. The complex can also be 
formed at 4°C in the absence of EDTA.
4.1. Clinical and Biochemical Aspects of Oestrogen Receptor Molecular
Forms
In normal non-lactating breast, oestrogen receptor containing 
cells are present in very small numbers. Hormone sensitive cells increase
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rapidly during pregnancy and lactation (Muldoon, 1978; Mohla et al. ,
1981). Malignant transformation of breast epithelial cells may initially 
involve one single cell or a number of cells. During growth of the tumour 
oestrogen receptor synthesis may be activated or abolished, and this may 
be related to the degree of differentiation of the tumour (Millis, 1980; 
Fisher ^  Sl.') 1981 ). If activation of receptor synthesis occurs then the 
tumours will be hormone responsive and this forms the basis of hormone 
treatment (Section 1.2.5.1). On the other hand if the cells close down 
receptor synthesis then the tumours become hormone independent and are 
not likely to be hormone responsive. An intermediate situation may exist 
(Nenci et al.,1976).
Oestrogen receptor has gained much support as a prognostic 
index as well as in prediction of tumour response (Hawkins et a^ ., 1980; 
Leake, 1981b). The subject of 'false positives' has been of great concern 
over the past few years. Several markers of hormone dependence have 
therefore been suggested but these have met with mixed success (Section 
1.2 .3 .3). One such marker for hormone sensitivity has been the presence 
of the 88 molecular form of oestrogen receptor in human breast cancer 
(Wittliff and Savlov, 1975). Data from Wittliff's group shows a very 
consistant response rate to endocrine therapy of 0/ 75% if the tumour 
biopsy contained the 88 form. Patients with only the 48 form in their 
tumours do not show such a favourable response (Wittliff, 1980). Several 
other investigators found no significant relationship between receptor 
molecular form and response (Dao and Nemoto, 1980; Gapinski and Donegan, 
1 9 8 0). If they had used Wittliff's criteria of selecting patients then 
several potential responders would have been classified as non-responders 
to hormone therapy. It remains intriguing, however, as to why the invest-
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gators have found such differences in the molecular form of receptor in 
relation to patient response.
4.1.1 Factors affecting Receptor Molecular Form
The data of Freedman and Hawkins (1980) provides evidence 
that most tumours initially possess the 88 form of ER^. In rat mammary 
carcinoma no relationship could be detected between hormone dependence or 
independence of tumour and molecular form, both types exhibiting pre­
dominantly the 88 form (Vignon and Rochefort, 1978; Freedman and Hawkins, 
1 9 8 0). The method of storage affects the receptor molecular form as 88 
is degraded faster than 48 receptor (Namkung e^ Ëï."' 1979). Measurement 
of ER^ content may also depend on the procedure used (Braunsberg, 1975; 
Poulsen ^  1 9 8 1). The results presented in this thesis substantiate
the view that all tumours may initially possess the 88 cytoplasmic form. 
However, different tumours have favourable potential for converting the 
88 form into the 48 form. This most probably is related to a specific
protease(s), the concentration of which may vary from tumour to tumour
or even within a single tumour. This protease(s) seems to alter only the 
aggregation property of the 88 form, not its oestradiol binding capacity. 
Different storage and assay procedures employed in the various laboratories, 
could therefore, lead to the variable distribution of 48 and 88 forms 
reported and reflect the different extents of 'exposure' to this protease(s) 
Jensen ^  aj. (1975) could not demonstrate tumours containing only the 48 
form in any receptor positive tumour. Further only a few cases of 48 
containing tumours were reported by McGuire e^ a^. (1975b). In keeping 
with this observation Freedman and Hawkins (1980) found only one receptor 
positive case (1/19) to possess only the 48 form. In contrast, a signifi­
cant proportion of receptor positive tumours were found to contain only
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the 4S form of receptor in the studies reported by Wittliff (1980) and 
Dao and Nemoto (1980).
The results presented in Figures 11-29 and Tables 2-6 indicate 
that several conditions can affect the 4S : 88 distribution on the sucrose 
density gradient (8DG). The results presented in Figure 11 were obtained 
from a tumour with predominantly the 88 form of ER^. After an incubation
3
period of up to 150 min. with HE^, there was no change in the sedimentation 
profile. It is not known whether further incubation of the same cytosol 
would have resulted in any change in the profile. However the fact that 
the receptor profile can change with time is clearly demonstrated in 
Figures 12.1 and 12.2. As shown in both these Figures, when the cytosol
3
was labelled for 1h with HE^ the profile obtained was of the 48 + 88 type 
(Figures 12.1 A and 12.2A). When the same cytosol was incubated for 24h
3
with HEg followed by DCC treatment and analysis, there was a decrease in 
the 88 peak height with an increased peak height in the 48 area. This 
demonstrates that most probably proteolysis of the 88 form of ER^ is taking 
place (Figures 12.IB and 12.2B). In addition, if the same cytosol, showing 
48 + 88 profile after short periods of incubation, was incubated for 23h
3 3
without HEg then labelled for 1h with HE^ and subsequently treated with 
DCC, the receptor concentration obtained was found to be less than the 
control (1h incubation with steroid). There was also a complete loss of 
the 88 form and decrease in the 48 peak (Figures 12.1C and 12.2C) suggesting 
that empty receptor is more labile. This leads to either loss or alteration 
of the steroid binding site of the receptor. It is possible that the 
Type II sites (Panko et 1981) represent Type I sites which have been 
enzymatically altered in vivo or in vitro (reflected in a high value). 
Alternatively, the detection of Type II sites may not represent an in vitro 
artifact but the result of a physiologically meaningful process: Type II
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cytoplasmic sites representing the degraded excess Type I sites or the 
newly synthetized receptor, and Type II nuclear sites, the degraded 
nuclear functional receptor - since nuclear Type II sites are correlated 
with response (Clark and Markaverich, 1981).
The two peaks noted in Figure 12.2 in the 4S area are also 
reported by others (Kute ^  a^.,1978). This most probably represents 
receptors proteolyzed to different extents. In most experiments resolution 
of such peaks may be masked by their relative concentrations. Studies of 
Sherman £t (1976) have led to the identification of raero-receptor ( /\/3S), 
the lowest molecular weight form which can bind oestradiol. However, the 
physiological significance of such a form is not known. Another interesting 
consideration to emerge from the above results was that long term incubation 
with steroid results in 8S— ^4S conversion with no loss of total binding 
capacity. In the absence of ligand, however, a similar conversion is 
followed by (or associated with) a further modification of the oestrogen 
binding site. Therefore an initial mild proteolysis of 88— ^48 (assuming 
88 formation is independent of the presence of ligand) renders the receptor 
more prone to proteolytic digestion. Notides £t (1973), however, 
report an opposite view. 8tudying human myométrial tissue they found a 
greater selective degradation of occupied receptor. Others also report 
that the steroid receptors are stabilized with ligand occupation, in 
agreement with our results (Peck et ^ . , 1973b). 8urprisingly though 
Kute e_b (1 9 7 8) have reported they could not observe an 88— >48 con­
version with time. It is not clear, however, how many tumours were 
analyzed in their study. Tumours tend to vary in their proteolytic activity 
(8herman e^ ^ .  , 1980). Time of incubation, therefore, seems to be an
important parameter in the final profile obtained (Freedman and Hawkins,
I98O; Tilzer et al., 1981).
- 234 -
The studies of Freedman and Hawkins (1980) and Gaubert et al. 
(1982) make it unlikely that if the BS— >4S is physiologically meaningful, 
it takes place in the cytosol. Nevertheless, a nuclear location of such 
an event is a possibility. Lysosomes have been shown to be translocated 
into the nucleus as a result of oestrogen stimulation (Szego, 1975). It 
is found that limited tryptic digestion of receptor destroys the DNA binding 
site (Andre and Rochefort, 1973). However, Sala-Trepat and Vallet-Strouve 
(1974) show that Ca^ '*' stabilized receptor (which fails to bind to DNA, 
see Andre and Rochefort, 1973) can bind to chromatin. Dickerman and 
Kumar (1982) have indicated that a separate histone binding site may be 
present on the receptor. It is possible, therefore, that some of the 
receptor in the nucleus may lose its DNA binding site but remain bound 
to the chromatin with an intact oestradiol binding site and provide a 
buffering capacity' for the DNA bound oestradiol-receptor complex. This 
mechanism may be important at physiological temperature. In the same 
context, it may be of interest if the 8S— >4S converted receptor can be 
converted back to 88. Muldoon (1980) has suggested that not all trans­
located receptor is degraded, indicating that a receptor molecule can be 
further used after triggering an initial event. The above studies with 
the human tissue imply the following sequence of events in a very simplistic 
view.
repair
8cheme 2 degraded*  3S<----- 48  ^ -, —  48/' 88---------  o > proteolysis ^
form which can acquire
the ability for DNA binding
The 48 form which may undergo mild proteolysis may become more prone to 
ultimate degradation. Microsome bound receptor or other membrane bound 
receptors (Muldoon, 1980; Parikh ^  a3.,1980) may represent either newly 
synthesized receptor or receptor undergoing repair. Murayama et al. (1980b)
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have suggested that a possible role of the 8S aggregate is to prevent 
proteolysis of receptor vivo■ It is also of interest that the proges­
terone receptor shows seasonal variation in functionality (Boyd and Spelsberg 
1979; Boyd-Leinen ^  , (1982). This may even indicate the variation of
such a protease which could regulate receptor vivo. Others have indicated 
that proteolysis of progesterone receptor occurs(Dougherty and Toft, 1980; 
Vedeckis £t a]^ . > 1980)
In addition, Figure 13 shows that Ca^ "** promotes the 88— > 48 
conversion resulting in a sharp symmetrical 48 peak. This sharp 48 peak 
was also characteristic of tumours which showed heavy aggregates at the 
bottom of the tube with disturbed 88 area, suggesting that at least some 
48 molecules have lost the ability to non-specifically aggregate. 8chneider 
and Dao (1977) observed a similar Ca^ '*’ promoted effect which they could 
inhibit with PM8F. Others have found PM8F very ineffective in human 
tissue (Lukola and Punnonen, 1982). We therefore used DFP to suppress 
this enzymatic activity effectively (Figure 13C). The use of DFP (and 
Leupeptin) led to a lower value of total binding capacity being measured.
This is in agreement with various authors (Notides et al., 1976; Lovgren 
e^ , 1979). However it is difficult to state how such an effect is 
brought about. 8ome form of change in receptor structure is plausible.
An effect of tetracine, for example, on the molecular form of oestrogen 
receptor is documented (Kim e^ ^ . , 1982). Competition for the steroid 
binding site by protease inhibitors is also indicated (Baker et al.,1978).
An alternative explanation is possible. Recently it has been demonstrated 
that mild trypsinization of receptor preparations from human breast cancer 
lead to an increase in the total binding capacity (Pettersson £t , 1982). 
It is therefore possible that, whereas in DFP-free cytosol this process is 
continually proceeding, in the DFP-containing cytosol this process will be
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inhibited. The same may apply for the estimation of higher binding 
capacity obtained on overnight incubations (Figures 12.1 and 12.2).
Both trypsinization and Ca^’*' promoted 4S receptor formation have been 
shown to result in loss of the DNA binding ability of the receptor 
(Andre and Rochefort, 1973) although one report suggests that Ca^ '*' pro­
moted transformation leads to enhanced binding to nuclei (Sala-Trepat and 
Vallet-Strouve, 1974). Interestingly Ca^* promoted proteases from different 
species show different properties with respect to their sensitivity to DFP. 
Whereas the data presented in Figure 13 and by Rochefort & Bauleiu (1971) 
clearly indicate that Ca^ **" promoted protease activity in the immature 
rat uterus cannot be inhibited with DFP, the data presented in Figure 13C 
and Figure 51 show that DFP does protect the human receptor. Notides 
e^ (1976) and Daxenbichler at a]^ . (1980) have also found DFP very 
effective in human tissues.
Such data indicates that different proteases are present in
different tissues within the same or different species, It is possible
that the protease responsible for 88— » 48 conversion may be the same but 
2+that Ca may be promoting other enzymatic processes which may hydrolyze 
not only DFP but also other proteins associated with the 88 form. Such 
an effect will render DFP ineffective. Recently, for example it has been 
shown that the 88 form of the glucocorticoid receptor is converted to the 
48 form by RNAases (Tymoczko and Phillips, 1983) which presumably is inde­
pendent of any proteolytic effect. Generally in the human breast tissue 
cytosol, incubation with DFP and heating to 30°C for 30' for activation 
purposes led to receptor aggregation (Section 3-2.3-2.7). However, in some 
other tissues DFP had no effect. A report mentioning two different proteases 
with differing effects on receptor structure has just been published 
(Gregory and Notides, 1982). Ca^ '*’ activated proteases have also been
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described for progesterone receptor in chick oviduct (Vedeckis et ,
1980).
Figure 14 shows the effect of incubation of tumour cytosol
-8 -9
with varying ligand concentration in the range 10 - 10 M. This
tumour cytosol showed predominantly the 4S type of receptor. With
increasing concentration of radioactive ligand there was an increase
in the total receptor concentration measured during the 1h incubation
at 4^C, although in going from 5 x 10  ^to 10 ^Mthis increase was relatively
-9 -9much lower than over the range 10 to 5 x 10 M. There was no increase in 
the proportion of 8S suggesting that the lack of 88 form is not due to 
different kinetic properties of the two forms. Similar results are 
presented by Wittliff et s^. (1976) who found no difference in the kinetics 
of the 48 and 88 forms. It must be pointed out, however, that in the 
mouse mammary gland 48 and 88 forms did show variation in their ligand 
binding properties (Muldoon, 1979). Nevertheless, this only affects 
the very early part of association kinetics (first 10 min) and the 48 
and 88 forms were from two different physiological states of the mouse.
One essential feature demonstrated in Figure 14 is the 88 shoulder present. 
This is reproducible at all these ligand concentrations tested. This 
strongly suggests a possible 88 to 48 conversion, which therefore must 
only be affecting the receptor aggregation properties (or the availability 
of other proteins) and not the steroid binding site.
Figure 15 shows the effect of temperature on the interconversion 
of the receptor molecular forms. Two different effects were observed. In 
Figure 15, on keeping tumour cytosol at 20°C for 1h , there was an increase 
in the 48 region of binding with some aggregation of the receptor towards 
the bottom of the tube. There was also an increase in total binding 
capacity on warming. The increase in the 48 receptor concentration could
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be a result of either unfilled 4S receptor being present or the conversion 
of 8S into the 4S form with some receptor forming heavy aggregates. That 
temperature promotes 8S— »4S conversion was suggested by some other experi­
ments (data not presented) where heated cytosol showed receptor present 
exclusively in the 4S form (without any change in receptor concentrations), 
in contrast to control cytosol kept at 4°C. The formation of heavy aggregates 
in these experiments were low suggesting that protease mediated 8S— >48 con­
version was dominant. Thus, the extent of aggregation (88— >Aggregates) and 
of proteolysis (88— >48) is a balance which depends on the amount of proteo­
lytic content of the particular tumour. These results also indicate that 
the proteolyzed 48 form is unable to aggregate but is relatively stable at 
raised temperatures. Kute £t ^1. (1978) have presented similar results.
Michel ^  (1981) have found that warming the cytosol obtained from
various mammary carcinomas reduces the receptor ability to bind to Heparin - 
8epharose, most probably indicating loss of receptor aggregating ability.
Figure 16 represents the experiment conducted to determine the 
optimum concnetration of DCC required for removal of free radioactive 
steroid without affecting the total binding. This tumour showed a profile 
which cannot be quantitated on 8DG as the 48 peak extends with the aggre­
gating material towards the bottom of the tube. Such tumours were classified 
as DCC^, 8DG^ and are further mentioned in Table 3.1. It is not clear as to 
what leads to such a profile. It probably represents loss of the 88 form, 
either as a direct result of receptor conversion from 8S— >48 or dissociation 
of steroid from the 88 form. It is possible that such a profile could be 
a result of delay from the time of mastectomy to storage and/or assay. 
Nevertheless, the results presented in Figure 16 demonstrate that, with 
increasing concentrations of DCC, there was an increased removal of non- 
specifically bound counts without any significant effect on the specifically
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bound radioactivity. The final DCC concentration of 0.5% (w/v) was chosen. 
Further increases in DCC concentration were avoided since this leads to 
both absorption of protein and stripping of receptor-bound steroid (Peck 
and Clark, 1977; Poulsen, 1981). It should be mentioned here that in 
the analysis of Peck and Clark (1977) the protein concentration was very 
low (1-2 uteri/ml) whereas in the present analysis protein concentration 
generally varied from 3-10mg/ml and therefore protein concentration will 
tend to negate the DCC adsorption effect. Figure 17A and 17B further 
show that when using the same final concentration of DCC, the non-specific 
components can vary from tumour to tumour and is independent of the protein 
concentration range tested (see also Poulsen, 1981). The blood proteins, 
binding the oestrogens (mainly SHBG) can affect the receptor measurement, 
but not to any great extent (Hahnel & Twaddle, 1979). SHBG has now been 
suggested to play an important role in carcinogenesis. In post-menopausal 
women, low SHBG binding capacity is regarded by most (Murayama et al., 
1980e; Moore e^ a_l. , 1982) to indicate a greater chance of developing 
breast and endometrial carcinoma. However, the prognostic significance 
of SHBG is controversial (Mason ^  , 1981; Murayama and Asano, 1981).
Nevertheless, the results presented in Figure 17A and B cannot be taken 
to indicate a difference in the SHBG level of various patients. This is 
because the nature of the tumour will dictate the extent of SHBG found 
in the cytosol of a particular section. It is further shown in Figure 
17A and B that cytosol prepared from a relatively homogeneous tissue 
(immature rat uterus) does not show such a variation in non-specific 
counts as that in human breast tumour cytosol preparations.
4.1.1.1 Storage in Sucrose/glycerol
During the course of the present investigation it was shown 
that an alternative to liquid nitrogen can be used for storage of human
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breast tumours. This involves storing tissue in sucrose/glycerol buffer 
(Section 2.2.1.1, Figures 18-20 and Table 2). Liquid nitrogen, the 
currently favoured form of storage for breast tumours has been found 
by many investigators not to be entirely satisfactory (Wittliff and Savlov, 
1975; Leake et al., 1979). Three weeks from the time of storage, the 
receptor degrades although the 4S form seems to be relatively more stable 
than the 8S form (Namkung et a3., 1979). Similar results were found in 
lyophilized breast tumour tissue (Janes et , 1982). In the sucrose/ 
glycerol buffer two different processes were observed - either there was 
retention of the 8S form for a very long time (Figure 18) or 8S was 
gradually degraded to the 4S form, apparently without loss of total 
binding capacity (Figure 20). The storage data in sucrose/glycerol shown 
in Figure 18 was obtained from the analysis of an axillary node tumour 
mass. There was no loss of the 8S form for up to 96 days. Even after 
96 days receptor could still be detected using Scatchard analysis 
(Section 2.2.2.3, data not shown) with However on the
gradient the molecular form was lost. This apparently results from a 
certain extent of aggregation induced by storage (as also shown by 
Rochefort and Baulieu (1971) for stored cytosol) but predominantly 
from some form of alteration in the molecular structure of the receptor.
The receptor molecules (perhaps, on separation from certain other proteins) 
appear very unstable on gradients. The same tumour when analyzed on the 
517th day (Figure 19A) shows that once again there was a smear of counts 
across the gradient with some aggregation (<100% recovery of counts), when 
the cytosol was analyzed on a low salt gradient. The same cytosol when 
applied to a HDK.^ gradient (Figure 19B) allowed the detection of a 48 
peak with some loss of radioactivity towards the top. This most probably 
represents the dissociated receptor form from about the 48 region to the 
bottom of the tube (and including aggregated receptor) which is now
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concentrated in the 4S area. One, however, cannot ignore the possibility 
that for some unknown reason, KCl may in fact stabilize the aged receptor. 
Again, on the 517th day the receptor concentration was detectable with the 
DCC method.
It is shown in Figure 20 that in contrast to the previously 
mentioned retention of the 8S form for a long period in sucrose/glycerol 
buffer, some tumours show an 88 —> 48 conversion after very short periods 
of storage. Depending on the time of analysis these tumours could be 
classified into 88 or 88 + 48 types. Due to the unavailability of 
enough tumour material, a fact also recognized by 8herman e^ (1980), 
it was not possible to determine a complete conversion of 88 into the 
48 form. However, the very few tumours presented in Table 3-1 in the 48 
alone class probably arose as a result of such an interconversion since 
some of these showed a second section in the 48 + 88 class. This result 
clearly highlights the importance of measuring tumour molecular form as 
soon after mastectomy as possible if molecular form is to be used as a 
discriminant. This applies to every type of storage system used. Results 
presented in Tables 5 and 6 further substantiate that in different tumours, 
varying concentrations of 48 and 88 could be found, probably reflecting 
different concentrations of protease(s) being present.
It therefore seems that storage of human breast tissue in 
sucrose/glycerol buffer either preserves the 88 form or results in the 
loss of this molecular form into the 48 form. This does not affect the 
steroid binding site for a considerable duration of storage (Figure 20 
and Table 2), whereas long term storage may result in loss of molecular 
form and/or receptor concentration. This may be significant since even 
short-term storage in liquid nitrogen generally leads to a loss of
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receptor concentration compared to control (Namkung ^  al., 1979; also 
seen by Toppila £t al. (1982) for gynaecological tissues). In the 
present investigation, tumours showing high receptor values were studied 
for molecular forms. Nevertheless Scatchard analysis conducted by 
Miss Marion McMenamin in our laboratory showed that in tumours with very 
low receptor concentrations (<20 fmole/mg protein), both cytosol and 
nuclear receptors can be preserved for up to at least 12 weeks.
The sucrose/glycerol storage results of human breast tissue 
suggest that in cases where storage in liquid nitrogen is delayed with 
deleterious effect on receptor, the surgeon can section the biopsy and 
store it in sucrose/glycerol buffer at -20°C prior to shipment to the 
biochemical laboratory. Hasson et (1981) have stressed the importance 
of avoiding such a delay. They found receptor levels in specimens from 
mastectomy to be significantly lower than the initial frozen section 
specimens. In Hasson's study, however, no consideration was given to 
intratumoural variation which could occur (Section 3-1-3). Our results 
clearly show that sucrose/glycerol can be employed for such a purpose 
and may also be used for the analysis of molecular forms but that the 
latter, if required, must be determined rapidly (within 7 days). Sucrose/ 
glycerol buffer (or other storage methods) should be used only if the 
fresh sample cannot be analyzed. An efficient coordination between the 
biochemical laboratory and surgical theatre staff is required for the 
analysis of fresh tumours. However, this is not always practical. . In 
addition the number of samples that can be processed and the time factor 
involved in sucrose density gradient procedures are drawbacks of SDGA.
The recent application of high pressure liquid chromatography should 
prove useful (Pavlik jet , 1982). It is possible that, keeping the 
time factor constant, the various molecular forms may be indicative of
- 243 -
some form of tumour characteristic, such as possible extent of protease 
present and its association with hormone response and/or metastasis. It 
is interesting that plasminogen activator and receptor content have been 
found to be correlative by Sutherland (1980); plasminogen activator may 
also be involved in 8S— ?>4S conversion, as noted by Sherman (1980)
Taking various factors into account, it has been shown that sucrose/ 
glycerol buffer is a better method of storage than liquid nitrogen. The 
8S— ^ 4S conversion observed by various investigators therefore seems to 
be the result of methodology involved and does not represent an vivo 
state although such a process may still take place vivo.
For reasons unknown, sucrose/glycerol buffer does not preserve 
the immature rat uterine ER^ (Figure 21). If this is a result of 
leaching out of the receptor into the medium such leaching could not 
be determined, probably as a result of the very low concentration of 
protein in the medium for which the DCC assay is unsuitable (Poulsen,
1981). The indication‘however, was that the receptor was degraded since 
storage for 1 day resulted in the appearance of a previously non-existant 
4s peak followed by a drastic reduction in both the 4S and 88 forms.
The protease (or phosphatase or other enzymatic activity) involved in 
receptor degradation seems to be present in immature rat uterus but is 
compartmentalized in some mammer. This degradation of receptor may in­
volve a different cellular metabolism of receptor other than the 8S— >4S 
conversion seen in human breast tumours, indicating perhaps different 
protease(s) in different target cells. Gregory and Notides (1982) have 
recently demonstrated two different types of proteases with different 
effects on receptor structure. This protease, whether present in nucleus 
or cytoplasm, may get artifactually activated during storage or during 
homogenization. Lysozomal membranes may be sensitive to storage and
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nuclear membrane may similarly be prone to rupture as a result of post 
storage thawing. Chromatin associated serine protease activity has been 
demonstrated in the rat liver (Tsurugi and Ogata, 1982) but this does 
not appear to be the protease encountered here since DFP, a serine 
protease inhibitor was found to be of limited effectiveness in the 
immature rat uterine cytosol (Figure 50), The latter, however, was not 
stored but fresh cytosol. Plasminogen activators have been found in imma­
ture rat uteri (Peltz e^ al., 1983) but these were indicated to be 
inhibited by DFP. The situation therefore remains unclear.
4.1.1.2 Effect of Ionic Strength and Sodium Molybdate
The results presented in Figure 22 were directed towards 
studying the effect of ionic strength and sodium molybdate on the 
sedimentation profile of ER^ from human breast cancer. The low salt 
(HED) profile of the predominant 88 form (Figure 22A) was changed to the 
predominant 48 form when the same cytosol was loaded onto HEDK. ^ ^ gradients 
A similar effect is observed if the salt concentration is increased to 
0.4M. This suggests that the 88 complex is sustained by relatively weak 
ionic associations between protein molecules and that probably in vivo 
the receptor exists in the 48 state (Stancel e^ , 1973a). However 
since it is not possible to determine the intracellular protein concen­
tration, the actual in vivo state of the receptor will perhaps remain 
unresolved for a considerable period of time and for this reason, the 
88 complex so formed in low salt conditions cannot be disregarded. The 
88 complex could arise from either self-association of receptor or as a 
result of aggregation with other soluble proteins. The exact role of 
such an association is not known but Murayama ^  (1980c) have shown
that the 88 complex arises as a result of specific proteins present in
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the soluble fraction which associate with the 4.53 complex (native 
form). Similarly the molecular constituents of the 8S progesterone recep­
tor complex are also composed of specific associations of proteins with 
the 4S complex (Murayama et , 1980d). The formation of the 83 complex 
is thought to prevent the receptor from undergoing proteolysis jn vivo 
(Murayama et aJ., 1980b). However as shown in Figure 12.1 & 12.2, the 83 
complex is liable to undergo degradation to the 4S form in vitro. This 
most probably arises prior to centrifugation analysis when an 8 3 ^ 4 3  
interconversion will make the 43 available for proteolysis. As has been 
suggested previously, this degradation may take place as a result of 
artifactual release of certain nuclear proteolytic enzymes on cell dis­
ruption (assuming the process of 83— » 4S is physiologically significant), 
therefore the soluble 88 complex may still serve as an indicator of the 
extent of this protease(s).
The formation of the 88 complex (or higher aggregates) may be 
an in vitro indication of the receptor's ability to form such complexes 
in vivo. This may be a way of preserving the 88 complex in the cytosol 
since large molecular weight compounds will not diffuse across the nuclear 
membrane (Gorski and Gannon, 1976). There have been reports of specifically 
associated inhibitors of activation with the receptor - perhaps the 8S 
complex is a reflection of such an association. 8teroids may then allow 
the receptor to dissociate into the 48 form (i^ vivo), the form which 
now either possesses or acquires the ability to bind to DMA. The ability 
of receptor to undergo aggregation may serve another important function in 
the nucleus. The possibility of a positive co-operative effect of 
receptor on certain genomic sites for induction of message has been 
suggested by Yamamoto and Alberts (1976). Perhaps, then, such aggregation 
of receptor reflects an in vivo requirement for an association amongst
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receptors at a regulatory site {multimeric complexes). The report of 
Govindan et al. (1982) have suggested a similar proposition for the 
glucocorticoid receptor.
Several workers have recently focused attention on the compound 
sodium molybdate which promises to be an important tool in understanding 
the receptor molecular forms and the process of activation (reviewed in 
Grody ejb , 1982). It has been claimed recently that, in the presence 
of sodium molybdate the receptor sediments faster than 8S (Sherman £t ,
1980). However, it is shown in Figure 220 that the inclusion of sodium 
molybdate in the present work did not result in any significant increase 
in sedimentation value (cf Figure 22A). This is in agreement with the 
data of Mauck et (1982) and Moncharmont e^ (1982), who studied 
the effect of molybdate in calf uteri, and the data of Krozowski and 
Murphy (1981) who studied human myométrial and MCF-7 human breast cancer 
cell receptor.
The proposed mechanism of molybdate action include (i) inhibition 
of phosphatase (Sando etal., 1979 a,b), (ii) inhibition of RNAase and protease 
(Chong and Lippman, 1981-82), (iii) direct interaction with receptor or 
associated proteins (Noma £t ^ .  , 1980), (iv) intercalating Ca^ *** ions 
(Ratajczak et , 1981), (v) possible interaction with sulphydryl groups 
(Kalirai and Banerjee, 1981). It is easy to see that if more than one of 
these mechanisms is involved, then variation in experimental techniques 
may account for disagreements in the literature. Although sodium molybdate 
has been shown to be useful in both qualitative and quantitative assessment 
of receptor in human breast cancer (Anderson ^ . , 1980), as yet no 
data is available which shows that the overall rate of receptor positivity 
and response has been increased. In any case the difference in receptor
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concentration shown in Figure 22, in the presence or absence of molybdate 
cannot be ascribed solely to molybdate since two different sections of 
the tumours were analyzed (Section 3.1.3).
Figure 22 demonstrates another important but scantily studied 
feature. The results are those of a human male breast cancer patient.
Male breast carcinomas are very frequently found to be receptor positive 
and this may relate to early presentation at the surgery, while the tumour 
is still relatively more differentiated. Both the higher incidence of 
male breast tumours being receptor positive and possible application of 
hormone treatment to them is recognized (Gupta et a]^., 1980; Friedman 
e^ ^ . , 1981; Kraybill e^ al^., 1981; Pegoraro e_t , 1982). Another 
feature presented in Figure 22 is the consistence of ER^ concentration 
when expressed per unit DNA which may imply that male breast tumour is a 
more concentrated and homogeneous mass of tumour cells than is obtained 
with female breast carcinoma.
4.1.1.3 Protease Inhibitors
Figure 23.1 and 23.2 represent the effect of two protease 
inhibitors, PMSF and Trasylol, on receptor sedimentation profile.
Although Schneider and Dao (1977) used PMSF for inhibiting the effect 
of a protease(s) in human breast tumours, others have found it in­
effective in human tissue (Lukola and Punnonen, 1982). It may be impor­
tant however, that Schneider and Dao’s study involved only low temperature, 
salt dependent effect on proteolysis of receptors whereas most other 
investigators have used higher temperatures (e.g. for heat induced 
transformation). Increased temperature may activate certain other 
proteolytic enzymes or enzymes responsible for degradation of PMSF 
itself. In Figure 23.1, however, it is shown that, in the absence of
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any heat induced effects, PMSF was unable to protect the appearance of 
some 4S form of receptor. ' There may be other reasons for the presence 
of a minor 48 peak and these include dissociation during centrifugation 
and proteolysis of 88 during storage. Since the PMSF effect was studied 
in only two tumours, which were both 88 dominant (low level of protease(s)) 
the effectiveness of PMSF at low temperatures cannot be deduced from the 
present work.
Attempts to stabilize receptor molecular form with Trasylol 
were unsuccessful (Figure 23.2). The 8S form was particularly affected 
and this probably involved both loss of receptor into the 4S form and 
aggregation. It is not possible to comment on Trasylol promoted aggregation 
but the 8S— ^48 conversion could be attributed to the introduction of 
ionic strength into the cytosol. Trasylol, which is used mainly for 
injections into humans to suppress certain proteolytic events in the 
blood, is provided in isotonic medium. It is therefore possible that 
the 48 area seen in Figure 23.2, in the presence of Trasylol, represents 
salt-induced 88 dissociation. This is stressed since two different 
sections of the tumour were analyzed and the 4S : 88 distribution may 
simply be a result of intra-tumoural variation. Trasylol therefore does 
not prevent the appearance of 48 receptor although the formation of 48 
possibly may have occurred endogenously during storage or at the re­
warming process. If the tumours are stored prior to analysis then the 
efficacy of any protease inhibitor on the molecular form should not be 
judged on separate sections. Birnbaumer et al. (1983) have also cautioned 
against the assumption that molecular forms obtained in the presence of 
Trasylol and PMSF represent the non-degraded form of receptor. These 
authors were studying chick oviduct progesterone receptors. This is not 
to infer that PMSF should not be used at all. For instance, Wilson and
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French (1979) have found it very useful for the analysis of androgen 
receptor.
4.1.1.4 Buffers
It has been documented that buffer systems can affect the 
receptor conformation on SDGA (Gaubert et , 1982)i On this basis 
it could be argued that the very small number of predominantly 4S con­
taining tumours detected in this present series was a result of the use of 
Hepes (Table 3.1). Figure 24, nevertheless, shows that results obtained 
with Hepes were comparable to those obtained in Tris and Hepes was there­
fore not the cause of present results. Gaubert e^ (1982) have found 
that, at least in the mouse mammary system phosphate buffer prevents any 
88— >48 conversion. Hepes was used in the present investigation since its 
PK^ value is close to the pH at which the experiments were conducted. It 
is not known if this in any way influenced the separation of molecular 
forms on the gradient. For example, the separation of receptor from other 
proteins during centrifugation may lead to certain receptor sites being 
exposed to different chemical environments in various buffers, which may 
influence the final configuration (see Mauck ^ . , 1982). Another 
point demonstrated in Figure 24 is that storage in Hepes (sucrose/glycerol 
buffer) does not result in any alteration of sedimentation profile whether 
analyzed on Hepes or Tris gradients.
4.1.1.5 Protein Concentration
The protein concentration of tissue cytosol has been shown to 
alter receptor sedimentation profiles (8tancel e^ sŒ., 1973a, b). However, 
in the protein concentration range used in the present results, 3-10mg/ml,
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no significant variation in the sedimentation profile was obtained 
(Figure 25). The receptor was found to sediment at 7-88 at the tested 
protein concentration range of 2.4-11mg/ral. This most probably indicates 
that the 48 + 88 profile seen in other tumours is independent of protein 
concentration and is related to other factors. Protease(s) effects seem 
to be the major candidate but the effect of the protease itself should be 
carefully interpreted. It may not always be the case that the 88— >48 
conversion requires the proteolysis of the 88 form. Recently it has been
found that there are other protein factors which may be required for the
conversion of 48 —  ^88 (Murayama et , 1980a,b,c; Colvard and Wilson,
1981) and, therefore, if these factors are destroyed or are present in
limiting amounts, the 48 : 88 distribution will be affected. In the
same context RNA has been implicated as one such factor in determining 
the 88 form in the glucocorticoid receptor system (,Tyraoczko and Phillips, 
1983). If this also applies in the case of the oestrogen receptor then 
extraction of RNAase in the soluble fraction may influence the 48 : 88 
distribution. Sherman ^  a2. (1980) used a protein concentration range 
3-12mg/ral for their analysis and report similar results. In addition 
they have pointed out that at least 40fmole/rag of receptor should be 
used for 8DGA for correct determination of the hydrodynamic properties 
of receptor.
4.1.2 Distribution of Various Molecular Forms
The distribution of various molecular forms of oestrogen 
receptor in human breast tumours fell predominantly into the 88 and 
8S + 48 class with variation in the concentration of each in the latter 
(Figures 26B, C, D and Table 3.1 and 3.2). A few tumours showed the 
predominant 48 profile, as shown in Figure 28.1 A. A subclass was found
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to represent what has been designated as DCC"**, SDG- (Table 3-1 and 
Figure 16). These showed quantifiable receptor by DCC analysis but 
not by SDGA. This situation may arise as a result of proteolysis on 
the gradient or during the storage procedure or as a result of destruction 
prior to storage. Some other authors have also had to use the DCC*, SDG- 
term in cytosols where 88 could not be demonstrated clearly (lino et al.,
1980). It must be mentioned that in accordance with other published re­
sults (Geier e^ , 1979; Freedman and Hawkins, 1980) very few tumours 
showed the predominant 48 profile. Even amongst the tumours which showed 
predominant 48 form in one section, some showed a second section in the 
48 + 88 class, although this was rare. These two sections were not 
necessarily studied on the same day but within 60 days of storage, the 
criteria set for the present work. The storage data (Table 2) 
had already indicated that there are some tumours in which this time 
period does not alter the sedimentation profile and therefore this 
variation obtained between two sections may represent,(ij a greater 
concentration of protease in one section, possibly linked to the position 
of the section within the tumour (8ection 3.1.3), (ii) experimental 
variation. It becomes increasingly important that investigators should 
set unified criteria not only for storage but also for the duration of 
storage. With the same reasoning, the vast majority of tumours falling:.;, 
into the 48 + 88 type (Table 3.1) could be the result of such an inter- 
conversion taking place during storage and/or the post storage warming 
(to 4°C) period. This similar problem may be inherent in the liquid 
nitrogen method of storage (Jensen at , 1975; Dao and Nemoto, 1980)
and lyophilization of tissue (Janes et ^ . , 1982). These methods usually 
do not take into account the relative positioning of the section within 
the tumour. It is therefore possible that tumour powder used for analysis
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may have acquired a large quantity of protease from within the central 
section and this will therefore influence the sedimentation profile.
The influence of protease in the distribution of variable 4S : 8S was 
also indicated by Tilzer et (1981).
During the present investigation the receptor rich tumours 
(DCC assay) were generally selected for gradient analysis. This decision 
was made for reasons which include (i) a minimum value of receptor con­
centration is required for hydrodynamic analysis (Sherman et a]^., 1980), 
(ii) if an intratumoural variation of receptor molecular form was to be 
found then this should be clearly demonstrated and (iii) since the 
availability of tumour sample is limited and further sections were some­
times required for further biochemical analysis, a demonstration of a 
clear 8S receptor was felt necessary (based on literature survey). This 
selection of tumours for analysis is probably reflected in the very high 
number of 8S containing tumours detected (Table 3.2). Nevertheless, 
others have shown that receptor rich tumours can be predominantly the 
4S type (Wittliff et , 1976; Dao and Nemoto, 1980) and similarly 
that low receptor content tumours can be predominantly 8S (Freedman and 
Hawkins, 1980).
In no case in the present results (Table 3.1 and 3.2) was the 
receptor present exclusively as 48, as shown for example in the Figure-2 
of the paper by Wittliff and Savlov (1975). There always seemed to be 
either a shoulder present in the 7-88 area or some form of aggregated 
material in this region. This probably also provides the clue that 8S— >48 
conversion must have occurred. It, therefore, seems likely that a complete 
conversion of 88— ^48 is most probably what Wittliff's group was observing. 
As previously noted the 88— >48 conversion is a consequence of the
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handling of tumours e.g. method and extent of homogenization, time and 
method of storage, time and method of thawing of stored tissue, extent 
of time lapse from biopsy to storage or assay. All these factors may 
contribute towards the final 4S : 88 ratio obtained. In this context, 
it is not surprising that several authors have concluded that inclusion 
of the 48 value, irrespective of whether or not 88 is present, can increase 
the predictive value of ER^ in relation to response (Dao and Nemoto,
1980; Gapinski and Donegan, 1980) in keeping with the observation 
that tumours showing higher receptor content are likely to show a greater 
chance of response. It therefore is difficult to resolve why Wittliff’s 
result showed such a consistent and close relationship between molecular 
status and response. It is possible, but unlikely, that a sub group of 
patients, probably of an advanced stage may be referred to the surgeons 
from whom Wittliff*s group obtain samples. It is also possible that, 
in fact, Wittliff's group may be employing some form of very strict 
criteria with respect to storage etc. which is giving them such reproducible 
results and this in fact may be reflecting some form of predictive nature 
of the proteolytic content of the tumours. It may be possible to re­
produce these results in other laboratories but identical conditions 
will be required for such an achievement. The need for inter-laboratory 
quality control is an absolute requirement for such assays and the need 
for this has recently been recognized (King, 1980; Zava at , 1982), 
although present work in this context is being directed towards measuring 
receptor content, not the molecular form. It may be argued that SDGA will 
not increase the 70% or so response rate obtained by simple DCC assay of 
both soluble and nuclear oestrogen receptor (Leake at , 1981).
4.1.2.1 Intratumoural Variation
Results have already been presented in the literature
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recognizing intratumoural variation with respect to receptor concentration 
and in extreme cases such variation may lead to diagnosis of one section 
being receptor positive and another receptor negative (Poulsen, 1981;
Izuo , 1982). In general, it was found that the tumour preserves
its receptor status in different sections, whether the sections were taken 
randomly or selectively (Figure 27 and Tables, 5, 6 and 7), however, the 
relative concentration of the molecular forms can vary. As far as is 
known no study has been reported where intratumoural variation with 
respect to molecular form has been analyzed. Kiang and Kennedy (1977) 
have studied simultaneous and sequential biopsies in the same patient on 
SDG and report that these are consistant in their qualities and quantities, 
However, recent work has shown that not all receptor positive primary 
tumours retain receptors in the secondaries (Leake £t , 1981 ; Harland 
e t ^ . ,  1983).
In the present work 4 tumours were found (4/74) which showed 
one section in the 4S class and a second section in the 48+88 class 
(Table 3.1). It is therefore concluded that in extreme cases, situations 
can arise where a false estimation of receptor molecular status could be 
detected (discussed below).
With respect to receptor concentration, it was found that the 
central sections showed lower soluble and nuclear receptor concentration 
than the peripheral sections (Table 4). This was, however, not always 
the case. 8ometimes the peripheral sections showed lower receptor 
values than the central sections. These results are generally in 
agreement with others with respect to variation in the soluble receptor 
(Hawkins et al., 1977; Masters et ^ . , 1978; Tilley e^ al^, 1978;
Poulsen, 1981 ; Izuo et al., 1982). However, with respect to the
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nuclear receptors these results are at difference with those presented 
by Silfversward al. (1980). It is not possible to comment as to why 
such a difference has been noticed. Recent studies with human endometrial 
carcinoma (Castagnetta , 1983) would tend to favour the results shown
in the present work. The loss of both soluble and nuclear receptor to­
wards the central area of the tumour is probably a consequence of that 
section representing the oldest part of the tumour with altered blood 
supply (Folkraan and Cotran, 1976) and resulting necrosis, not visible to 
the naked eye.
Table 5 also presents results from tumour sections studied 
selectively (Figure 9) except that here the sedimentation pattern was 
also judged. With respect to receptor concentration, the results were 
no different to those already discussed for Table 4. The molecular 
status of the tumour was generally also preserved whether the sections 
were studied selectively (Table 5) or randomly (Table 6). However, 
where both the 4S and 8S forms were detected, these were found to vary 
among different sections of the same tumour. Figure 27 illustrates one 
such example. The protein/DNA ratio indicated in the associated table 
(shown in Figure 27) suggests that the low concentration of receptor 
in the periphery could be the result of a lower cellular content of the 
peripheral section, as indicated by the low DNA value. DNA, however, 
cannot be taken as an absolute index of tumour cell number since there 
may be non-receptor containing normal or cancerous cells present. Histo- 
chemical analysis (Nenci, 1981) has revealed that such situations 
prevail in human breast carcinomas. In addition leukocyte infiltration 
of some tumours could give a false estimation of receptor value when 
expressed per unit DNA, as has been indicated by Silfversward et al. (1980). 
Importance of measuring tumour cell content has been stressed (Hawkins
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et , 1977; Van Netten , 1982) although some Investigators have
failed to relate receptor to tumour content (Wittliff ^  , 1976).
Castagnetta e^ al. (1983) have reported that a more meaningful comparison 
between human endometrial carcinoma sections can be made if receptor con­
centration per unit DNA are compared. Human endometrial carcinomas may be 
relatively more homogenous than breast tumours since Romano et (1979) 
have reported that wide variations with respect not only to DNA content but 
also receptor expressed per unit DNA can be obtained in human breast tumours. 
In addition, whereas the human endometrial carcinoma intratumoural study has 
revealed that there exists an ’all or none' phenomenon with respect to 
receptor concentration in different sections, this process is much more 
gradual in human breast cancer. Nevertheless, from the very small number of 
tumours analyzed(Table 5 and 6 ) it is indicated that DNA may provide a better 
index of representing receptor concentration than that expressed per unit 
protein (e.g. tumour number 1 in Table 5). The maximum variation obtained in 
receptor concentration with respect to protein concentration was 13.7 fold 
whereas the maximum variation on DNA basis was 4.5 fold. Axillary nodes 
analyzed, however, showed an opposite effect, in that the intratumoural 
variation increased when receptor concentrations were expressed per unit 
DNA (tumour number 2 in Table 6 and tumour sample represented in Table 7). 
However, since lymph nodes are more prone to leukocyte infiltration, DNA 
may only be of value for primary tumours. Auer ^  (1980) have shown
that tumour cells can contain an aneuploid condition, but that such a 
situation is usually associated with receptor negative tumour cells.
The foregoing conclusions are purely preliminary since the number of 
tumours analyzed was small. A detailed analysis is needed. What has 
been clearly shown, is that tumour ER^ 4S : 8S ratio can vary
between different sections of the same tumour. In addition to other 
possible reasons for such a situation, one reason must include the
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variation of protease content in different regions of the tumour. It 
cannot be said at present, however, whether this variation is a reflection 
of variability of cellularity or variations within individual cells.
Figure 28.1 and 28.2 show two examples where the tumour can be 
interpreted and classified into two different categories, depending on 
which section was analyzed. Routine analysis may be limited by the 
amount of material available, a difficulty recognized by others (Sherman 
et al., 1980). In Figure 28.1, one tumour section shows a predominant 
4S profile whereas an 88 peak can also be clearly demonstrated in a 
different section. This is an example of extreme variation noted in 
4/74 tumours. Figure 28.2 is an example of a case where such variation 
was found in the 48 form. The tumour shown in Figure 28.2 can be 
classified as either a 48 + 88 type or as a predominant 88 type. In 
the present work, for uniformity both sections were classified as a 
48 + 88 type (Table 3*1) although section B should really have been 
classified as a predominant 88 type. Nevertheless, the quantitation 
of 48 receptor in such profiles is subject to considerable error because 
of the nature of the 48 peak (/v'26%). However, with respect to criteria 
for relating tumour profile with response, both sections indicate the 
patient as a potential responder. It is also important to point out 
that in Figure 28.2B, a proportion of receptor was present as heavy 
aggregate. If this represents only the 88 form then the proportion of 
48 receptor was overestimated and this section should have been classified 
as 88 type.
It has previously been indicated that certain tumours may 
possess factors which can lead to receptor aggregation at the bottom 
of the centrifuge tube. Receptor aggregation has been observed in other 
systems (Rochefort and Baulieu, 1971) and seems to represent a general
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property of receptor. Polysaccharides may be involved (Nishizawa e;b al., 
1981; Kim e^ , 1982). However, self-association of receptors and 
association with other proteins cannot be ignored (Stancel et al., 1973a; 
Murayama et , 1980a,b,c). This aggregation property cannot be ascribed
solely to vitro artifacts. An vivo function for aggregation is 
possible or may relate to cell cytoskeletal structure (Mueller et ,
1978; Schliwa , 1981 ; Barrack and Coffey, 1982). Aggregation
was quite prominent in some of the human breast tumour cytosols analyzed 
in low salt gradients (Tables 5 and 6). Such aggregation can lead to a 
false estimate of the 4S : 88 ratio if only one form is able to aggregate. 
This is not the case in Figure 28.1, where there was complete recovery of 
specific counts on the gradient and therefore no aggregation. In one 
case studied (data not shown), 1h incubation at 4°C showed a high amount 
of receptor aggregation. However, in the same cytosol when incubated 
for 24h at 4°C, aggregation was not observed. Instead, a considerable 
rise in 48 concentration occurred. One explanation of such a situation 
is that only 88 aggregates and all 88 is degraded to 48 during the 24h 
incubation.
4.1.2.2 Protease Mediated 88-- » 48 Conversion
The varying distribution of 48 and 88 forms within the same 
tumour prompted an investigation to determine if 88— >48 conversion may 
take place between homogenization and gradient analysis. Immature rat 
uteri are known to contain only the 88 form. Immature rat uterine 
cytosol was mixed with human breast tumour cytosol. The result 
(Figure 27) shows that 88— ^48 conversion does occur on mixing these 
cytosols, even at 4°C. The tumour used for this experiment gave 
the 48 + 88 profile. Receptor concentration of the tumour cytosol was 
low to avoid interference with the resolution of the rat receptor.
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Sato et (1981a) have also performed similar experiments and have 
shown that such 8S— >4S conversions could be accelerated by temperature 
and lead to loss of DNA binding by receptor. In a similar context, some 
preliminary results (data not shown) indicated that immature rat uterine 
cytosol, after mixing with breast tumour cytosol, failed to give a 4S— >5S 
transformation. This same proteolytic process may be involved in Ca^* 
promoted effects (Figure 13; see also Schneider and Dao, 1977). It is 
concluded from these data that a protease(s) activity is present in 
human tissue which also recognizes immature rat uterine receptor.
Analysis of mature rat uterine cytosol showed the presence 
of two molecular forms (Figure 30) similar to those found in certain 
human breast tumour cytosols. The rat receptor molecular form seems to 
fluctuate to a certain extent depending on the stage of the oestrous 
cycle. The 4S : 8S ratio seems to be highest at oestrous when the uterus 
has just passed the period of maximum exposure to oestradiol. The ratio 
seems to be lowest at metoestrous, the time of lowest oestradiol stimula­
tion. Oestrogen induced trypsin like activity in the mature rat uterus 
has been reported by some authors (Katz e^ al., 1976; Kneifel £t al., 1982) 
Hakim (1980) has also shown a variety of oestrogen-induced proteases in 
human tissue. In human breast tumours a similar effect is observed since 
increased cleavage of human breast tumour ER^ is correlated with plasmi­
nogen activator (Sherman et , 1980). Fluctuation of progesterone
receptor with the oestrous cycle in guinea pig uterus has been reported 
(Milgrom ^  , 1972). Mammary gland and other tissues have all been
shown to contain various molecular forms of receptor (Section 1.2.2.2.1, 
Milgrom e^ ,1973c) and seem to depend on the hormonal background of 
the animal. Gaubert a2. (1982) have shown that this 8S— »4S con­
version in cytosol can be prevented by homogenizing the tissue in either
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phosphate buffers or buffers containing sodium molybdate. Such a specific
mechanism in which the receptor steroid binding site is not affected
suggests a true vivo role for this protease. It may be of significance
that such a process (8S— >48) seems to be common to other steroid receptors
(Hazato and Murayama, 1981; Prins and Lee, 1982). Investigators have
also located large concentrations of such a protease in nuclei, affecting
both oestrogen (Murayama & Fukai, 1981) and progesterone receptor
(Vedeckis et 1980). Such a protease might serve a nuclear function
either regulating the amount of receptor which can bind to correct DNA 
and/or
acceptor sites/initiating receptor degradation. Fractionation may 
release this protease into the soluble fraction. Serine proteases are 
known to be present in chromatin (Carter and Chae , 1976; Tsurugi and Ogata, 
1982).
It is suggested that 5S may represent the form which has a 
higher affinity for oestradiol (Welchman and Notides, 1977) and this may 
be linked to the duration of stay of receptor on the chromatin. The 
presence of a high concentration of protease may explain why some 8S 
containing tumours fail to respond to endocrine therapy. The protease(s) 
may not allow sufficient time for the receptor to bind to and activate 
DNA, Therefore the tumour is non-responsive. The salt extraction of 
nuclear receptor may not allow the detection of heterogeneity in nuclear 
receptor since present investigations all use high salt gradients (48 
cytoplasmic receptors may comprise of two forms, see Section 4.2.2).
However, Andre et al. (1978) have used micrococcal nuclease to digest
nuclear receptor and have found two forms on low salt gradients, the 
4S and the 6S form. It is even possible that the 8S— >4S conversion may, 
in fact, be the signal for a rapid degradation of the receptor. A 
conformational change in receptor protein may be the signal required
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for such degradation, as is found for other proteins (Wheatley, 1982).
Such an 88— »48 conversion really represents a 4S aggregating type— >4S 
non-aggregating type conversion. The 4S aggregating type (8S) may also be 
released by other mechanisms, such as dephosphorylation (Auricchio et al.,
1982) and this possibly contributes towards the recycled receptor. At 
least some of the recycled receptor is able to undergo a second round of 
translocation (Muldoon, 1980). It is possible that some of the proteolysed 
receptor may undergo repair in the cytoplasm. Detection of microsomal 
bound receptor may represent both newly synthesized and receptor under­
going repair (Muldoon, 1980; Parikh et 1980). It should be pointed 
out that the effect of dephosphorylation is measured as loss of oestradiol 
from nuclei and may not indicate loss of receptor itself.
A possible model of steroid hormone action is proposed (Section
4.3).
- 262 -
4.2. Activation/Transformation Study
The terminology used in steroid receptor research, with regard 
to activation and molecular transitions has led to much confusion! The 
two terms, activation and transformation (4S-+5S) of oestrogen receptor, 
have been used interchangebly to describe the state of receptor which has 
acquired an increased affinity for DNA or chromatin. True transformation, 
nevertheless, has only been observed for oestrogen receptors. The recent 
use of the term activation to describe the form of receptor which, after 
phosphorylation (Sando ^  , 1979a,b) acquires the ability to bind
hormone, has further confused the issue. Unless specified, the latter 
concept should be disregarded with reference to the present discussion.
Activation and transformation of oestrogen receptor may not be 
independent events. Nevertheless whether activation proceeds, occurs 
concomitantly with or follows transformation is unclear. Activation may 
be taken to mean (a) the dissociation of receptor from inhibitors and 
modulators, to give the active form (active implying the availability of 
receptor for DNA binding, but prior to acquisition of DNA binding ability),- 
(b) a simple conformation change (no 4S->5S required) common to all 
steroid receptors and (c) association of another subunit(s) to the 4S 
subunit to yield the 5S receptor which now represents the DNA-binding 
form. Support for concept (c) comes from the fact that nuclear oestrogen 
receptor shows properties similar to the 58 form that can be generated in 
the cytosol (Notides, 1978). If, however, the second subunit(s) (Thampan 
and Clark, 1981) were to be a nuclear protein then concepts (a) and (b) 
are possible. Data is consistent with the existence of inhibitory factors 
mentioned in (a) but there remains no proof in vivo.
The study of Bailly et al. (1980) has suggested that receptor
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activation (to the DNA binding form) is a first order process, and 
consequently independent of a second subunit. The same study has further 
suggested that transformation is a second order process which involves 
binding of another subunit. Their methodology however, is open to criticism. 
In their method, rapid dilution of high salt cytosol for DNA binding purposes 
can, itself, induce a 4S— > 5S change (Notides, 1978). Further, separation 
of low receptor concentrations on overnight sucrose density gradients may 
promote 58— >48 transition giving a false indication that 48 represents 
the active form. In the absence of any detailed knowledge of 48— >58 
equilibrium the correlation of test tube data with that of 8DGA should 
be interpreted very carefully.
It may be important that it is only after heat activation that 
receptor triggers RNA polymerase activity (Mohla et , 1972). This heat 
activation is associated with a 48— >58 change for the oestrogen receptor 
(Figure 46). The 58 complex may represent a functional unit required to 
form a tight complex with DNA and essential for the triggering off of a 
signal. The formation of multiple 58 complexes (aggregation) is also a 
possibility. The fact that such a 58 complex is not observed for other 
steroid receptors does not argue against the formation of such a complex.
The 5S human receptor can be shown to form under physiological conditions 
(Notides et , 1976). The glucocorticoid receptor recently visualized 
electronmicroscopically (Govindan ^  , 1982) seems to comprise a dimer
on the DNA. Therefore the possibility that there is an equilibrium between 
a higher molecular weight (active?) form and the conventional 48 form for 
other steroid receptors seems likely but such an equilibrium is strongly 
in favour of the dissociated form. Proteolysis during extraction and the 
fact that the second subunit may be a nuclear protein for receptors other 
than oestrogen, may also obscure transformation studies.
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At present, the only known form of regulating receptor-DNA 
interaction seems to be the regulation of receptor concentration itself 
(Clark and Peck, 1979). The process of receptor activation may normally 
prevent excessive gene activation. In recent years this idea has been 
reinforced by studies of DNA-binding of oestrogen-receptor and anti - 
oestrogen-receptor complex (Rochefort and Borgna, 1981; Katzenellenbogen 
£t ^ . , 1981; Evans et ^ . , 1982).
4.2.1. The DNA-cellulose binding assay
To further assess the role of the DNA-binding ability of receptor 
as one mechanism of control in normal cells, the DNA binding assay was 
developed. Yamamoto and Alberts (1974) have reported that the binding 
of receptor to double stranded DNA is not a sequence specific effect, yet 
the observation (Simons ^  , 1976) that the activated-receptor complex
binds strongly to DNA-cellulose has proved very useful as a measure of 
the active receptor. Using the DNA-cellulose competitive binding assay 
(Kallos and Hollander, 1978), Mulvihill £t a^. (1982) have demonstrated 
the presence of specific DNA binding sites for hormonally responsive genes 
(for progesterone receptor). Use of DNA-cellulose has also been made by 
Pfahl (1982) to demonstrate specific binding of the glucocorticoid- 
receptor complex to the mouse mammary tumour proviral promoter region.
The use of purified nuclei to study oestrogen receptor-chromatin inter­
action has proved of little success, especially with the mammary gland 
(Park and Wittliff, 1977). DNA-cellulose has proved a very useful and 
convenient tool for studying activated oestrogen-receptor complex (Park 
and Wittliff, 1977; Sato e^ , 198la; Katzenellenbogen et al., 1981).
It has also proved useful for analysis of oestrogen-receptor and drug 
receptor interaction in other systems (Evans et al., 1982).
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4.2.1.1 Immature Rat Uterine Soluble Oestrogen Receptor
It was shown that DNA-cellulose does not retain any significant 
free steroid (Table 8). This was found to be the case whether steroid was 
provided in buffer or in receptor depleted cytosol. This result is in 
agreement with that of Pfahl (1982). In the presence of receptor, however, 
radioactive steroid binds to DNA-cellulose (Table 9.1 and 9.2). The bound 
counts can be extracted in part with salt (Table 9.2). The DCC assay used 
(Park and Wittliff, 1977) most probably underestimates the salt extracted 
receptor bound counts but heat-dependent activation can still be demon­
strated (Table 9.1). After several washings of the DNA-cellulose bound 
receptor and subsequent salt extraction receptor is relatively pure and 
most probably adsorbs to the DCC (Poulsen, 1981 ; Powell e_t ^ . , 1981).
The extraction buffers contain 0.4 - 0.6M salt which itself, has been 
shown to effect the DCC assay (Peck and Clark, 1977).
Underestimation of salt-extracted activated receptor by DCC 
analysis was also indicated by the results shown in Figures 31 and 32.
If the salt extracted receptor, without any previous DCC stripping, was 
loaded onto low salt gradients the receptor aggregated to the bottom of 
the tube leaving some free steroid trailing towards the top of the gradient 
In high salt, however, a 5S peak can be detected but the trailing effect 
of free steroid was persistent. The receptor most probably looses steroid 
during centrifugation due to low protein concentration, an effect also 
seen by Bailley ^  (1980) and Nishizawa e^ (1981). However, if
the receptor is extracted from DNA-cellulose in buffers containing protein 
and then loaded onto gradients containing protein up to 70% of the steroid 
could be shown to be still macromolecular bound (Figure 32). This
sedimented as a sharp 5.58 peak particularly in BSA containing gradients
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(Figure 32B). It is believed that the rest of the counts may also be 
macromolecular bound but that these bind to the sides of the cellulose- 
nitrate tube during centrifugation. This binding appears to be very 
tight since even alcohol extraction of the tube was unable to yield 100% 
recovery of counts. This use of proteins was also made by Yamamoto (1974), 
where better results were found in the presence, than in the absence of 
proteins. However, as shown in Figure 32C, the choice of protein should 
be made carefully since in the presence of human - -globulin the process 
of receptor extraction was inefficient. Thus, both DCC and SDG (in the 
absence of exogenous proteins) may underestimate the total concentration 
of DNA-cellulose bound activated receptor. Finally, the activated complex 
sediments as a 58 species.
When using DNA-cellulose, the use of competitor was found 
unnecessary (Table 9.2), and both Figures 31 and 32 confirm that no 
non-specific component could be detected on the gradients. DNA-cellulose 
therefore selectively retains the oestrogen-receptor complex and confirms 
that it is a DNA binding protein. Other DNA binding proteins are known 
including the lactose repressor, which binds to specific sites on DNA 
other than their specific sites in the gene-control regions (Bourgeois 
and Pfahl, 1976). It is not known if the nucleotide sequence of these 
sites is different or the same. Similarly certain stretches on calf 
thymus DNA (DNA-cellulose) may preferentially retain the oestrogen-receptor 
complex. One great advantage of the DNA-cellulose assay is that it omits 
the need for receptor purification, a process which may remove certain 
components required for specific selection of DNA binding site (Mulvihill 
et al., 1982).
Temperature dependence of immature rat uterine ER - DNA interaction
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is shown in Figure 33. It was found that 30°C for 30 min. provided 
maximum binding to DNA (80-90% of total input; also see Tables 10 and 
11). Significant ( /v 30%) binding was also found in non-activated 
cytosol. This indicates that a proportion of receptor is activated 
even at 4°C possibly as a result of 0.15M salt present in the incubation 
mixture, salt may be dissociating inhibitors (Section 1.1.5.3.2). Traish 
^  (1979) have found that in intact uterine cells the formation of
the 5S complex (activated receptor) is a temperature dependent event 
but can take place at 4°C over a longer time interval (22h). Gschwendt 
(1980) used a chromatographic procedure for his DNA-cellulose assay and 
reported 80% binding of activated oestrogen-receptor complex from chick 
oviduct. These results suggest that on heat activation oestrogen receptor 
either acquires another subunit(s) with a DNA binding site on it or else 
that the receptor itself unfolds to expose a DNA binding site(s).
The 80-90% DNA binding ability of immature rat uterine 
oestrogen-receptor complex is in disagreement with the results presented 
by Bailly e_t (1980) and for glucocorticoid receptor by Le Fevre et al.
(1979). Whereas the differences reported by Le Fevre et al. can be 
ascribed to different systems being studied, the differences obtained 
with Bailly at are more difficult to explain. These possibilities
can be put forward - (a) in our experiments, fresh cytosol was always 
used whereas Bailly e^ al. used uteri stored for up to 4 weeks in liquid 
nitrogen which must have destroyed some of the DNA binding potential of 
receptors (also see Figure 57C which was obtained from uteri stored in 
sucrose/glycerol for just 1 day - there was a loss of 5S forming potential 
in these cytosols), (b) Bailly e^ used EDTA in their buffers, an 
agent which is known to inhibit activation (Sala-Trepat and Vallet- 
Strouve, 1974; Sato ^  , 1978a), (c) the experiments conducted by
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Bailly al. involved up to 8 -fold dilution of cytosol, a process 
which would be unfavourable for a bimolecular reaction. It should also 
be noted that the failure to show a temperature dependent activation 
step for uterine cytosol by Sato at (1981a), may also be due to 
previous storage.
Although a direct comparison of DNA-cellulose and nuclei is 
inappropriate, it is interesting that in vivo translocation also allows 
90% of the receptor to move to the nuclear fraction (Williams and Gorski, 
1972). The 5S complex formed in vitro therefore may possess the same 
properties of binding to DNA as vivo. However the other subunit 
present in the 5S complex (Thampan and Clark, 1981) may perhaps direct 
the receptor to correct acceptor sites (Leake, 1976).
In the present study it was observed that 70% of the total 
counts bound to DNA-cellulose were salt extractable. This involved one 
salt extraction at 4°C for 1h with buffer containing 0.6M KOI (Figure 
33, Table 10 and Table 11). This procedure is similar to that used by 
others (Clark and Peck, 1976; Katzenellenbogen ^  , 1980) for whole
nuclei. An interesting feature to emerge from the present data was 
that a constant proportion of total bound receptor was extractable from 
the DNA irrespective of the use of activated or non-activated cytosol 
for the binding incubation. This implied that a fixed proportion of 
activated receptor binds to higher affinity sites on the DNA and is 
insensitive to a single salt extraction, that is, there must be an 
equilibrium between tight-binding and loose-binding sites on the DNA.
The possibility of two different types of 53 receptor has been ruled 
out (Juliano and Stancel, 1976) although Ruh ^  (1981) point out
that heterogeneity within receptor may occur. Dickerman and Kumar (1982)
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have shown that receptor is capable of distinguishing between various 
deoxynucleotides. The deoxyguanosine in particular shows much greater 
affinity for the receptor and there is a possibility, therefore, that 
a stretch of deoxyguanosine may serve as a salt resistant site.
The physiological significance of differential extraction of 
receptor from nuclei is currently a matter of debate (Clark and Peck,
1979; Barrack and Coffey, 1982; Ikeda et , 1982). Nevertheless it 
is interesting that, when using whole nuclei, the proportion of receptor 
that is salt extractable (Katzenellenbogen ^  al., 1980) is similar to 
that from DNA-cellulose (present study). Ruh and Baundendistel (1977) 
have proposed that antioestrogen-receptor complexes only bind to salt 
extractable sites. Barrack et (1983) have found a difference in the 
proportion of salt extractable androgen receptor from normal and cancerous 
human prostate. Perhaps DNA-cellulose could shed further insight into the 
specificity of this reaction. Some studies involving antioestrogennreceptor 
complex binding to DNA-cellulose are already in progress (Evans et al.,
1982). Whereas Katzenellenbogen ^  al. (1981) have found fewer binding 
sites on DNA for the antioestrogen-receptor complex, Evans ^  al. (1982) 
report that the number of binding sites are the same but that the anti­
oestrogen -receptor complex has a lower affinity for the DNA. The latter 
may be related only to salt extractable sites.
Maximum binding of activated receptor to DNA occurred after 
a constant time of approximately 1h with lOOug DNA (Figures 34 and 35). 
Interestingly, however, when the effect of contact time of DNA with a 
fixed receptor concentration was studied (Figure 34) the alcohol 
extractable sites were filled very rapidly but the lower affinity 
site(s) (salt extractable sites) showed a time dependent occupation.
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The saturation obtained must be a consequence of receptor limitation.
The above also rules out the possibility that access of HDK.^ buffer 
to the DNA“bound receptor is the limiting factor in the salt extraction 
efficiency. At shorter contact times of receptor with DNA-cellulose the 
binding equilibrium between salt extractable and salt resistant sites 
must be in favour of the salt resistant form since proportionately there 
were more salt resistant counts at shorter contact times. Spelsberg 
(1976) has shown the existence of multiple affinity acceptor sites on 
chromatin. It appears from recent experiments that chromatin associated 
proteins are involved in determining the specificity of binding whereas 
binding to naked DNA is non-specific (Ruh and Spelsberg, 1983). In 
keeping with the above, Figure 35 shows that whereas lOOug DNA provided 
the optimum concentration for measuring total activated receptor in 
the system, the alcohol extractable counts increased with increasing 
DNA concentration.
Figure 36 shows that using a fixed amount of DNA (lOOug), 
increasing receptor concentration reveals non-saturable binding in the 
range tested (confirming the data of Ruh and Spelsberg, 1983). This 
confirms that in the previous experiments DNA binding sites for the 
receptor were not limiting. The protein concentration in the entire 
system was kept constant by adding a heated (37°C for 2h in the absence 
of steroid) aliquot of the same cytosol to the required volume. It was 
noted, surprisingly, that the heated cytosol was still able to bind about 
50% of the specific counts represented by the intact cytosol. However, 
these counts did not interfere with the assay for the reasons explained 
in Section 3.2.1.2.6. In addition a recent paper by Leach et (1982) 
has suggested the presence of a heat stable factor in the glucocorticoid 
receptor system which acts similarly to sodium molybdate. This factor
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both stabilizes the unbound receptor and prevents its DNA binding. It 
should be remembered that fresh cytosol was used in the present investiga­
tion which may be significant with respect to the above result. When 
sodium molybdate was introduced into the cytosol either just prior to 
activation or from the time of incubation with radioactive steroid, the 
receptor activation, as judged by the DNA-cellulose assay was inhibited 
(Figure 37). The possible modes of action of this compound were discussed 
in Section 1.1.5.3-2 and Section 4.1.1.2. Interestingly, it was found 
that when homogenization was performed in the presence of sodium molybdate 
the activation seen at 4°C was completely abolished (Figure 38). Neverthe­
less , heat activation always provided /V 20% receptor activation irrespective 
of the stage at which sodium molybdate was introduced (Figures 37 and 38). 
This most probably indicates that molybdate only slows down the rate of 
activation. A similar observation was also made by Mauck ^  a_l. (1982) 
for calf uterine oestrogen receptor. During the course of the present 
investigation it was noted that EDTA also provided a similar result (data 
not shown). It has been suggested that molybdate may chelate endogenous 
metal ions (of. EDTA) which may be required for activation (Ratajczak 
e^ , 1981). There is also some evidence that receptors may be métallo- 
proteins (Lohraar and Toft, 1975; Shyamala, 1975; Schmidt et al.,
1981), and therefore a direct interaction of molybdate or EDTA with receptors 
themselves cannot be excluded. It has been reported by (Cong and Lippman, 
1981-82) that ATP-promoted oestrogen receptor activation in MCF-7 cells 
is also only partially inhibited with sodium molybdate. If the effect of 
molybdate or EDTA is on the rate of activation then an extended time course 
should promote further activation. For EDTA indeed this has been found 
to be the case (Hyder and Myatt, unpublished observation) but only after 
overnight incubation at 4°C. Although a similar effect at higher temperature
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is expected, there is also the process of deactivation which follows 
receptor activation (Buchi and Ville, 1976; also found for glucocorticoid 
receptor by Aranyi, 1983). It therefore appears that EDTA and molybdate 
may play a common role in inhibiting receptor activation. Bailly et al.
(1980) in their attempt to distinguish between activation and transforma­
tion used EDTA in their buffers, hence that data should be interpreted 
with great care. EDTA has been known to inhibit not only activation but 
also transformation (Jensen and DeSombre, 1972; Sato et al., 1978a).
It was noted (Figure 37 and 38) that whereas in the absence 
of molybdate the difference between salt extractable and alcohol extract- 
able counts was approximately 4-5 fold, this difference in the presence 
of molybdate was only 2 fold. Molybdate seems to have a greater effect 
on the DNA-binding of salt extractable counts. The significance of this 
observation is not clear.
4.2.1.2. Human Breast Tumour Soluble Oestrogen Receptor
In contrast to the DNA binding results of immature rat uterine 
receptor, the level of DNA binding by human breast tumour cytosol receptor 
was far less and more variable (^30%) (Figures 39 and 40). Due to lack of 
sample availability not many samples could be analyzed, but the results 
presented are generally in agreement with those of others (Park and 
Wittliff, 1977; Sato et al., 198la). Figure 39 confirms that temperature 
dependent activation of oestrogen receptor takes place in human breast 
tumour cytosol but this is far less dramatic than that observed for rat 
uterine receptor (Figure 33). Sato et al. (1981a) found that whereas 
some tumour cytosol preparations showed temperature dependent activation 
others lost the DNA binding ability on heating. In another report (Sato
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et al., 1981b) it is mentioned that in oestrogen-independent mouse Leydig 
cell tumour, heating cytosol for activation destroys the DNA binding 
ability whereas dialysis at low temperature promoted DNA binding. 
Proteolysis of receptor is indicated. The use of DFP in the present 
investigation (Figure 40) suggests that serine protease(s) in tumour 
cytosols destroy the DNA binding site of receptor. This either results 
from proteolysis of the DNA binding domain of receptor itself or of 
another component which during the activation conditions binds to the 
receptor. This result is consistent with those reported for other 
human tissues (Notides et al., 1976; Lukola and Punnonen, 1982). Human 
tissues in general possess protease(s) which are absent or not active in 
immature rat uterine tissue.
DFP was found to suppress the total oestrogen binding capacity 
of tumour cytosol. The possible reasons for this are presented in 
Section 4.1.1. In human tissue DNA binding studies it was found necessary 
to compute the DNA-binding obtained in the presence of competitor. In 
some cases this was significant because of the very low percentage of 
receptor binding to DNA-cellulose (see also Park and Wittliff, 1977;
Sato et al., 1981a and Table 12).
It is difficult to explain why after taking the necessary 
precautions (inclusion of 0.15M KCl and DFP) the total receptor binding 
to DNA does not exceed /v 30% of the input concentration (30% was the 
maximum binding obtained using DNA-cellulose). It is possible that there 
is a large amount of receptor activation inhibitor or that there is absence 
of a factor(s) promoting activation. There is also a suggestion that in 
the human uterus, post-menopausal receptor is non-functional (Strathy 
et al., 1982 ) with respect to DNA binding. Nevertheless, as shown
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in the next section, a very large proportion of human breast tumour 
receptor is capable of binding to soluble DNA (especially the 8S form) 
and therefore the problem does not seem to be lack of factor(s) required 
for DNA binding. The problem seems to be associated with the heating 
step. In vitro transformation studies (Section 3.2.3-2.7) revealed that 
this process leads to receptor aggregation (especially in the presence 
of DFP) or receptor proteolysis from 88— >4S (sometimes even in the 
presence of DFP). Aggregation may therefore mask the DNA binding site 
and proteolysis may lead to the loss of DNA binding ability. Limited 
heat dependent activation may result from both receptor present in the 
active form and some active receptor dissociating from the aggregated 
material during the incubation with DNA-cellulose.
It is interesting that Lukola et al. (1980) and Charreau 
and Baldi (1977) found that a greater nuclear uptake can be observed 
if the acceptor is present during the warming step. This would suggest 
that the active receptor, in the absence of an acceptor, becomes rapidly 
deactivated (see Aranyi, 1983) either in the aggregated form or as a 
proteolyzed form. In the present investigation and in those of others 
(Park and Wittliff, 1977; Notides et al., 1976; Sato et al., 198la),
the receptor was incubated with DNA-cellulose after heat activation.
These results strongly suggest that it may not be entirely correct to 
conclude from ^  vitro experiments that there is an excess of inhibitor(s) 
or lack of activation factor(s) when DNA or chromatin binding could not 
be observed or was limited (Haselbacher and Eisenfeld, 1976; Fox, 1977; 
Shen et al., 1979; Strathy et al., 1982). Thus loss of DNA binding may 
result from an artifactual loss of activating factor(s), acquisition of 
inhibitory factor(s) or alteration in receptor structure. The aggregation 
and proteolysis problem may also be responsible for the apparent lack of
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temperature dependent activation in mature rat uterine cytosol (Myatt 
et al., 1982a) and in the variable level of receptor binding to oligo- 
deoxythymidine observed by Thrower et al. (1976) who were using mature 
rat uteri irrespective of oestrous stage (see also Figure 30).
Table 13 indicates that the DNA-cellulose bound human receptor 
is more difficult to extract with salt than the activated immature rat 
uterine soluble receptor. In fact, the situation is reversed, that is, 
there are about 70% alcohol extractable counts compared to approximately 
30% in the immature rat uterine DNA-bound receptor. Once again, a similar 
situation is observed with intact nuclei prepared from other human tissues 
(Katzenellenbogen et al., 1980). It has been found by Kasid et al. (1982) 
that in the MCF-7 human breast cancer cells, the processed receptor is 
inaccessible to salt extraction. This observation lends further support 
to the view presented by Love et al. (in press) that by salt extracting, 
most investigators would underestimate nuclear receptor in human breast 
tumours. However there is one possibility which we cannot ignore in 
explaining the differential salt extractability of DNA-cellulose bound 
human oestrogen receptor. It is possible that most of the DNA-bound 
receptors are loosely attached and are released during the washing 
procedure, giving a false distribution.
4.2.2 Interaction of Cytoplasmic Oestrogen Receptor - Soluble Calf
Thymus DNA
Low salt SDGA, used by Park and Wittliff (1980), involving ER^ 
interaction with soluble calf thymus DNA showed that a vast majority of 
soluble receptor from human breast tumour (especially 8S) was capable 
of interacting with DNA (cf results in previous section). However,
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setting up of this assay required a control experiment. Immature rat 
uterine soluble receptor was used (Figure 4l). It was shown to sediment 
primarily at 8S (Figure 4lA) in the absence of DNA. On adding DNA to 
the cytosol, this peak was shifted to the bottom of the tube in con­
junction with the DNA (also see Majumdar and Frankel, 1978). Since 
immature rat uterine cytosol generally contained a much lower protein 
concentration compared with human breast tumour cytosol, it was decided 
to introduce a large amount of non-specific protein into the assay system 
to determine its effect on DNA binding (Figure 41C). Cytosol was made 
lOmg/ml with respect to BSA and then, after incubation with HE^, DNA 
was added. The receptor was still able to bind to DNA and sediment to 
the bottom of the tube. There was however, a small 4.63 peak of HE^,
14 Q
CO-sedimenting with the C-BSA marker suggesting that some HE^ has been 
non-specifically associated with the BSA. The possibility however, is not 
discounted that there may be other proteins in the tumour cytosol which 
may block DNA binding ability, by either directly interacting with the 
receptor or by interacting with the DNA. The latter seems unlikely since 
such a vast excess of DNA was used (Img/ml). It is seen in Figure 4l that 
not all receptor binds to the DNA and there is a minor peak left behind 
on the gradient. Possible explanations must include (a) insufficient time 
for equilibration between DNA and receptor, this may in turn depend on the 
equilibrium between the quasi -stable states of the receptor (Kim et al.,
1982), (b) lack of other factors required for activation, (c) dissociation 
of receptor during centrifugation and (d) a possible equilibrium between 
activated and non-activated receptor.
The same assay when repeated for human breast tumour cytosol, 
containing predominantly the 8S form, showed a similar result (Figure 42). 
However two tumours which were found to contain very distinct 48 and 88
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peaks, showed that only the 8S peak was displacable with DNA. An 
example is presented in Figure 43. This result is in agreement with 
Park and Wittliff (1980) who propose that low salt 4S receptors are 
inactive in DNA binding and this therefore supports their theory of 
unresponsiveness of 4S containing tumours. However, this is not always 
the case. Some tumours were found where a vast majority of the 48 peak 
also bound to the DNA (Figure 44). The data therefore clearly demonstrates 
a heterogeneity in the ability of 48 receptor to bind DNA.
It is suggested that the proteolyzed 4S receptor fails to 
aggregate to 88 and does not readily bind to DNA (Rochefort and Baulieu, 
1971; Lukola and Punnonen, 1982). The 88 dissociated form represents a 
48 form which can acquire the ability to bind to DNA. The proteolyzed 
48 receptor may bind to DNA but with very low association kinetics 
(probably non-specifically). Situations are known where such weak 
associations do occur (Muldoon, 1981 ; Mataradze et al., 1982). There 
may be several reasons why an intact 88 dissociated receptor is found in 
the 48 region. Possibilities may include (a) relaxation of 88 structure 
as a result of mild proteolysis (b) absence or limitation of certain other 
components which are known to interact with intact 48 receptor to form 
the 88 form (Murayama et al., 1980b). These situations could arise as 
a result of storage or experimental handling. The possibility that 
intact 48 forms can exist has recently been demonstrated by Colvard and 
Wilson (1981) for the androgen receptor.
An interesting result was found in one case where there was 
only partial 48 and 88 binding to DNA. Whereas lack of 48 binding came 
as no surprise, the absence of 88 interaction was unusual. Perhaps 
such an aggregated receptor does exist in the cytoplasm of the cell
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preventing translocation of receptor into the nucleus in the absence of 
ligand. Ligand most probably shifts the equilibrium towards the intact 
4S complex which moves to the nucleus and binds other factors to become 
activated receptor (58).
88 48 ---   " ACTIVE ---- ^  DNA
^48  X > DNA
(proteolyzed) 
in vivo?
A similar equilibrium model was recently reported by Raaka 
and 8amuels (1983) for the glucocorticoid receptor. It has also been 
noted by Tymoczko and Phillips (1983) that RNAase treatment of gluco­
corticoid receptor increases DNA binding ability and shifts the molecular 
form to 48. Wrange and Gustafsson (1978) also found that partial proteolysis 
of the glucocorticoid receptor shifts the sedimentation profile towards 
the lower molecular form and increases the DNA binding ability of the 
glucocorticoid receptor. However further proteolysis led to destruction 
of the DNA binding site. For oestrogen receptor it is clear that molybdate 
prevents 8S— >4S dissociation and simultaneously prevents transformation 
of the receptor to the 58 form (Muller et al., 1982). All this suggests 
that an 88— k48 dissociation is essential for activation of receptor.
In Figure 45, the most probable reasons for the receptor to exist in the 
88 complex were (i) a large concentration of inhibitor or (ii) a relatively 
high protein concentration of the cytosol compared to other analyses. A 
possible proteolysis of the 88 receptor DNA binding site cannot be ignored, 
although this seems unlikely.
It is interesting that in contrast to the temperature dependent 
activation previously shown (Figures 33 and 39) no such requirement was 
necessary for the analysis just presented. This most probably indicates
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that 4S— ^activated state is promoted by the presence of DNA 
(Yamamoto, 1974). It is also possible that such a vast excess of DNA 
(Img/ml) may actually bind the receptor non-specifically. Some of these 
experiments were therefore repeated in the presence of 0.15M KCl (data 
not shown). Receptor was shown to bind to DNA but, under these conditions, 
it was not possible to conclude which molecular form bound as all receptor 
is initially 4S (e.g. see Figure 22).
These results indicate that the human breast cancer soluble 
receptor sedimenting in the 4S region of the gradient may comprise both 
proteolyzed receptor and dissociated 88 receptor. The latter remains 
in equilibrium with the 88 form.
4.2.3 Receptor Transformation
The 48— >58 transformation of oestrogen receptor has been 
suggested to represent a physiological event (Traish et al., 1979). 
Nevertheless, it has been suggested that such a process does not occur 
in human breast tumours (Fazefcas and MacFarlane, 1980). Results pre­
sented in this thesis suggest that such a transformation may be demon­
strated under defined conditions.
4.2.3.1 Immature Rat Uterine Receptor Transformation
In accordance with transformation results presented from 
intact uterine cells (Traish et al., 1979), Figure 46 shows the in vitro 
temperature and time dependent formation of the 58 peak. In addition 
Figure 46A (low temperature control) shows a shoulder at about 58 which 
could explain the small extent (r-y30%) of DNA-cellulose binding seen in 
the non-activated cytosol (Table 10). These results would suggest that
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it is the 58 form which binds to DNA. This transformation step most 
probably Involves binding of another subunit to the native 48 receptor. 
Nevertheless, it is debatable whether the 58 form represents a homodimer 
(Notides et al., 1981) or a heterodimer (Thampan and Clark, 1981). It 
is likely that the second subunit either provides the DNA binding site 
or allows some conformational change in the receptor molecule exposing 
the DNA binding site. This 58 complex obtained is indistinguishable 
from that obtained from salt extraction of intact nuclei (Notides,
1978) or DNA-cellulose (Figure 328). In the present investigation it 
was found that the 58 form could be demonstrated in either 0.15M or 
0.4h KCl gradients following heat activation of either low salt or 
0.15M KCl containing uterine cytosol. However, heat activation in 
low salt buffer followed by low salt gradient analysis led to aggrega­
tion of the receptor to the bottom of the tube (data not shown).
It is further shown in Figure 47 that if the activation was 
followed by progressive dilution and sedimentation analysis, then there 
was a loss of counts towards the top of the gradient. This most probably 
results from the lack of protein environment which may help the receptor to 
retain the DNA-binding subunit. It could be suggested that such a process 
is one of the ways of terminating receptor occupancy of the acceptor 
site - the release of a second subunit from the receptor will lead to 
a relaxed K^ for (or vice versa) and subsequent loss of response.
Some of the results presented by Bailly et al. (1980) involved separation 
of receptor on 0.4M KCl gradients, followed by an 8-fold dilution (to 
reduce salt concentration) and subsequent DNA-binding analysis. Those 
results, therefore, are expected to show only suboptimal binding (in 
fact only 30-40% DNA binding was observed in their case). Although 
not clear from Figure 47, dilution always led to a shift of the 5.5-5.68
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peak (Figure 47A) towards the 4.6S marker (Figure 4YB) suggesting an 
effect of dilution on the 48— >58 equilibrium. However, as previously 
suggested, the 58 form may be still intact on dilution and releases 
only as a result of lack of protein environment. This could be checked 
by post-labelling the gradients. The possibility of a 'pulling out’ 
effect of Eg by the cellulose nitrate tube should also be considered 
and future experiments should be conducted with protein coated tubes.
4.2.3.2 Transformation of Human Breast Tumour and Normal Endometrial
Cytosol Oestrogen Receptor
The simple view that loss of 48— >5S transformation in a 
ERg^/ER^" tumour may explain the defective receptor, was not readily 
upheld and these studies are relatively incomplete.
It was found that the 48— * 58 transformation just described 
for immature rat uterine receptor (Section 4.2.3.1) cannot be demon­
strated in either ER^’^/ER^’'* (Figures 48.1 and 48.2) or in ER^^/ER^" 
(data not shown) breast tumour cytosol. The absence of 4S— *58 is 
not confined to cancerous tissue. Normal human endometrial samples 
also fail to show such a transition (Figures 57 and 58).
In breast tumour cytosol, there was generally a loss of 
receptor binding after activation conditions (30°, 30') but the extent 
of this varied from experiment to experiment. In contrast human endo­
metrial samples generally showed a rise in total specific binding after 
activation, implying exchange of endogenously bound oestradiol (or 
other metabolites).
Kute et al. (1978) and Fazekas and MacFarlane (1980) reported
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a similar lack of 4S— *58 transformation in human breast cancer cytosol.
A similar result was found for lactating mammary gland receptor (Park
and Wittliff, 1977). Nevertheless, Notides et al. (1976) had previously 
reported that human myométrial receptor, which under identical conditions 
fails to show 48— >58 change, does undergo transformation but only in 
the presence of DFP, lower ionic strength (0.15M compared to 0.4M KCl 
usually used) and elevated temperature during centrifugation. They 
suggested that the equilibrium between 48— >58 is different for the 
human oestrogen receptor than for the rat receptor.
The methodology of Notides et al. (1976) was therefore adopted
for some of the present experiments with the exception that the ammonium
sulphate precipitation step was omitted. This latter step was avoided 
because (1) other subunit(s) which may be involved in activation/trans- 
formation might be eliminated (2) some results have already provided 
evidence that ammonium sulphate precipitation may affect the acceptor 
recognizing ability of the receptor (Feit and Muldoon, 1983).
The effect of elevated centrifugation temperature (20°C) on
48— *58 change was studied, first without the inclusion of protease
inhibitors. Human breast tumour cytosol receptor showed a slight increase
in its sedimentation value from 48 to 4.68 (co-sedimenting with the BSA
marker) (Figures 49A and B). However this shift was found to be very
variable and seemed to depend to an extent on receptor concentration
(Table 14). A small conformational change or association of certain
factor(s) to the 48 receptor cannot be ignored but the 4.6 to 4.88
seemed to be the maximum value obtained under these conditions. The
14sedimentation profile of C-labelled markers were not affected by 
ionic strnegth, an observation in agreement with others (Katzenellenbogen 
et al., 1980; Ledden et al., 1981). The immature rat uterine cytosol
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receptor failed to sustain its 58 form under these conditions and 
there was either a loss of oestradiol, or the appearance of both 4.68 and 
aggregated forms(Figures 49C andD and Figure 50A). The 4.6 - 4.88 peak 
was also found in human endometrial cytosols (Figure 59A).
It is believed that the 4.68 - 4.88 receptor represents 
the proteolyzed receptor which failed to retain its aggregation property. 
There was a complete recovery of counts on the gradient. The presence 
of aggregation potential of receptor has been shown to be correlated 
with its DNA binding ability (Rochefort and Baulieu, 1971; Lukola et al., 
1981). Another possibility which must be considered is that we may simply 
be observing the 4.68 as a result of loss of other subunit(s) required 
for aggregation either to the 5-68 state or to the bottom of the tube.
Using DFP, a potent serine protease inhibitor, receptor 
sedimenting in the 68 region can clearly be demonstrated (Figure 51 A).
In the absence of DFP this value fell to 4.68. It is further shown 
(Figure 51 A) that the 68 form undergoes aggregation either as a result of 
self-aggregation or aggregation with other molecules. This process, 
however, most probably arises during the earlier part of centrifugation.
A similar result was found for human endometrial receptor using either 
DFP or leupeptin (Figure 59B and 6OA). Bailly et al. (1980) have 
previously shown that immature rat uterine 58 form also undergoes 
further aggregation on heating, and a similar effect was observed here 
in Figure 50A and B. DFP however, failed to conserve the 58 form of rat 
receptor (Figure 50B). Leupeptin was found to preserve the 58 form in 
rat cytosol in a similar fashion to the 68 form in human breast tissue 
(Notides, personal communication). This is suggestive of a hetero­
geneity in enzymes responsible for receptor metabolism. Use of DFP
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or leupeptin alone was found to be ineffective in some tumour and 
endometrial cytosols. Heterogeneity of proteases, affecting receptor 
probably occurs in both tissues of different species and within the 
same individual or even tissue (Hazato and Murayama, 1981; Gregory 
and Notides, 1982).
Mixing human breast tumour cytosol with immature rat uterine 
cytosol was found to abolish the aggregation potential of rat receptor 
(data not shown). This not only prevented 4S— *5S change but also 
inhibited the DNA binding potential (also see Sato et al., 1981a, b).
It is interesting that experiments (conducted at 20°C) 
which show loss of aggregation potential of receptor still leave the 
oestradiol binding site intact. In such cases the receptor is neither 
degraded nor the oestradiol dissociated. This most probably is a 
result of an early separation of proteolytic components (or protease 
required factors) on the gradients (Charreau and Baldi, 1977). The 
oestradiol-receptor interaction is most probably sustained by hydro - 
phobic interactions since such interactions are known to increase with 
temperature (Notides et al., 1976).
The formation of 6S complex in human tissues was found to
be sensitive to ionic interaction (Figures 51.|^ and 60). Increase in
ionic strength from 0.15M to 0.4M KCl in gradients resulted in a single
peak at around 4.6S. This was found to be the case irrespective of the
presence of DFP. This suggests that the formation of 6S complex is a
result of interaction of other subunit(s) with the 4S receptor through
ionic bonds. The fact that immature rat uterine 58 receptor can be
observed in 0.4M KCl gradients (at 4°C) suggests that bonds other 
than ionic bonds are involved (Notides et al.,1976).
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It was further observed that the formation of 6S complex in 
human breast tumour cytosol was dependent both on the concentration of 
receptor and its molecular form (Table 15 and Figure 52). The presence 
of both 4S and 8S low salt profile resulted in a 4S + 6S peak when 
centrifuged through 0.15M KCl gradients at 20°C. If the concentration 
of 4S and 6S were such that these could be resolved then a profile, as 
shown in Figure 52A, was seen. Otherwise a very broad peak extending 
from 4.6 to 68 was noticed (Table 15 and Figure 55C). The results from 
human endometrial cytosol showed a lesser degree of dependence on receptor 
concentration for the formation of 68 complex. This most probably is a 
result of the initial presence of only the 8S form in the cytosol, in 
the presence of DFP (results not shown) thus, it seems likely that the 
receptor which forms an 88 complex in low salt yields the 68 form in 
the presence of 0.15M KCl.
The possibility that 6S form may represent the active form 
of oestrogen receptor in human breast cancer tissue was initially 
suggested by Wittliff et al. (1976). However they were unable to 
demonstrate such a form after heat activation (Wittliff et al.^1978).
The possibility that such a form does exist at elevated temperature 
is demonstrated in present results (Figure 51). It was later found 
that the 68 form can also be demonstrated at 4°C, as was reported by 
Wittliff et al.. ( 1976) (Figure 54). The formation of 6S complex most 
probably results from dissociation of inhibitor(s) during the early 
part of centrifugation and possibly allowing receptor dimerization.
This explains why DNA binding cannot be observed at 4°C in a test tube 
assay. The reason why Notides et al. (1976) may have failed to see the 
higher molecular form receptor in human myométrial tissue at 4°C could 
have been due to either (a) different reaction mechanisms in different
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tissues or (b) due to their use of ammonium sulphate which would then 
alter the 48— >58 transition by altering the structure of receptor or 
removal of some other components which would promote formation of 58 
receptor.
The results presented in Figure 51 - Figure 56 help to 
explain why investigators have failed to observe both the 68 form 
after heat activation and DNA binding, even in the presence of DFP.
(The results Section 3.2.3.2.6 and 3-2.3.2.7 should be consulted for 
explanation of Figures 53-56). Most investigators failed to see 6S 
or DNA binding due to proteolysis since such work was generally done 
in the absence of protease inhibitors (Kute et al., 1978; Sato et al., 
1981a). Proteolysis may also explain why in other systems a lower 
in vitro DNA binding value is recorded or different molecular forms 
observed (discussed in Section 4.2.1.2). In the presence of DFP some 
investigators still find a low DNA binding value (Lukola and Punnonen, 
1982; present results e.g. Figure 39). This could be explained by some 
of the results observed on 8DGA that although DFP prevented proteolysis, 
aggregation was still taking place (Figure 51). This aggregation may 
mask the DNA binding site. However, in some analysis, the DFP effect 
was overridden and both proteolysis and some aggregation occurred.
One tumour was found to show the 68 form after heat activa­
tion (Figure 56) in the presence of DFP and centrifugation at 4°C in 
0.15M KCl gradient. However, this tumour was homogenized in HD rather 
than the usual HDK.^^. It remains to be answered whether this result 
is significant. Homogenization in KCl may extract or activate certain 
proteins which the low salt buffer may not. It was previously noted 
(Figure 22) that extraction of tumours with HED and subsequent analysis
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on HEDK.^^ at 4°C yielded only a 48 peak. EDTA may have prevented the 
48— >68 transition. (This result is in variance with those presented 
by Wittliff_et _al. (1976), who showed that low salt 88 containing tumours 
formed a 68 peak under these conditions - Wittliff et were however, 
using Tris in their assay which has been shown to accelerate activation 
(Notides, 1978)).
Before analyzing the significance of 68 form so detected, two 
further results which were obtained with human endometrium must be discussed. 
First it is seen in Figures 61.1 and 61.2 that sodium molybdate on its own 
failed to prevent the proteolysis of receptor to the 4S form. Sodium molybdate 
has also been suggested to function as a protease inhibitor (Chong and Lippman 
1981 -82 ). However, at 20°C centrifugation it fails to function in a similar 
manner to DFP. It was expected that sodium molybdate might combine with pro- 
tease(s), separate it on gradient and then allow 48— >68 transition. Alterna­
tively, once the 68 form is formed it may prevent degradation. However, this 
did not take place. Not all proteases are protected by sodium molybdate 
(Hazato and Murayama, 1981). Sodium molybdate has been found to be less effec­
tive with increasing ionic strength (Moncharmont et al.. 1982). There is 
also the possibility that in these tissues receptor existed as 4S initially 
due to prior degradation, though endometrium was usually used fresh.
Finally the effect of DCC was tested on receptor transformation (data 
not shown). It was found that analysis either before or after DCC treat­
ment yielded the similar 63 peak. DCC therefore did not alter the 68 pattern 
seen in the absence of any DCC treatment suggesting that DCC was not 
absorbing any necessary additional proteins.
The results presented in the literature indicate that the human 
nuclear receptor sediments at 48 (Geier et al., 1979; Katzenellenbogen
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et al., 1980) but these experiments involved 0.4 - 0.6M KCl extraction 
and gradient analysis. Results shown in Figure 51 would argue that 
either only one subunit is being extracted or that the transformed 
form extracted is dissociating during centrifugation in 0.4M KCl.
Another possibility which must be considered is that KCl extraction 
may release certain proteases from the chromatin which could result in 
the proteolysis of the 6S form. Serine proteases are demonstrated on 
the rat liver chromatin (Tsurugi and Ogata, 1982).
A recent report by Linkie (1981-82) has shown that trans­
formed receptor can be extracted from human endometrial nuclei. However, 
the procedure used by Linkie for extraction and assay, is not clear.
It seems that Linkie used glycerol during analysis which is known to 
prevent aggregation of receptor to those components which sediment to 
the bottom of the tube. It may be significant that micrococcal nuclease 
digestion of chromatin-bound receptor showed a 68 complex (note no KCl 
was used) (Andre et al., 1978; Rochefort and Andre, 1978). Progesterone 
receptor only initiates transcription when present in the 68 state and 
glucocorticoid receptor shows a possible dimer on electronmicroscopical 
examination of DNA bound protein. Eckert and Katzenellenbogen (1982) 
have recently detected a higher molecular weight nuclear antioestrogen- 
receptor complex from MCF-7 breast cancer cell nuclei. The high molecular 
weight form is not seen with oestrogen-receptor complex. It may be that 
antioestrogen helps the receptor to retain the second subunit with 
greater affinity. This would allow a greater retention time of receptor 
on the chromatin, perhaps preventing recycling and other oestrogenic 
effects. The importance of 68 form should not be disregarded at present 
and further research must be directed to optimise conditions for its
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detection. In vitro transcription work using isolated 4S, 6S and 88 
forms would be instructive.
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4.2.4. CONCLUSIONS
(a) Several factors were shown to influence the human tumour 
cytosol oestrogen receptor in low salt gradients. Some of these factors 
could be clinically significant and lead to misinterpretation of data.
It is therefore essential to establish interlaboratory quality control 
with respect to molecular forms, if this criteria is to be used for 
clinical work. At present, however, the gradient method is more time 
consuming and uneconomical than the simple measurement of both soluble 
and nuclear receptor measurements in relation to determining patient 
response. The problem of the amount of sample available is increasing, 
probably as a result of a trend towards an earlier detection of disease. 
Gradient analysis requires at least 400-500mg tissue. However, the 
recent application of high pressure liquid chromatography may circumvent 
these problems. In any case if the measurement of molecular forms is
to be pursued for clinical application a set criteria must be established
(b) In contrast to the earlier reported results in the literature,
it was shown that a human breast tumour 6S oestrogen receptor complex 
can exist at elevated temperatures (20°C) in 0.15M KCl gradients. This 
may be analogeous to the 5S form in that the human 68 complex may bind
to the DNA. The presence of 68 complex was dependent on inclusion of 
DFP or leupeptin in the cytosol and on the presence of a predominant 
88 complex in low salt. Previous reports have most probably measured 
the proteolyzed 88 complex as 48 on high salt gradients. The present 
studies have only suggested, and not proved that the 68 form may be 
the DNA binding form.
4.3. A Proposed Model for Steroid Hormone Action
With the wealth of contradictory data in the literature, it
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is difficult to propose a single model for steroid hormone action, that 
will not be subject to criticism. Nevertheless, combining the results 
presented in the literature with those presented in this thesis, the 
following simplified model is presented. This may be valid for both 
the rat and human tissue.
In vivo, oestradiol enters the cell by passive diffusion 
and binds to its specific receptor. The empty receptor is most probably 
located in the localized areas of the soluble fraction, that is, is not 
freely available in the cytoplasm (Figure 62A). It may be present 
attached to membranes, cytoskeleton or as high molecular weight aggregates 
This process would prevent not only proteolysis but also the movement of 
receptor onto the chromatin. The in vitro 88 formation may be a mani­
festation of receptor aggregation potential. Binding of ligand by the 
receptor would allow it to detach itself and be available throughout 
the free water content of the cell. This process would allow receptor 
activation to take place either in the cytoplasm or in the nucleus.
The process of activation vitro (Figure 62B) of the soluble 
receptor (in the absence of proteases) would have to take into account 
the 88— >48 equilibrium. The 88 in itself most probably represents an 
inhibitory complex of the receptor. It will only be the available 4S 
receptor which is able to undergo activation to the 53 (or 68) form.
This is based on observations that processes which lead to disruption 
of 88 complex increase the rate of activation. Conversely, compounds 
which stabilize the 88 complex prevent activation and 48— >58 formation.
In vitro, the release of proteases from tissues (abundant in human tissue) 
can modify the process of activation and the process would then depend 
on intact 48 receptor available (or other proteins required to bind to
Figure 62. A proposed model for oestrogen receptor interaction 
in vivo (A) and the relationship between various 
molecular forms in vitro (B).
* = The S values given are those accepted in the
literature to represent different molecular 
species. These are not to be taken as absolute 
values.
= oestradiol
X = a second subunit(s) required for the binding
of oestrogen receptor to DNA.
CM = Cell membrane
NM = Nuclear membrane
= DNA
A.
-  2 9 2  -  
In vivo state*
Steroid released in 
unmetabolized form.
CM
/ Degraded 
(AS + X or 
complete loss)N.
^Degraded Protease ^
/ Phosphatase
Repair
and/or
Phosphorylation+x
+X
AS 5S.
Degraded
NM
58
+X
+E
Protein
DegradationCM
B. In vitro state
Soluble receptor
DNA ^ --- 58
Aggregate 88 :^AS AS
(proteolyzed)
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the 4S receptor). At present therefore, it seems that most confusion 
in literature relating activation with transformation and/or DNA binding 
ability stems from artifactual proteolysis. The proteolysis of receptor 
in vivo may however hold physiological significance, as discussed below. 
Another parameter influencing receptor activation seems to be the great 
tendency of the intact receptor to aggregate. This may mask the DNA 
binding site of the receptor.
The vivo binding of receptor to chromatin should be 
saturable, at least to the specific sites. The gene sequences to be 
transcribed may possess certain specific regions in or around the 
start of transcription region. Receptor may also be involved in 
binding to other structures in the nucleus (including the nuclear 
matrix).
It is more difficult to suggest how the receptor is released 
from the nucleus (Figure 62A). It is possible that several mechanisms 
are involved in this process depending on whether a receptor protein 
molecule is to be preserved or degraded. Dephosphorylation of receptor 
is indicated as one such mechanisms. However, a dephosphorylation 
mechanisms explains release of oestradiol from the nucleus, but the 
fate of receptor is still unclear. More interestingly, specific proteases 
are found in certain target tissue nuclei which have been shown to have 
a very strong for the receptor. It will be interesting if these 
proteases are involved in not only regulating the activated receptor 
but also in their final degradation.
It is yet to be established what is the nuclear molecular form of 
oestrogen receptor in the human tissue. Salt releases the 58 form of
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receptor from immature rat uterine nuclei but only the 4S form from 
nuclei obtained from human tissues. It is not possible to conclude from 
these results that 4S represents the nuclear form in human tissues since 
the interaction of 4S receptor with other components may be relatively 
weak. Some other procedures of isolation have indicated higher molecular 
form nuclear receptor. The problem therefore remains unresolved.
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